Home Blog Page 3

History Recreated: Wagon Creates Special History Lesson for Kearney Students | Local News

KEARNEY – In 1958, the Kearney Hub published a photo of a fourth-grade class from Kenwood School gathered around a table model of a boxcar.

As many newspaper readers did at the time, Doris Abood cut out the photo and put it in a drawer because her son Dick was in the picture.

Last November, 63 years and two generations later, that image was recreated by Amy Burns’ fourth grade class at Faith Christian School. His students gathered around the same model boxcar and stagecoach, which are now on display at the Fort Kearney Museum at 131 S. Central Ave.

The museum is owned by Marlo and Jennifer Johnson, who are the grandparents of 10-year-old Amelia Sunderland, who is in Burns’ class.

Amy Burns

“When Ms. Burns sent a letter to parents about the upcoming Nebraska History Unit, it gave me an idea,” said Michelle Johnson, mother of Amelia and daughter of Marlo and Jennifer Johnson.

With Marlo’s blessing, she pulled the cart and stagecoach out of the museum display, took them to Faith Christian School, and shared them with Burns’ class. Burns asked his students to recreate the photo taken 63 years earlier.

People also read…

The cart and stagecoach were made over 60 years ago by a regular customer of the former Roy’s Cafe on Central Avenue. Café owners Doris and Ray Abood displayed them in their restaurant to celebrate the pioneering spirit and history of the area. Their son Dick took them to show his fourth grade class at Kenwood School.

A few years later, the Aboods gave them to Johnson for display at the Fort Kearney Museum, but Doris kept that clipping.

1958 Kearney Hub

Here is the 1958 Kearney Hub newspaper clipping showing a Kenwood School class admiring models of a boxcar and stagecoach. In the last row, 11th student from the left, is Dick Abood.

Hub File

“I found this clipping when I was going through their belongings after they died,” said Dick Abood, now a professor of pharmacy at the University of the Pacific in Stockton, California. He kept the original but scanned it into a computer and emailed it to other family members so they could have a copy as well.

Abood said the cart and stagecoach were hand-built by an elderly man who lived in a one-room house with dirt floors next to his grandparents’ property in Kearney. “My dad bought this property and the man gave the items to my dad. I must have been around 7 or 8 at that time,” he said.

Burns was thrilled to display the museum’s model wagons last fall when her 13 fourth-graders made their own miniature boxcars as part of their Nebraska history unit.

When this Kearney Hub photography clipping appeared, “The kids were in awe! They thought that was pretty cool,” Burns said. She liked being able to make that connection with the past.

“Teaching is my passion. I believe that if you don’t have fun, you don’t learn, and you don’t learn if you don’t have fun,” she said. His 22 years of teaching experience includes 13 years in Fremont and eight years at college in Kearney.

Johnson said Burns was “so good with the kids. She is a truly phenomenal teacher. She makes sure they learn, but she also makes it fun and interesting. It was so cool to see the kids enjoying the craftsmanship and detail of these precious replicas.

Amelie Sunderland

Amelia Sunderland is in Amy Burns’ fourth grade class at Faith Christian School. She has been helping out at her family’s Fort Kearney Museum since she was 4 years old.

Kearney Hub File

Johnson grew up helping out at her family’s Fort Kearney Museum. “I would go out and feed the fish and see where all the visitors were coming from. I also helped my mother with the counter. My grandfather ran the boat so there was always a way to get involved and help out,” she said.

Currently the director of Great Plains Art & Antiques at 625 E. First St., Johnson is thrilled to see 10-year-old Amelia so happily involved. The first member of Johnson’s fifth generation, Amelia will inherit the museum, her mother said. She will be well qualified. She has hosted mini-tours there since the age of 4.

[email protected]

Iran: Officials encourage starving citizens as part of ‘big economic plan’

Over the past four decades, the Iranian regime has been infamous for making false claims. As a result, today’s citizens no longer even believe in the date of state newspapers. Iranian officials continue to spread incorrect data and have launched a disinformation campaign against the protests, leaving thousands of citizens in turmoil.

The Iranian people are forced to confront not only the regime’s financial mismanagement and failures, but also its state-sponsored propaganda and misleading statements. However, their perseverance in continuing and expanding their protests across the country proves that the mullahs have failed to deceive society. With no other way to quell the unrest, regime officials resorted to increasing security measures and launched bloody crackdowns on helpless protesters.

Grand economic plan or starving citizens?

Since its inception, the regime has exploited international, regional and national crises to deny the legitimate demands of the people. As authorities and Islamic Revolutionary Guard Corps (IRGC) commanders line their pockets with national resources, more and more Iranian families have fallen below the poverty line.

Adding to the crisis, systematic corruption has further intensified financial turmoil in the country. Since Ebrahim Raisi – the butcher of 1988 – took office in August 2021, the IRGC has extended its dominance over the Iranian economy more than ever to offset its huge expenditures to fuel extremist entities in the Middle East and launch terrorist plots around the world.

Instead of avoiding terrorism, nuclear bomb projects and senseless hostility against regional states and the West, Raisi’s government is more focused on offsetting its budget shortfalls at the expense of citizens by removing subsidizing and rationing essential items under ridiculous pretexts, including “combating smuggling” and “Russia’s invasion of Ukraine”.

Mocking the regime’s claims, citizens said, “Ukrainian officials haven’t rationed bread yet as their country was invaded, but Iranian authorities rationed bread because of the war in Ukraine. Woe to so much glory.

“The regime wrongly announces the removal of subsidies and the reduction of the food basket of poor citizens as a “great economic plan”. However, the only result of his lies is to starve society,” observers observed. say. “The Iranian people no longer suffer from starvation and suffering, and the regime’s looting policies have led thousands to anti-regime protests across Iran.”

Who are the profiteers?

On Sunday May 13, the News of the day The website quoted state security force spokesman Mehdi Hajian as he expressed concern over the volcanic situation in the society, saying, “The implementation of a ‘big plan economy “will have side effects in all countries, and profiteering individuals will pursue their interests”.

Today, the Iranian people are well aware that IRGC commanders and state-backed mafias control almost the entire financial system. In July 2011, the regime’s former president, Mahmoud Ahmadinejad, called IRGC commanders “broker brothers”.

On July 4, 2011, at a specialist conference on “New Strategies for Preventing and Combating Commodity and Currency Smuggling”, Ahmadinejad said: “Corruption will be created immediately when many people get allowances above the law. The numbers are not low; annual revenue associated with smoking in Iran is between $1.3 billion and $1.48 billion. This figure tempts international smugglers, not to mention our fellow smugglers.

Read more: IRGC Commander Hassan Ra’yat: Profile of a Mafia Boss in Iran

Over the past few years, Iranian citizens have repeatedly revealed the location of IRGC warehouses, where the state-backed mafia stored essential hygiene items and pharmaceutical drugs during the country’s worst health crisis, the coronavirus pandemic.

“Since March 21, we have discovered 3.3 million liters of cooking oil, more than 5,300 tons of wheat and flour, 2,700 tons of livestock products and 3,300 tons of rice, hoarded or passed smuggled. During this time, we have identified and detained 1,284 defendants and delivered them to justice,” Hajian said.

However, the security official failed to elaborate on why these essential goods have been scarce in the markets despite their achievements in combating smuggling and hoarding?

Hajian later implicitly admitted the role of the state-backed mafia in the smuggling and hoarding operations, stating, “This amount of smuggling is definitely impossible to conduct individually. We must step up the framework measures at the country’s entry points and adopt excessive restrictions. The police should access data from the Ministry of Industry, Mines and Trade.

Overview of Drug Discovery Services Market from report covering SWOT, Drivers, Growth value and other factors, . – The Daily Val

The corporate research report prepared by the Drug Discovery Services Market DECISIVE MARKETS INSIGHTS research team includes comprehensive analysis of crucial market elements such as newly launched market products, scientific breakthroughs, various significant market complexities, competitive landscape analysis, major organizational assets and expenditures , and many other market critical components affecting the entire massive industry. The marketing intelligence study provided in this report also examines the dealers, suppliers, and distributors of critical market players, including current market breakthroughs, innovations, and brand promotion events. It also discusses the best course of market activities recommended by industry experts to achieve the crucial business goals and objectives.

Please click on the link below if you intend to make a direct purchase @:-https://www.decisivemarketsinsights.com/drug-discovery-services-market/27848892/buy-now

The Drug Discovery Services Market report is segmented into following categories;
By type:
Medicinal Chemistry, Biology, Drug Metabolism and Pharmacokinetics (DMPK) Services
Per application:
Oncology, Neurology, Infectious Diseases and Immune System, Digestive System Diseases, Cardiovascular Diseases, Other Therapeutic Areas
By key players: Thermo Fisher Scientific, Inc. (USA), Albany Molecular Research, Inc. (USA), Charles River Laboratories International, Inc. (USA), Evotec AG (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), GVK Biosci

This market research report also assesses and evaluates the various manufacturing technologies, effective business strategies of the major companies entering the market. Additionally, the various industry estimations, critical industry techniques, tactics, and methods adopted by the leading market players are well presented in an organized structure. There is also a well-established in-depth review of the business product portfolio, business history, current events, promotion and funding plans, recent announcements, critical strategic objectives, competitive environment and services advanced trading.

For a sample copy of the report, visit @ https://www.decisivemarketsinsights.com/drug-discovery-services-market/27848892/request-sample

Why should you buy this report?
• Information about the market data presented in this research report, consumer and end-user analysis, production costs, raw material studies and production strategies. monetize everything briefly discussed.
• The research report also predicts different prospects for economic growth from 2021 to 2028.
• Company survey information also looks in detail at various pricing techniques around the world.
Data, tables, graphs and data are used to depict the entire market sector in this comprehensive analysis of various market trends and methods.

In order to make a pre-order request, please click on the link below:-https://www.decisivemarketsinsights.com/drug-discovery-services-market/27848892/pre-order-enquiry

Key questions addressed in the report:-
• What will be the main problems and obstacles in the industrialized market over the next eight years?
• What is the current market potential and rate of growth opportunity across the industry?
• What are the essential findings and analysis of Porter’s Five Forces model made by business analysts?
• What government activities are likely to affect regional market circumstances?

Please contact us and our expert will get back to you within 30 minutes:
Critical market insights
Sunil Kumar
Head of sales

E-mail – [email protected]
Website – https://www.decisivemarketsinsights.com
United States +18317045538
UK +441256636046
Address: – 26 Broadway, Suite 934, New York, 10004

Social connections:


Head-to-head record: Infinya (OTCMKTS: HAIPF) vs. UPM-Kymmene (OTCMKTS: UPMKY)

Infinite (OTCMKTS:HAIPFGet a rating) and UPM-Kymmene (OTCMKTS:UPMKYGet a rating) are both commodity companies, but which is the better investment? We’ll compare the two companies based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Valuation and benefits

This table compares the revenue, earnings per share (EPS) and valuation of Infinya and UPM-Kymmene.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Infinity N / A N / A N / A N / A N / A
UPM-Kymmene $12.38 billion 1.14 $1.77 billion $2.65 9.98

UPM-Kymmene has higher revenues and profits than Infinya.

Analyst Notes

This is a summary of current ratings and price targets for Infinya and UPM-Kymmene, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Infinity 0 0 0 0 N / A
UPM-Kymmene 0 1 0 0 2.00

UPM-Kymmene has a consensus target price of $39.00, suggesting a potential upside of 47.45%. Given the higher possible upside of UPM-Kymmene, analysts clearly believe that UPM-Kymmene is more favorable than Infinya.


This table compares the net margins, return on equity and return on assets of Infinya and UPM-Kymmene.

Net margins Return on equity return on assets
Infinity N / A N / A N / A
UPM-Kymmene 13.76% 12.57% 8.65%

Volatility and risk

Infinya has a beta of 1.15, suggesting its stock price is 15% more volatile than the S&P 500. Comparatively, UPM-Kymmene has a beta of 1.23, suggesting its stock price is 23% more volatile than the S&P 500.

Insider and Institutional Ownership

0.6% of UPM-Kymmene shares are held by institutional investors. 11.5% of Infinya shares are held by insiders. By comparison, 1.0% of UPM-Kymmene shares are held by insiders. Strong institutional ownership indicates that hedge funds, large fund managers, and endowments believe a company will outperform the market over the long term.


UPM-Kymmene beats Infinya on 7 of the 8 factors compared between the two stocks.

Infinya Company Profile (Get a rating)

Infinya Ltd, through its subsidiaries, manufactures and sells writing and printing paper, wrapping paper, cardboard and corrugated board, and recycled paper products in Israel and the foreign. It offers collection and recycling services for waste paper, cardboard and plastic waste, electronic waste and other recyclable materials; and offers cardboard packaging solutions for food, cosmetics, pharmaceuticals, textiles, high-tech, games, plastics and metals. The company also offers office supplies, paper and paper products, technology and peripherals, hobbies and crafts, furniture, food and cleaning products. The company was previously known as Hadera Paper Ltd. and changed its name to Infinya Ltd in February 2022. Infinya Ltd was incorporated in 1951 and is based in Hadera, Israel.

UPM-Kymmene Company Profile (Get a rating)

UPM-Kymmene Oyj operates in the forest-based organic industry. It operates through UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers, UPM Plywood and other operating segments. The company supplies eucalyptus, birch and softwood pulp grades for tissue, specialty and graphic papers, boards and packaging; sawn timber for construction, packaging, distribution, carpentry and furniture; and renewable wood-based diesel and renewable naphtha for fuel distributors, transportation, and the petroleum and petrochemical industries. It is also involved in the generation of electricity through hydroelectric, nuclear and condensing power plants. In addition, the company offers self-adhesive papers and film label stocks for product and information labeling to label printers and brand owners in the food, beverage, personal care, pharmaceuticals and retail; release papers for labels and liners, fine papers and flexible packaging, as well as production lines for label and packaging papers for retailers, printers, publishers, distributors and paper converters; and graphic papers for advertising, magazines, newspapers, home and office to publishers, cataloguers, retailers, printers and merchants. In addition, it provides plywood and veneer products for construction, vehicle flooring, liquefied natural gas shipbuilding and other manufacturing industries; wood and wood-derived biomass, and forest services for woods and forest owners; outdoor building products and aggregates for injection molding and extrusion; wood-based lignin products for industrial use and cell culture hydrogel products for biomedical applications; and biomedical products. The company mainly operates in Europe, North America and Asia. UPM-Kymmene Oyj was founded in 1995 and is based in Helsinki, Finland.

Get news and reviews for Infiniya Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Infinya and related companies with MarketBeat.com’s FREE daily email newsletter.

Inflation punches cash-strapped Sacramento neighborhood • Sacramento News & Review

The view from Lemon Hill, a working-class community where stress and anxiety dominate the day.

By Sasha Abramsky, Capital & Main

This story is produced by the award-winning journalism association Capital & Main and co-published here with permission.

Seven miles south of downtown Sacramento is Lemon Hill, an unincorporated “census-designated place” whose sunny name belies its struggles.

The residential streets of Lemon Hill are a mix of square apartment buildings and starter bungalows with barred windows. Its main thoroughfares, Stockton Boulevard and 47th Avenue, are home to industrial warehouses, machine shops and more than a few Asian restaurants and grocery stores.

For residents, this area is “Little Saigon,” a hub for Vietnamese and Cambodian immigrants who have settled in the city over the past few decades. There are noodle shops and pho restaurants and huge Vietnamese supermarkets. There are a few cemeteries and a few motels that rent rooms by the week. On Lemon Hill Avenue, several churches and the offices of community organizations stand amid overgrown, derelict land enclosed by chain-link fences topped with barbed wire. In recent years, the grounds have become favorite haunts for vagabonds.

About a third of Lemon Hill’s 15,000 residents live below the poverty line, and the median household income is just under $40,000 a year (compared to $69,400 in Sacramento). It’s not as poor as parts of the Central Valley, or the far north of the state or some desert towns by the Salton Sea. Lemon Hill is just another hardscrabble community. Crime is high; gangs, prostitutes and drug dealers haunt the corners; and paycheck-to-paycheck living keeps those who would move stuck in place.

Now, as two years of pandemic shutdowns come to an end, residents of Lemon Hill, like those in working-class communities across California, are grappling with the shock of record price stickers. Inflation is eating away at consumers’ purchasing power in a way not seen in nearly half a century. Meat prices alone have risen 16% over the past year. Gas prices hover around $6 a gallon and utilities continue to climb. For individuals and families without a financial cushion, when commodity prices rise, bills go unpaid, textbooks and prescription drugs go unpurchased, and life is one of constant anxiety.

Talk to the residents of Lemon Hill and you’ll hear that just staying afloat is getting harder and harder.

Property values, historically, have been low in this neighborhood. The bungalows and low-income housing co-ops along its residential side streets were affordable for working-class families, and many immigrants moved in. Now, however, with crime still high and income low, the cost of living in Lemon Hill has skyrocketed. Redfin reports that the median price of a home in the ZIP code has increased 17.9% in 2021. While the cost of a home (median price in Lemon Hill: $388,000) remains well below parts the wealthiest in the Sacramento area, it is increasingly unaffordable for residents of Lemon Hill.

“I’m 43, a single mother of five minor children, and divorced,” says Angelina Escobar, one of many students I interviewed at the Charles A. Jones Career and Education Center in the heart of Lemon Hill. The center runs courses for adults who want to train as physician assistants, pharmacy technicians, nursing aides, and a few other professions.

Those who attend are mostly low-income. In Escobar’s case, her main sources of income are the money she receives from the home support services program to care for her daughter, who has autism; child support; and $934 per month in SNAP benefits.

“I fight a lot,” she says. “I learned to budget what I have. It’s emotionally stressful. We live day to day, with no extras. Every day we eat rice, beans and any other meat products we can get. I make homemade tortillas to stretch. We don’t have extras like cereal. Even a gallon of milk is worth five dollars. I end up spending about $350 a month on groceries after food stamps.

For Escobar, the recent surge in inflation has proven devastating.

“It’s crazy. Laundry is expensive. I don’t have a washing machine. I spend $80-$90 a month on laundry. My daughter has autism, so she spits up a lot. I constantly have to do laundry A year or two ago it was half that price.

As gas prices rose, Escobar’s 2020 Highlander, on loan from his daughter’s father, proved a liability. It now costs over $80 to fill up. Even her rent, capped because she’s in affordable housing, has gone from $1,081 a month to $1,222 over the past three years.

Escobar endeavored to build up a nest egg; last year, despite her best efforts, she only managed to save about $160.

While the national inflation average was 7.9% in February and 8.5% in March – the highest rate in four decades – and 8.3% in April, Californians are being hit by much higher increases in housing costs and gasoline prices, two of the main drivers of inflation.

As of May 9, the national gasoline price average was $4.33 per gallon. And, although President Biden has tapped into the strategic oil reserve, it is likely to head north the longer the war in Ukraine continues. In California, however, it has been well above $4.33 for months. In most parts of the state, gas prices approach $6 a gallon, and it’s not uncommon to see prices much higher than that. And while Governor Newsom wants to offer rebates of $400 per vehicle, as well as tax rebates targeted at low-income consumers, to negate the impact of those higher prices at the pump, that relief may come too late for many residents on the edge.

Trang, 56, a Vietnamese immigrant who only asked for her first name, moved to California to care for her elderly mother. Almost every month, she now has to dip into her little pot of savings to cover the extra costs of buying gas, food and other necessities. At his local Shell station recently, a gallon of regular gasoline was selling for $5.99.

“Even before inflation, my income was never enough,” Trang says. “Now, with inflation, it’s worse. I worry about my retirement. You’re supposed to put money in, but I keep taking it out.

Likewise, Rachelle Yu, a 21-year-old Lemon Hill resident who also studies at the Charles A. Jones Center, finds that record price increases are costing money she doesn’t have. Even though she only heats her home to 67 degrees in the winter, she still spent $200 a month this year on utilities as energy costs soared.

Crishane Del Carmen, who lives in Elk Grove, a suburb 15 miles south of Sacramento, and commutes to Lemon Hill daily, now spends more than $100 a week on gasoline. She drives a 10-year-old car that gets about 25 miles per gallon and can’t afford to upgrade to a more fuel-efficient vehicle. (Driving through the streets of Lemon Hill, you see mostly old bangers; hybrids and fuel-efficient electric vehicles are almost non-existent in this neighborhood.)

Del Carmen only receives $80 a month in SNAP benefits and has started buying food in bulk to try and save money — though even that involves an upfront expense: her Costco grocery bill is $150 a month, she says. Before the price spikes, she always tried to buy organic food; now, however, it is a luxury she has had to give up.

For Angelina Escobar, the consequences of inflation go beyond the simple need to budget food purchases more effectively. She has, for example, noticed that the costs of the drugs she needs, and that her daughter needs, have also increased. Last year, she had to spend her tax credit to help cover these increased expenses. Without government assistance in the time of the pandemic, she does not know how she will continue to cover her costs.

Ella Marchenko, 23, a local pharmacy student, knows that feeling well. A long-time sufferer of type 1 diabetes, she has to buy diabetic snacks and glucose tablets that she can eat at night when her blood sugar drops. But over the past few months, she’s been horrified at how much it costs now. A small packet, she said, cost $2.50. Now it’s $2.98.

Meanwhile, Marchenko and her husband, who live with her parents as they try to save money for their own home, try to make ends meet on her salary by working as a dispatcher at a transport company. of cars. It’s a losing proposition.

After taxes, she says, he takes home just over $500 a week — and, despite skyrocketing inflation, over the past year he’s only received a $500 raise. $1 an hour wage. But with her tasked with driving her school-aged siblings to their extracurricular activities each day, and with the two commuting — he to work, she to her studies at Lemon Hill — they now spend more than a third of their after-tax gas income for their two Honda Accords.

“I’m scared to think about it,” Marchenko says. “It’s definitely going to be a struggle. Prices are going up all over the place. We try not to spend money, because we have to spend everything on gas and food.

Recently, they started removing subscription services like Netflix. If gas prices continue to rise, she says, she may have to find a job, which will make it that much harder for her to complete her education and qualify for her pharmacy technician license. , and all the more likely to trap her in poverty. .

Copyright 2022 Capital & Main

11th World Pharmaceutical Industry Conference & Exhibition

Greetings. We are hosting the 11th Global Pharma Conferences & Expo on December 21-22, 2022 in Dubai, United Arab Emirates. The Pharma Conference revolves around the theme – “Discover the World of Pharmaceuticals”.

The UCCGonferences OCM wishes to invite pharmacists, experts, professors, students, practitioners, medical specialists, clinician scientists, technologists and other healthcare professionals to the Pharmaceutical Utility Conference.

Our main objective is to bring leading researchers, scientists and academic researchers to exchange, discuss and share their experiences and research findings on all aspects of pharmaceuticals. This conference aims to provide attendees working in pharmaceutical medicine with a venue to maintain state-of-the-art knowledge and skills in their fields including pharmacology, pharmaceutical sciences, pharmaceutical biotechnology, intelligent drug delivery systems, engineering pharmaceutical, pharmacognosy, digital pharmacy, clinical pharmacy, pharmaceutical analysis, pharmaceutical chemistry, pharmaceutical formulations, pharmaceutical regulatory science and other disciplines.

We look forward to making the conference not only a learning opportunity, but also a destination where you can have fun and relax before starting your work. By attending the Pharma conference, you will have the chance to grow both professionally and relationally. Your presence will be greatly appreciated.

Pharmaceuticals 2022 is the best chance to network with scientists, researchers, pharmacologists, experts, practitioners, academics, professors and students from all over the world and discuss best practices, share the vision of therapy and the latest trends and innovations in the world. pharmaceuticals, opportunities and challenges.

UCGConferences Pharma Conference and Expo will have plenary sessions, workshops, symposium to discuss and share the importance of drugs and their effects on human physiology.

Conference highlights include Pharmacology, Pharmaceutical Sciences, Pharmaceutical Biotechnology, Intelligent Drug Delivery Systems, Vaccines, Pharmaceutical Engineering, Quality Assurance, Pharmacognosy, Digital Pharmacy, Medical Marketing, advancing R&D: towards new drugs, clinical pharmacy, pathophysiology, pharmaceutical microbiology, computer applications in pharmacy, pharmacy practice, pharmaceutical analysis, pharmaceutical chemistry, pharmaceutical formulations, pharmaceutical regulatory science, regulation pharmaceuticals, pharmacy, industrial pharmacy, pharmacy development services, drug delivery technologies, pharmacy development services, biopharmaceuticals

Hurry up

Important information:

11th World Pharmaceutical Conference & Exhibition

Short name: PPNUCG2022

Date: December 21-22, 2022

Location: Dubai, United Arab Emirates

Scientific program: it will only include plenary speakers, keynote speakers, panel discussions and presentations in parallel sessions.

Audience: World Leaders, Industrialists, Trade Commissioners, Students, Entrepreneurs, Executives

Email: [email protected]

Visit: https://pharmaceuticals.ucgconferences.com/

Call for papers: https://pharmaceuticals.ucgconferences.com/submit-abstract/

Register here: https://pharmaceuticals.universeconferences.com/registration/

Call us/WhatsApp: +442033222718

Target Audience: CTOs, VPs, Directors, Senior Executives, Wholesalers, Manufacturers, Scientists, Physicians, CEOs, Pharmacists, Professors, Established and Emerging Academics, and partners around the world in an open dialogue to test ideas and expose research to a wider audience.


Unified Citation Journals is a platform for the latest discoveries in technology, science, engineering, medicine, medical clinic and advanced discoveries and health. At Unified Citation Journals, we advance healthcare and improve performance for the benefit of humanity.

Unified Citation Journals empowers and publishes scholarly research. We will include special issues and symposium papers in related journals around the world. Apart from publishing, we also promote upcoming books covering different fields of science, medicine, engineering, technology, etc. Unified citation reviews help authors, publishers, and distributors grow their business in multiple ways.

More details: https://ucjournals.com/

Submit your e-posters today!

ePoster Community is an electronic presentation medium for your scientific posters that allows you to present and publish the latest scientific research of your interest in front of viewers, learners and the open access community around the world. An ePoster is worth a thousand words; it’s self-explanatory – it stands on its own and does most of your explaining numerically. We invite researchers to submit their posters and make them visible. ePosters can contain many different rich resources such as research papers, case reports, presentations, company profiles, assignments, images, trending news, projects, summaries, findings, applications, links, etc. More details: https://eposters.universeconferences. com/

#PharmacyandPharmaceuticalSciences #Anatomy&Pathophysiology #BioinformaticsandBio-materials #Pharmacognosy&Botony #NanotechnologyinPharmacy #Medicinal&BiologicalChemistry #PharmacologicalStudies #InsightsofCancerPharmacology #ClinicalPharmacy #PharmaceuticalCare #PharmaceuticalBiotechnologyandMicrobiology #PharmaceuticalEthics&RegulatoryAffairs #FutureofPharmacy&Pharmacists #TraditionalMedicine #Phytochemistry #PharmaceuticalIndustry #PharmaBusinessManagement #PharmaceuticalConferences #Pharmacology #AnalyticalandBioanalyticaltechniques #Biosimilars #BABEStudies #Toxicology #ClinicalResearch #Clinicalpharmacy #Antibiotics #ForensicResearch #MedicinalChemistry&CADD #Pharmacognosy #Phytochemistry&NaturalProducts #PharmaceuticalRegulatoryAffairs #NovelDrugDeliverySystems #GMP #GCP&QC #NeuropharmacologyConferences #PharmacologyConferences #NeuropharmacoloyConferences2022 #GlobalNeuropharmacologyMeeting #ClinicalNeuropharmacoly

Connect with us:

URL: https://pharmaceuticals.ucgconferences.com/

Email: [email protected]

LinkedIn: https://www.linkedin.com/in/dr-richard-raven-ba254122b/

Facebook: https://www.facebook.com/profile.php?id=100079444840737

Twitter: https://twitter.com/alwaysrichard97

YouTube: https://www.youtube.com/channel/UCS1TFe3nzRlREovQIjYMPkg https://youtu.be/KpgkChkvGxI

WordPress: https://pucg2020.wordpress.com/

Youtube sharing link: https://youtu.be/KpgkChkvGxI

Pinterest: https://in.pinterest.com/alwaysrichardraven

Tumblr: https://www.tumblr.com/blog/view/pharmaconferenceandexpo

mewe: https://mewe.com/i/richardraven

Instagram: https://www.instagram.com/pharmaconferenceucg/

Community: Gathering Conferences Utilities

Reg. No. 12330203

Registered at UCG, 12 Constance Street, London, England, E16 2DQ, United Kingdom

Utility Conference Gathering, O. Reg. No. 12330203 Registered at UCG, 12 Constance Street, London, England, E16 2DQ, United Kingdom.

Utilitarian Conferences Gathering offers a wide range of events, Meetings, Conferences, Workshops, Symposium. We have a dedicated team that aims to acquire the technologies, adopt the knowledge of business needs and accelerate with the best ideas and strategies. Utilitarian Conferences Gathering is a pioneer in event management and collaboration. We are a full-service event provider specializing in medical, clinical, healthcare, life science, engineering, pharmaceutical, environmental science, health care event services. engineering, business, agriculture and food for the academic and industrial sectors. We set ourselves apart from our competitors through our commitment to quality, round-the-clock service, and unmatched pricing. We are able to offer you the best event, meeting experience under one roof. At Utilitarian Conferences Gathering, we ensure that you, the client, choose the most appropriate event.

More information: https://ucgconferences.com/

Facebook: https://www.facebook.com/utilitarianconferences.gathering.7

Description of the Share Buyback Program Authorized by the Ordinary General Meeting of May 19, 2022

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

Daix, May 19, 2022

In accordance with article 241-2 of the general regulations of the AMF (General regulations of the Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the share buyback program of Inventiva SA (the “Company”) as approved by the Ordinary General Meeting of May 19, 2022.

  • Titles concerned: shares issued by Inventiva SA
  • Maximum share of capital that can be bought back by the Company: 10% of the total number of shares making up the share capital at any time.
  • Maximum number of own shares that may be acquired by the Company, based on the number of shares making up the share capital as of April 30, 2022: 4,087,355; however, taking into account the 64,401 treasury shares, only 4,022,954 treasury shares are available for acquisition.
  • Allocation of treasury shares as of April 30, 2022: the 64,401 treasury shares held as of April 30, 2022 are allocated to ensuring the liquidity or stimulation of the Inventiva share market through the intermediary of an investment services provider acting independently within the framework a market making contract that complies with a code of ethics recognized by the Autorité des marchés financiers.
  • Maximum price per share: 40 euros.

The objectives of the share buyback program under the 19th resolution of the Ordinary General Meeting of May 19, 2022 are:

  • to buy or sell shares under a liquidity contract entered into with an investment services provider, under the conditions set by the market authorities;
  • to set up and perform obligations related to stock option programs or other allocations of shares to employees and corporate officers of the Company and, in particular, to allocate shares to employees and corporate officers of the Company within the framework of (i) profit-sharing, or (ii) any plan to purchase shares, stock options or free allocation of shares under the conditions provided for by law, in particular by articles L.3331-1 s. of the Labor Code (including any transfer of shares referred to in Article L.3332-24 of the Labor Code), and to carry out any hedging transactions relating to these transactions;
  • to deliver ordinary shares upon the exercise of rights attached to securities giving access to the capital of the Company by reimbursement, conversion, exchange, presentation of a warrant or in any other way;
  • to reduce the share capital of the Company by canceling all or part of the shares acquired; and
  • more generally, to carry out any operation that would be authorized by law or any market practice that would be accepted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by means of a press release.
  • Program duration: 18 months from the Ordinary General Meeting of May 19, 2022.

The Company, at its discretion, may purchase shares under the program on one or more occasions and at the times it determines; there can be no assurance that the Company will exercise the power to purchase shares to the maximum extent permitted, if at all.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from strong expertise and experience in the field of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there is no currently no approved treatment.

The Company has established a strategic collaboration with AbbVie in the area of ​​autoimmune diseases which resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a trial Phase IIb clinical trial, conducted by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) VI. As part of Inventiva’s decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended clinical efforts with odiparcil and is reviewing available options regarding its possible further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 80 people with in-depth expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It has an extensive library of approximately 240,000 pharmacologically relevant molecules, of which approximately 60% are proprietary, as well as a wholly owned research and development center.

Inventiva is a public limited company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited toforecasts and estimates regarding Inventiva’s pipeline and preclinical and clinical development plans, future business, expectations, plansgrowth and Inventiva’s prospects and the adequacy of Inventiva’s cash resources and cash trail; and whether or to what extent Inventiva may use the share buyback program and the purposes of any use of the share buyback program. Some of these statements, forecasts and estimates can be recognized by the use of words such as, but not limited to, “believes”, “anticipates”, “expects”, “intends”, ” plans”, “seeks”, “estimates”, “may”, “will”, “will”, “could”, “could”, “should”, and “continue” and similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on the beliefs of management. These statements reflect opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or events to differ materially from those expressed or implied by these statements. Future events are difficult to predict and may depend on factors beyond Inventiva’s control. There can be no assurance with respect to pipeline product candidates that clinical trial results will be available within the expected timeframes, that future clinical trials will be initiated as planned, that the product candidates will receive the necessary regulatory approvals, or that any of the milestones by Inventiva or its partners will be achieved on schedule, if at all. Actual results may differ materially from any anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including the fact that Inventiva is a clinical phase with no approved products and no historical product revenue, Inventiva has suffered significant losses since its inception, Inventiva has a limited operating history and has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, Inventiva’s future success depends on successful clinical development, regulatory approval and subsequent commercialization of current and future product candidates, preclinical studies or prior clinical trials are not necessarily predictive of future results and the results of Inventiva’s clinical trials may not support the he claims of Inventiva’s product candidates, Inventiva may encounter significant delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of the relevant regulatory authorities, the recruitment and retention of patients in the clinical trials is an expensive and time-consuming process and could be made more difficult or impossible by multiple factors beyond Inventiva’s control, Inventiva’s product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition and Inventiva’s business, preclinical study and clinical development programs and schedules, its financial condition and its results of operations could be materially and adversely affected fected by the current COVID-19 pandemic and geopolitical events, such as the Russia-Ukraine conflict and the related and potential impacts on Inventiva’s timely initiation, recruitment and completion of clinical trials planned. Given these risks and uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Further, forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the financial year ended December 31, 2021 filed with the Autorité des marchés financiers on March 11, 2022 and the Annual Report on Form 20-F for the financial year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 for additional information regarding such factors, risks and uncertainties.

All information contained in this press release speaks as of the date of the release. Except as required by law, Inventiva does not intend and has no obligation to update or revise the forward-looking statements mentioned above.


InventiveFrédéric CrenChairman and CEO[email protected]+33 3 80 44 75 00 Brunswick GroupYannick Tetzlaff / Tristan Roquet Montegon / Aude LepreuxMedia Relations[email protected]+33 1 53 96 83 83

Westwicke, an ICR companyPatricia L. BankInvestor Relations[email protected]+1 415 513-1284

main logo


First medicinal cannabis products will offer broader treatment options to patients

The successful assessment by the Medicinal Cannabis Agency of Cannasouth’s first medical cannabis products will provide broader treatment options for New Zealand patients and prescribers.

Cannasouth has had three products successfully assessed by the Government Agency for Medicinal Cannabis (the Agency).

Cannasouth CEO Mark Lucas says our products differ from other medicinal cannabis products on the New Zealand market because they contain different ratios of cannabinoids.

“The differentiated formulations of our products will provide New Zealand patients and prescribers with new treatment options compared to existing products on the New Zealand market. Currently, the products available offer very few formulation differences. We believe these products offer patients and prescribers a point of difference to meet the treatment needs of a wider range of conditions.

“Full-spectrum extracts contain complex mixtures of cannabinoids. Although the resulting technical challenges have taken us down a long regulatory road, the wait is worth it because of the benefits patients will derive from these enhanced product options.

In making this announcement, Mr. Lucas reinforced the complex nature of the medicinal cannabis industry and recognized the hard work of the skilled and experienced team at Cannasouth.

“This product approval is another sign that the industry is maturing, which will ultimately benefit those who need these drugs the most.

“Patients are desperately waiting for new, high-quality, competitively priced cannabis medicines to become available through the Medicinal Cannabis program. We are now one step closer to making more medical cannabis options available and providing prescribers and patients with more choice to treat a variety of medical conditions.

Suzanne Burge and Jack Lee are the founders of PillDrop, a leading online pharmacy and medical cannabis dispensary in New Zealand. Pharmacist Mr. Lee says, “These products contain a unique combination of cannabinoids. It’s great to see new products verified with a point of difference to meet the treatment needs of a wider range of patient conditions. We are seeing strong growth in demand for medical cannabis products.

The approval of these products by the agency is also a major step forward for Cannasouth in terms of generating revenue related to medicinal cannabis. Generating revenue from the sale of medicinal products in New Zealand, in addition to high quality dried flower biomass, is one of the company’s main objectives for 2022.

This will complement Cannasouth’s existing non-cannabinoid revenues generated by its subsidiary Midwest Pharmaceutics NZ Ltd, which sells products and services to the pharmaceutical supplements and health and wellness sectors.

Cannasouth is also set to harvest its first commercial crop of medicinal cannabis flower at its Controlled Environment Cultivation (CEA) facility in Waikato, while progressing towards GACP and GMP certification.

A list of all medical cannabis products that meet New Zealand’s minimum quality standard is available here. Cannasouth products will be added by the Ministry of Health in due course.

© Scoop Media

Apply by June 7, PG Admissions, Birla Institute of Technology, Mesra, Ranchi, India pg admission

Birla Institute of Technology, Mesra, Ranchi- 835215, a reputable university, is inviting applications for admission to M.Tech, M.Pharm. , MUP, and M.Sc. Programs (full-time, 2 years/4 semesters) at its Mesra campus for the 2022-23 academic session.

M.Tech programs are offered in (i) Aerospace Engineering (ii) Biotechnology (iii) Civil Engineering – Soil Mechanics and Foundation Engineering; Structural Engineering (iv) Computer Science and Engineering (v) Electrical Engineering (vi) Electronics and Communication Engineering (vii) Environmental Science and Engineering (viii) Mechanical Engineering (ix) Production and Industrial Engineering (x) Remote Sensing

M.Pharm program in the following specializations: (a) Pharmaceutical Chemistry (b) Pharmaceuticals (c) Pharmacology (d) Pharmacognosy (e) Pharmaceutical Quality Assurance
Other programs include a Master of Urban Planning (MUP) and a Master of Science. program in (a) Chemistry (b) Biotechnology (c) Geoinformatics (d) Physics

Detailed eligibility conditions are specified in the Prospectus downloadable from https://www.bitmesra.ac.in/

Applications can be submitted online at www.bitmesra.ac.in no later than 7.6.2022.

The application fee is Rs. 1,500/- (Rs. 1,000/- for SC/ST applicants) to be paid online by net banking/debit card/credit card.

Albert Labs obtains a license from Health Canada

Teacher Robert Britton, B.Sc. PhD, from Simon Fraser University , is a well-published natural products chemist with globally recognized expertise in natural product drug discovery, medicinal chemistry and cancer therapeutics. With a particular focus on oncology, Prof. Britton is creating new tools for late drug lead modification, new processes to improve drug manufacturing, and new strategies for synthesizing structurally complex natural products. Prior to his academic career, Professor Britton was a Principal Investigator in the Process Research Group at Merck.

dr. Ricardo Jorge Dinis-Oliveira , PhD, European PhD, DSc, is an expert toxicologist and pharmacologist. His scientific and academic interest lies in the fields of toxicology and pharmacology of psychoactive substances and drugs, focusing on their preclinical and clinical development stages. He is a member of the editorial boards and ambassador to several international scientific journals. Dr. Dinis-Oliveira is extremely well published, having authored more than 170 articles published in international indexed and peer-reviewed journals, and acted as author of some thirty-six book chapters, four books, four patents national and three international patents. In 2021, he was on the list of the top 2% of scientists in the world, which ranks the most cited scientists in the world. He is passionate about the pharmacology of psychoactive substances and recently assumed the position of editor of the new journal “Psychoactives”, an international peer-reviewed journal on psychoactive substances.

dr. Michael Raymont CEO of Albert Laboratories said: “We are delighted to welcome Professor Robert Breton and Dr. Dinis-Oliveira to our Scientific Advisory Board (SAB). Their exceptional expertise in natural product-based medicines and their in-depth knowledge of toxicology and pharmacology complement the expertise of our other SAB members. Improving drug discovery and gaining a better understanding and depth of the pharmacodynamics and toxicology of these compounds is key to creating value for Albert Laboratories shareholders as we move towards our goal of providing safe and effective medicines to revolutionize the treatment of mental health. »

Teacher Robert Breton added: “I am delighted to work with Albert Laboratories . Mushrooms have been an important source of new drugs and are, on the whole, pharmaceutically prolific and extremely promising. Albert Labs’ science-based approach to natural product drug discovery and development is a promising step towards creating new medicines for patients with urgent unmet needs and developing a future product pipeline for broader indications.

Dr Dinis-Oliveira said: “My team and I will perform extensive toxicological and pharmacological testing to ensure that all Albert Labs’ clinical work, with KRN-101, is carried out safely and efficiently. I look forward to supporting a company that will safely administer psilocybin as an adjunct to psychotherapy and other pharmacological chemical treatments for people with urgent and unmet needs. This is particularly the case for patients refractory to conventional treatments.”

Company of Albert Labs Inc.

A clinical research and drug development company, Albert Laboratories and its team of experts leverage advanced culture technology and natural extraction to accelerate the development of highly effective drugs for mental health. Albert Laboratories seek to develop solutions through an approved and accelerated clinical pathway focused on real-world evidence (RWE). RWE studies are an increasingly recognized and widely used pathway in the successful development of Covid-19 vaccines. This accelerated development path will facilitate Albert Laboratories in achieving its goal of gaining market authorization and creating high-performing licensed drugs.

Thanks to collaborations with research institutions, hospitals and government agencies, Albert Laboratories uses existing clinical infrastructure to provide and improve patient access to their treatment. Albert Labs’ drug, KRN-101, is being developed as a potential solution to cancer-related distress, a market of more than 15 million people with approximately 1 million new patients each year. From this initial orientation, Albert Laboratories will address broader mental health issues believed to affect more than a billion people worldwide.

Albert Laboratories (CSE: ABRT) (FSE: VB50) recently completed a Listing on the Canadian Securities Exchange (CSE) and filed a provisional patent for the scalable production of psilocybin-based natural medicines. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here ( https://youtu.be/otQezIvmIXI ).


Albert Labs International Corp.

dr. Michael Raymont

CEO & President

Website: https://albertlabs.com/


This press release contains forward-looking statements subject to assumptions, risks and uncertainties. Statements contained in this press release that are not purely historical are forward-looking statements, including, without limitation, any statements regarding the Company’s intentions, plans, estimates, beliefs or expectations regarding the future. Although the Company believes that such intentions, plans, estimates, beliefs and expectations in this press release are reasonable, there can be no assurance that such intentions, plans, beliefs and expectations will prove to be correct.

The Company cautions readers that all forward-looking statements, including, without limitation, those relating to the future operations and business prospects of the Company, are based on assumptions, none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are cautioned to rely on their assessment of these risks and uncertainties and not to place undue reliance on any forward-looking statements.

All forward-looking statements are made as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statements or to update the reason why actual events or results could differ or differ from those projected in the forward-looking statements. research statements. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

SOURCEAlbert Labs International Corp.

Quote Show original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2022/26/c1546.html

AG Tong leads a national coalition in defense of affordable drug prices

Press Releases


Attorney General Tong leads a national, bipartisan coalition advocating for affordable drug prices

(Hartford, CT) – Attorney General William Tong today led a bipartisan national coalition of attorneys general in two amicus briefs defending affordable drug prices before the United States Courts of Appeals for the Third Circuit and the District of Columbia.

The brief defends the actions of the US Department of Health and Human Services in cases filed by Sanofi SA, Novartis Pharmaceuticals, United Therapeutics Corp and NovoNordisk. Pharmaceutical giants either refused to comply or unilaterally enacted illegal restrictions on the 340B program demanding reduced drug prices for community health centers, clinics and institutions serving low-income and underserved patient populations. The 340B drug pricing program was passed by Congress in 1992 and has strong bipartisan support.

The pharmaceutical companies have challenged the violation orders issued by the US Department of Health and Human Services. The bipartisan, multistate coalition argues in its amicus briefs that HHS’s actions were legal and necessary.

“These drugmakers have flouted the law to illegally inflate their profits, ignoring the critical medical needs of vulnerable communities. Our nationwide bipartisan coalition urged HHS to use its enforcement power to compel drugmakers to comply with the law. HHS’s actions were both necessary and legal.” said Attorney General Tong.

“For nearly two years… drugmakers participating in the 340B program of the Public Utilities Act, 42 USC § 256b (“340B program”), have flouted their legal obligation to offer price safety net providers 340B reductions on essential prescription drugs. These drugmakers either limited 340B-covered entities to the use of a single retail community pharmacy (contract pharmacy) or conditioned the use of multiple contract pharmacies on intrusive audits of confidential and proprietary data of health care providers. The drugmakers allege that imposing conditions that restrict the use of contract pharmacies is appropriate because the term “pharmacy” does not appear in the text of Law 340B and these conditions are necessary to prevent drug diversion. and duplicate refund requests. But allowing manufacturers to unilaterally modify the 340B program is in direct violation of the statute and policies long pursued by Congress and advanced by the states,” the states assert.

The bipartisan coalition of attorneys general had previously urged HHS to hold drugmakers accountable for their illegal actions jeopardizing access to affordable prescriptions for low-income patients. Attorney General Tong has also written to drugmakers directly urging them to comply with the 340B program.

The amicus brief was led by Attorney General Tong and signed by Attorneys General Arkansas, Connecticut, Colorado, District of Columbia, Delaware, Illinois, Hawaii, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Minnesota , Nebraska, Nevada, New Jersey, New Mexico, North Carolina, Oregon, Pennsylvania, Rhode Island, Utah and Vermont.

Assistant Attorney General Lynn Wittenbrink and Deputy Solicitor General Michael Skold assisted the Attorney General in this case.

Twitter: @AGWilliamTong

Facebook: CT Attorney General

Media Contact:

Elizabeth Benton
[email protected]

Consumer requests:

[email protected]

How Poor Salaries and Limited Opportunities Frustrate Pharmacy Graduates in Nigeria

The Nigerian pharmaceutical industry is highly dependent on imports. The National Agency for Food and Drug Administration and Control recently confirmed that as much as 70% of drugs used in Nigeria are imported. Yet young pharmacists expected to champion the evolution of the country’s drug manufacturing sector to change the narrative are avoiding becoming production pharmacists due to low pay, limited career growth opportunities, among other factors, ALFRED OLUFEMI reports:

Folorunsho Tijesu’s dream of owning a drug manufacturing business motivated his decision to study pharmacy at the University of Ibadan. Before being admitted to pharmacy studies, the young pharmacist had hoped to work in a pharmaceutical manufacturing company before eventually starting his own business. But things took a different turn after she graduated in 2017.

After his mandatory one-year internship at a Lagos-based pharmaceutical company, he gave up on pursuing a full-time position as an industrial production pharmacist.

It should be noted that pharmacy students are trained to practice in different sub-specialties of the profession during their studies. After graduation, a trained pharmacist can choose to be a community pharmacist, hospital pharmacist, university pharmacist, or industrial pharmacist, among other options in the pharmaceutical sector.

They can also practice in other sectors of the economy after graduation, as there are cases of pharmacists in the banking, oil and telecommunications sectors. However, if there is one area of ​​pharmacy that these drug experts cannot afford to abandon for others, it is that of the production of drugs themselves.

This is why the lack of interest in the actual production of drugs by young pharmacy graduates should be of concern.

“During my computer days, I worked mainly at the factory, I went through different units. I started working in the liquid preparation unit where we made suspensions, syrups and all that. I also worked in the laboratory unit where the quality control analysis was carried out,” Folorunsho told our correspondent.

He said that while his time in the business was eye-opening and engaging, he decided against industrial pharmacy and changed his area of ​​practice.

Folorunsho, who now works as a stock manager at a private hospital, said he made a drastic turnaround due to the low pay of industrial production pharmacists he worked with during his internship days.

Their monthly remuneration, according to him, is derisory when compared to those of pharmacists working in hospitals or those in pharmaceutical marketing.

“I noticed that the compensation was not so encouraging. I was a computer science student, so the salary then was nothing compared to that of a graduate. But I compared what one of the pharmacists there told me he was earning to what others were earning in other areas of pharmacy practice. What he earned as a full-fledged production pharmacist is less than what he earned even as a trainee. I also got to hear the experiences of others,” he said. PUNCH Health.

He also noted that career prospects in industrial pharmacy are limited compared to other branches of pharmacy, adding that the challenge of working long hours is also daunting.

“Some companies may ask you to work from 8 a.m. to 5 p.m. or 6 p.m. and not all of us will like to work that way.”

Folorunsho seems to have temporarily put aside his dream of owning a pharmaceutical manufacturing company, saying it is also a capital-intensive business.

He said his current role as a stock manager involves the supply chain part of the pharmacy and pays better than working as a production pharmacist in industrial practice.

What is a production pharmacist?

Production pharmacists deal with the development, production and quality control of drugs and pharmaceuticals. They mainly work in pharmaceutical manufacturing plants.

Also called industrial pharmacists, production pharmacists make an invaluable contribution to the production of quality drugs. They are therefore important for the growth of the pharmaceutical manufacturing sub-sector of the pharmaceutical industry in any country.

Manufacture of drugs. Image credit: Linkedin

PUNCH HealthWiseHowever, the company’s findings revealed that due to the excessive concentration of the Nigerian pharmaceutical sector on importing finished products, more and more pharmacists are focusing on the business side of pharmacy by focusing on the marketing and sale of drugs.

According to the United Nations COMTRADE, which is a global trade database, Nigeria imported drugs and pharmaceuticals worth N2.97 billion in 2020.

A previous analysis of PUNCH Financials, which refers to a dataset compiled by CEIC, a global data company, also noted that Nigeria imported medicinal and pharmaceutical products worth $417.523 million in 2020, more than the most African countries.

The Pharmaceutical Society of Nigeria, in 2019, estimated that more than 70% of drugs consumed in the country are imported, leaving local drug manufacturing industries at a disadvantage in the face of competition from foreign companies.

Commenting on this, a former PSN chairman, Sam Ohuabunwa, during an interview with HEALTH PUNCHsaid that despite some government intervention, the industry is still struggling to come together.

“A lot of people still depend on imports. We run the risk of not being able to achieve the targets that have been set regarding the ratio of locally and internationally manufactured medicines. We thought we had to master it.

As I speak to you, the estimate (of locally produced drugs) is around 40 or even only 30%.

It was difficult. For example, the intervention we received from CBN during this COVID time when CBN started to support long term funding for pharma investors even though financial support is not all we need but at least c was the right decision,” he told our correspondent.

All rights reserved. This material and any other digital content on this website may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without the prior express written permission of PUNCH.

Copyright PUNCH.

All rights reserved. This material and any other digital content on this website may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without the prior express written permission of PUNCH.

Contact: [email protected]

ladakh: Exchange of students from Ladakh tested by the weather | Ahmedabad News

Ahmedabad: Students from the University of Ladakh who are in Ahmedabad for a week on an exchange program have only one complaint about the city: it’s hot! Most of the 59 students and two teachers in the University of Ladakh delegation said they fell in love with Gujarati cuisine and culture, but felt grilled in the high temperatures of Ahmedabad.
Saturday was the last day of the delegation’s stay in Ahmedabad. The team had arrived here on May 9 after an exchange agreement between the University of Ladakh and the University of Gujarat. The Indian Institute of Sustainability hosted this delegation.
“We come from a very cold place and felt like we were boiled and roasted in the heat of Ahmedabad which reached 45C this week. Apart from that, we really enjoyed our stay in the city. People are very friendly. What I really enjoyed was the Gujarati food,” said Hajrabanu, one of the delegation members.
Zubair Abbasi, an MSc chemistry student, said when they left for Ahmedabad, the temperature in Ladakh was as low as 12-13C. “The heat here has been a shock to me and my comrades,” Abbasi said.
Salman Khan, who is pursuing a master’s degree in travel and tourism management, said he loves everything about Ahmedabad except for the summer heat. “During our visit to Amul in Anand, we learned a lot about the very successful cooperative structure of doing business,” Khan said. “At the University of Ladakh, the number of female students is 75% while male students are only 25%. Our delegation of 59 students consists of 44 female students,” said Salim, a professor of environmental science.
“The program was aimed at the exchange of knowledge between students from two different states. While University of Ladakh students have learned about business, our students who will travel to Ladakh to learn about medicinal plantations,” said Sudhanshu Jangir, Director of IIS.

Meet Irish beauty brands on a mission to make the planet feel as good as you do

While we all know the importance of taking care of yourself, it’s just as important to make sure you take care of the environment while using your favorite products.

From their ingredients, sources, methods and packaging, a number of pioneering brands based in Ireland have laid the groundwork to ensure we can do both.

Here we take a look at some of the brands that are breaking the mold and providing sustainable local products that are designed to take care of our minds, our bodies and the planet.

modern botany

When they first landed in Schull people thought John Murray and Dr Simon Jackson were ‘crazy’ but the west coast of Cork proved to be the perfect setting for their brand which is based on the use of natural ingredients.

The duo created Modern Botany in 2016. The idea was to create
a natural products company based on the principles of pharmacognosy, the study of medicinal compounds obtained from plants or other natural sources, according to Dr. Jackson’s professional background.

“We’re all about plants, the power of plants, and the healing power of plants,” says John, who is both co-founder and chief sustainability officer.

Backed by science and led by nature, Modern Botany offers a range of 100% natural products, from their popular multi-tasking oil to their unisex natural deodorant.

Modern Botany Multi-Tasking Oil

For them, sustainability means looking at all aspects of the life cycle of their products.

Their multi-tasking oil can be used for face, body, hair and nails and is suitable for all skin types, including babies and during pregnancy. With refillable packaging, there’s no waste with this complete solution for dry skin.

John and Simon have also experimented with growing some of their own ingredients.

“The big thing about being sustainable is that we’re constantly reviewing and reviewing it and how we can be a little smarter,” says John.

Their products are packaged in glass and after recently testing refillable options, this is something they hope to incorporate into more products to further reduce waste.

Well-being on the ground

Peigín Crowley of Ground Wellbeing.
Peigín Crowley of Ground Wellbeing.

Another Cork-based brand, Ground Wellbeing, focuses on “how you feel about how you look”, according to founder Peigín Crowley.

“Our focus on wellness is to manage everything from burnout to insomnia, from anxiety to gut health, to menopause,” she says.

With over 20 years of experience in the world of spas, Peigín’s concept for Ground Wellbeing was born out of the pandemic and the goal of making wellbeing more accessible.

Mindfulness and getting a good night’s sleep are paramount for the brand and its customers with products that nourish, replenish and encourage self-care rituals.

Their sleep gift sets are their best sellers and include natural body oils, pillow sprays, and face balms. Their Balancing CBD Balm is another favorite.

Ground Wellbeing Sleep Set
Ground Wellbeing Sleep Set

Ground Wellbeing also incorporates home wellness products and Peigín and the team are currently working on products for people undergoing cancer treatment.

Everything Peigín has done has been done with sustainability in mind, and its collection of face and body balms and oils are 100% natural, with an average of 50% organic ingredients.

They avoid all harmful chemicals, promoting natural and organic life.

100% vegan and cruelty-free, Ground Wellbeing also emphasizes plastic-free shipping. All of their boxes and pouches are also made from a PEFC (Programme for the Endorsement of Forest Certification) accredited board, and they are planning to develop other refill initiatives as well. Currently, they offer bath salt and pillow spray refills, encouraging a 30% savings.

The handmade soap company

As someone who worked outdoors with their hands every day, Donagh Quigley knew the importance of natural, caring hand soap.

In 2010, he and his wife, Gemma, started the Handmade Soap Company in their kitchen. Now based in a renovated former linen mill in Slane, County Meath, Handmade Soap Company has sustainability in its DNA.

As their name suggests, each product is handmade, with every ingredient carefully selected. All of their bottles are made from 100% post-consumer recycled (PCR) materials, made from recycled products and can be recycled again.

The Handmade Soap Company focuses on eco-friendly body care and wellness while incorporating home fragrances.

They recently launched their most sustainable line to date: ANAM. The product line uses lifetime glass bottles, to be filled by the first ever 100% compostable refill pouch for liquid soap. As soap can be acidic and corrosive over time, this was a tricky design to perfect.

The range includes hand soaps and lotions as well as body oils, diffusers, essential oils and candles.

Donagh Quigley of the Handmade Soap Company.
Donagh Quigley of the Handmade Soap Company.

For Donagh and Gemma, the goal is to be the “kindest body care brand in the world” and this concept guides everything they do.

“The way we want to change the world for our clients is to enhance and enhance those micro-moments of self-care,” says Donagh.

“Every time you’re done doing the dishes and just want to wash your hands, if you’re using one of our products…you raise your hands to smell them after washing them under the tap and you say simply: ‘it’s good’.”

marine body

Dr Helena McMahon is one of the co-founders of Seabody, a Co Kerry-based luxury beauty and wellness brand that fuses science and sustainability to create skincare and supplements.

These are powered by high-purity organic bioactive marine molecules that Seabody manufactures in-house, using zero-waste technologies.

Founded in 2018, Seabody is on its way to becoming fully circular.

“Our mission was really to create a beauty and wellness brand that sustainably harnesses the incredible health and regenerative powers of algae,” says Dr. Helena McMahon.

She describes seaweed as an “incredible resource” with many molecules locked away in seaweed that have incredible health benefits.

Their most popular products include the Glycan Enrich Moisturizer while the Aquasurge Day Serum also receives rave reviews.

Seabody Aquasurge Day Serum
Seabody Aquasurge Day Serum

From day one, sustainability has been an important part of Seabody. They have a zero waste manufacturing process where they isolate several molecules and compounds from algae and create a variety of products, all of which have particular applications.

But their efforts don’t stop on the inside, their packaging is made of glass and uses biodegradable, non-toxic ink while their boxes are FSC (Forest Stewardship Council) certified. This guarantees that the products come from responsibly managed forests.

Each of the founders is invested in the ocean and the health of the oceans.

“If you’re using a natural resource, you need to make sure you’re doing it in a sustainable and sensitive way,” says Helena.

“Ultimately, you want to contribute positively to ocean regeneration and ocean health. That’s really important to us.

Ripple effects of abortion restrictions confound miscarriage care

As the Supreme Court appears poised to return abortion regulation to the states, recent experience in Texas shows that medical care for miscarriages and dangerous ectopic pregnancies would also be at risk if restrictions become widespread. .

A Texas law passed last year lists several drugs as abortion-inducing drugs and largely bans their use for abortion after the seventh week of pregnancy. But two of those drugs, misoprostol and mifepristone, are the only drugs recommended in American College of Obstetricians and Gynecologists guidelines for treating a patient after an early pregnancy loss. The other miscarriage treatment is a procedure described as surgical uterine evacuation to remove pregnancy tissue – the same approach as for an abortion.

“The challenge is that treating an abortion and treating a miscarriage are exactly the same,” said Dr. Sarah Pragerprofessor of obstetrics and gynecology at the University of Washington in Seattle and an expert in early pregnancy loss.

Miscarriages occur in about 1 in 10 pregnancies. Some people experience pregnancy loss at home and don’t need any additional care, other than emotional support, said Dr. Tony Ogburn, who chairs the OB department. -GYN from the University of Texas-Rio Grande Valley School of Medicine. But in other situations, he said, providers may need to intervene to stop the bleeding and make sure no pregnancy tissue remains, as a protection against infection.

Dr. Lauren Thaxton, an obstetrician-gynecologist and assistant professor at Dell Medical School at the University of Texas at Austin, has heard of local patients who miscarried and couldn’t get a pharmacy to fill their misoprostol prescription. “The pharmacy said, ‘We don’t know whether or not you’re using this medication for abortion,'” she said..

Thaxton, who supervises obstetrics and gynecology residents who have seen these patients, said sometimes the prescribing clinic does intervene, but it takes longer for the patient to get the medication. Other times patients don’t report the problem and miscarry on their own, she says, but without medication they risk further bleeding.

Under another new abortion law in Texas, a person who “aids or abets” an abortion after heart activity can be detected, usually around six weeks, can be fined up to minus $10,000 per event. Anyone can bring a civil action, which poses a dilemma for doctors and other providers. How do they follow the latest guidelines when others — from medical professionals to friends and family members — may question their intent: are they helping treat a miscarriage or facilitating an abortion?

Sometimes patients don’t realize they’ve lost their pregnancy until they come in for a checkup and no heart activity can be detected, said Dr. Emily Briggs, a family doctor who gives birth at New Braunfels, Texas. At this point, the patient may choose to wait for the bleeding to begin and the pregnancy tissue to be naturally released, Briggs said. For some, it’s too difficult, given the emotions surrounding pregnancy loss, she said. Instead, the patient can choose medication or a surgical evacuation procedure, which Briggs says may be necessary anyway to prevent a patient from becoming septic if there is tissue left in the eye. ‘uterus.

But now in Texas, new laws are creating uncertainties that may deter some doctors and other providers from offering optimal miscarriage treatment.

These situations can create significant moral distress for patients and providers, said Bryn Esplin, bioethicist and assistant professor of medical training at the University of North Texas Health Sciences Center in Fort Worth. “Any law that creates reluctance for doctors to meet the standard of care for a patient has a cascade of adverse effects for both the patient and everyone else,” Esplin said.

This is an emotional and legal dilemma that potentially faces not only obstetricians and midwives, but also family physicians, emergency physicians, pharmacists and anyone else who may be involved in health care. pregnancy. And Ogburn, who noted he was speaking personally and not for medical school, worries fears about Texas laws have already delayed care.

“I wouldn’t say that’s true for our practice,” he said. “But I’ve certainly heard discussions among doctors that they’re very hesitant to do any kind of surgery until they’re absolutely sure it’s not a viable pregnancy – even if the amount of bleeding would warrant intervention because it is life threatening to the mother.”

John Seago, legislative director of Texas Right to Life, described this type of hesitation as “a terrible misunderstanding of the law.” Even before the two bills were passed, existing Texas law stated that the act was not an abortion if it involved the treatment of an ectopic pregnancy – which most often occurs when the pregnancy develops. into the fallopian tube — or to “remove a dead, unborn child whose death was caused by spontaneous abortion,” he said, pointing to the law. Another area of ​​Texas law cited by Seago provides an exception to state abortion restrictions if the mother’s life is in danger or she is at “serious risk of substantial impairment of a major bodily function” unless an abortion is performed.

“It’s a pro-life position to allow doctors to make these life-and-death decisions,” Seago said. “And that can mean, in certain circumstances, protecting the mother in that situation and the deceased child.”

But interpreting the laws still poses challenges to care. At least several Austin-area OB-GYNs received a letter from a pharmacy in late 2021 saying it would no longer refill the drug methotrexate for an ectopic pregnancy, citing recent Texas laws, the report said. Dr. Charlie Brown, an Austin-based obstetrician-gynecologist who provided a copy to KHN. Methotrexate is also listed in Texas law passed last year.

An ectopic pregnancy develops in about 2% of reported pregnancies. Methotrexate or surgery are the only two options listed in medical guidelines to prevent fallopian tubes from rupturing and causing dangerous bleeding.

“Ectopic pregnancies can kill people,” said Brown, district president of the American College of Obstetricians and Gynecologists, representing Texas.

Tom Mayo, a law professor at Southern Methodist University’s Dedman School of Law in Dallas, understands why some in Texas’ pharmaceutical community might be nervous. “The penalties are quite draconian,” he said, noting that someone could be found guilty of a crime.

However, Mayo said her reading of the law allows the use of methotrexate to treat an ectopic pregnancy. In addition, he said, other Texas statutes and Roe v. Wade provide an exception to allow abortion if the life of a pregnant person is in danger.

Because Texas laws include a stipulation that there must be an intent to induce an abortion, Mayo said he would advise physicians and other clinicians to closely document the rationale for medical care, whether to treat a miscarriage or an ectopic pregnancy.

But Prager thinks laws in Texas — and possibly soon elsewhere — could increase doctors’ vulnerability to medical malpractice lawsuits. Consider the patient whose miscarriage care is delayed and develops a serious infection and other complications, Prager said. “And they decide to file a malpractice suit,” she said. “They absolutely can do it.”

Texas providers are still adjusting to other ripple effects that affect patient care. Dr. Jennifer Liedtke, a family physician in Sweetwater, Texas, who delivers about 175 babies a year, no longer sends misoprostol prescriptions to the local Walmart. Since the new laws came into effect, Liedtke said, the pharmacist has repeatedly refused to supply the drug, citing the new law – despite Liedtke writing the prescription to treat a miscarriage. Walmart officials did not respond to multiple requests for comment.

Since pharmacists go through this Walmart, Liedtke decided to send these prescriptions to other pharmacies rather than trying to sort out the misunderstanding again each time.

“It’s hard to form a relationship to say, ‘Hey, look, I’m not using this for elective abortion,'” she said. “‘I’m just using it because it’s not a viable pregnancy.'”

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism on health issues. Along with policy analysis and polls, KHN is one of the three main operating programs of the KFF (Kaiser Family Foundation). KFF is an endowed non-profit organization providing information on health issues to the nation.

Subscribe to KHN’s free morning briefing.

Local ginger powder fails to meet labeling standards in KNUST investigation

Scientists from the Kwame Nkrumah University of Science and Technology want the Food and Drugs Authority to step up scrutiny of ginger powder sold in the market.

The appeal follows a study published in the journal Heliyon which found that all ginger powder made in Ghana failed to meet labeling standards. Only one of the three products made in Ghana has been registered with the FDA.

Ginger is essential in our homes, especially in the kitchen. Its use increased during the height of the covid-19 pandemic, as many perceived it to possess anti-Covid-19 activity, particularly in reducing lung inflammation.

This study aimed to know the quality of powdered ginger products in the Ghanaian market.

The samples were taken from three major markets in Ghana and consisted of three local and four foreign ginger powders.

Ghanaian samples failed to meet labeling requirements compared to other foreign brands, which met these standards.

Two of them had no manufacturer information, batch numbers and expiration dates and one completely without a label.

“The present research shows that local manufacturers of ginger powder in Ghana are not complying with the labeling requirements as stipulated by the regulations.

“Two of these local products were unregistered and by inference not institutionally monitored (as indicated by the lack of an FDA number) but sold in the market without restriction,” said Isaac Kingsley Amponsah of the Department of Pharmacognosy.

Again, scientists have not found significant levels of harmful bacteria, fungi, and toxic metals. “It is the responsibility of the country’s regulatory agency to ensure compliance with standards through periodic monitoring”

UM Natural Products Center celebrates the 20th Botanicals Forum – The Oxford Eagle

For the first time since 2019, the botanical industry traveled to Oxford this spring for the International Conference on the Science of Botany.

The conference, organized each year by the National Natural Products Research Center within the University of Mississippi School of Pharmacybrought together leading figures from industry, government officials and academics for a week of discussion and sharing of ideas on the ancient, but evolving, study of medicinal plants.

This year’s conference was the 20th edition of the ICSB, but the conference has been on hiatus since 2020, due to COVID-19 creating travel difficulties. Being able to hold the conference in person after the delay only increased the excitement, said Ikhlas KhanDirector of NCNPR and Distinguished Professor of Pharmacognosy.

“It was great to be together after a long break,” Khan said. “People were enthusiastic and energized on the level you can feel. Everyone felt that the agenda was filled with exciting discussions and that the discussions during the breaks were very stimulating. »

This enthusiasm showed as the conference was well attended with 238 in-person attendees. Presentations included speakers from companies and organizations such as American Botanical Council, United Natural Products Alliance and the US Food and Drug Administration.

Tieraona LowDog, an internationally recognized figure in the botanical industry and founding member of the American Board of Integrative Medicine, delivered the keynote address.

In addition to lively discussions, the conference also provided an opportunity to recognize the achievements of participants.

Such a person was Mahmoud El Sohly, a research professor at NCNPR and professor of pharmacy and drug administration, who received the Outstanding Contribution to Natural Products Award sponsored by Waters Corp. Since 1981, ElSohly has led the UM Marijuana Project and is one of the world’s leading authorities on cannabis research. His work has received wide recognition, including from mainstream media such as NBC’s “Today” show.

This year’s conference also saw the inaugural McChesney Lecture. Named for James D. McChesney, a former UM professor of pharmacy who was instrumental in founding NCNPR, the conference will serve as a platform for botanical industry players to share new research. innovative.

“I am very honored by this prestigious conference creating a conference in my name,” McChesney said. “I hope it can be a venue for communicating significant advances in research and development in botanical and natural product efforts.”

It was only fitting that the first speaker be McChesney himself, who is President and CEO of Cloaked Therapeutics LLC. His talk detailed his company’s efforts to improve the safety and effectiveness of cytotoxic chemotherapies, drugs that target cancer cells.

McChesney hopes future speakers will follow his lead in bringing new and innovative ideas to the table.

“I hope to see reports of innovative progress in understanding how plants and natural product substances can benefit humanity by thinking ‘outside the box,'” McChesney said.

As the conference reaches such a milestone, Khan reflected on how important the ICSB has become over the past two decades.

“It’s an important step to take,” Khan said. “ICSB has become a community of stakeholder meetings and plays an important role in bringing together academia, industry and government.”

Lawsuit Involving Drugmakers, Pharmacy Intermediaries Over High Insulin Prices Could Impact Ohioans | Ohio News | Cincinnati

Click to enlarge

Photo: Sam Moghadam Khamseh, Unsplash

The companies that make prescription drugs and the pharmacy middlemen who buy them were quick to blame themselves for inflating prices. But now they are accused of conspiring to raise the cost of insulin, a drug that saves the lives of many people with diabetes.

Arkansas Attorney General Leslie Rutledge made the allegations in a lawsuit that was filed Wednesday in state court.

And while it was filed there, it could have implications in Ohio and nationally.

High insulin prices are a controversy across the country. And Ohio and 45 other states have already joined Rutledge in a lawsuit over a state’s ability to regulate pharmacy intermediaries that in 2020 won an 8-0 U.S. Supreme Court victory.

“Thousands of Arkansans rely on insulin every day to live their best lives,” Rutledge said in a statement. “These drugmakers and PBMs have inflated the price of insulin and other diabetes-related drugs to line their pockets. They have endangered the lives of thousands of Arkansans and Americans, who simply cannot afford this life-saving medicine. Today we begin the fight to stop this outrageous insulin price inflation.

The lawsuit names drugmakers Eli Lilly, Novo Nordisk and Sanofi as defendants. It also appoints Intermediaries or Pharmacy Benefit Managers, CVS Caremark, OptumRx and Express Scripts.

Of those companies and their trade associations, only Eli Lilly immediately responded to a request for comment.

“Lilly is disappointed with the inaccurate claims about Lilly’s insulins made by the Arkansas Attorney General,” spokeswoman Molly McCully said in part.

The lawsuit points out that insulin has been around since the 1920s and in its synthetic form since the 1980s. But, instead of getting cheaper, the cost rose 1,527% nationwide between 1997 and 2018, according to the pursuit.

“Now it’s between $300 and $700,” Rutledge’s statement said. “While insulin costs hundreds of dollars to buy at pharmacies, it costs less than $2 to produce.”

The lawsuit centers on the secretive system by which manufacturers give discounts to intermediaries, who decide which drugs are covered by insurance and which are the cheapest for patients.

CVS, Optum and Express Scripts manage drug benefits for more than 70% of covered Americans. So if drugmakers want to sell their products to them, they have a strong incentive to do whatever it takes to get them on the Profit Managers, or PBM, formularies. In congressional hearings, PBM and drugmaker executives both said that providing fat rebates and other rebates to PBMs was the primary way to achieve this.

The Arkansas lawsuit cites a 2019 congressional hearing in which an Eli Lilly executive said 70% of the $210 “list price” of the insulin drug Humalog goes to PBMs as discounts and rebates.

Critics of drugmakers and PBMs say drugmakers are wildly inflating list prices to meet ever-increasing demands for PBM discounts while protecting their own profit margins. The Arkansas lawsuit says the scheme was hugely profitable for both industries, but by hiding it, the companies violated the state’s deceptive marketing practices law.

“In effect, manufacturers’ list prices have become so distant from manufacturers’ net prices that they constitute false and illegal prices,” the Arkansas lawsuit states.

She also accuses the defendants of explicit collusion.

Despite publicly blaming each other for raising list prices, the lawsuit says drugmakers Sanofi, Novo Nordisk and Eli Lilly act as “presidential sponsors” of an annual convention of industry group PBM, Pharmaceutical Care Management Association. These conferences facilitate private meetings between PBMs and drugmakers and were often quickly followed by “stepping up” increases in insulin list prices, according to the lawsuit.

And while some drugmakers and PBMs have denied that rebates and rebates have inflated list prices, a study by a team at the University of Southern California found that every $1 increase in rebates is correlated with a $1.17 increase in list prices.

Big PBMs may only pay a fraction of list prices, but they hit consumers hard.

Uninsured people may have to pay the full cost, while co-payments and deductibles may be a percentage of that. Additionally, PBMs operate through layers of obscurity that often prevent insurers and the government from knowing how much PBMs pocket from the rebates they obtain on behalf of payers.

Of course, everyone pays when drugs become more expensive, either in the form of co-payments, deductibles, or coinsurance, or in the form of higher insurance premiums and taxes to fund government programs like Medicare and Medicaid.

But McCully, Lilly’s spokeswoman, focused primarily on the expenses diabetic patients face at the pharmacy counter.

“These claims (from Arkansas) are particularly surprising given the multiple affordability solutions offered by Lilly – where anyone is eligible to purchase their monthly Lilly insulin prescription for $35 or less, regardless of the number of pens or vials, whether uninsured or uninsured, use commercial insurance, Medicaid or a participating Medicare Part D plan,” she said in an email.

She said the company supports reforms “such as shifting rebates directly to people who use insulin and limiting out-of-pocket costs, to move America’s healthcare system from a series of patchwork solutions to a change system that helps people access and pay for their insulin.”

McCully cited other steps Lilly has taken to make its insulin affordable to consumers.

“Today, despite increased insurance deductibles, the average monthly cost of Lilly insulin is $21.80, down 44% over the past five years. That translates to $7-10 per bottle and $2-3 per pen,” she said. “We have also reduced the list price of our most commonly used insulin (Humalog) by 70% – bringing the list price back to what it was in 2008 – by introducing our own non-branded equivalent and making it available for any plan. of health who wants to put it on their form.

However, the unbranded version of Humalog — one of the specific insulin drugs Arkansas is suing — still isn’t cheap. List price is $82.41 for an individual bottle.

This story was originally published by the Ohio Capital Journal and is republished here with permission.

Stay connected with CityBeat. Subscribe to our newsletters and follow us on Facebook, Instagram, TwitterGoogle News, Apple News and Reddit.

Send CityBeat a news or story tip or submit a calendar event.

Global Drug Discovery Services Market Forecast to 2027 – Growth Potential Associated with Patent Expiration – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Drug Discovery Services Market Research Report by Type, Drug Type, Process, Therapeutic Area, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to from ResearchAndMarkets.com offer.

The global drug discovery services market size was estimated to be USD 11.71 billion in 2021, USD 13.32 billion in 2022, and is expected to grow at a compound annual growth rate (CAGR) of 13.94% for reach USD 25.63 billion by 2027.

The report categorizes drug discovery services to forecast revenue and analyze trends in each of the following submarkets:

  • On the basis of type, the market has been studied into biology services, drug metabolism and pharmacokinetics, and medicinal chemistry services.

  • On the basis of drug type, the market has been studied across biologic drugs and small molecule drugs.

  • Based on the process, the market was studied through candidate validation, outcome identification, lead optimization, target selection and target validation.

  • Based on therapeutic area, the market has been studied in cardiovascular diseases, digestive system diseases, neurology, and oncology.

  • Based on region, the market has been studied in Americas, Asia-Pacific, Europe, Middle East & Africa.

Market dynamics

  • Drivers

    • Growth in R&D investments in the pharmaceutical and biopharmaceutical industry

    • Attractive Increase in Demand for Outsourcing Analytical Testing and Clinical Trial Services

    • Research on rare diseases and orphan drugs

  • Constraints

    • Expensive drug discovery and development

  • Opportunities

    • Development in biologics and focus on drug discovery

    • Potential related to the expiration of patents

  • Challenges

    • Strict government rules for drug discovery and animal use

  • Cumulative impact of COVID-19

  • Cumulative impact of the 2022 Russian-Ukrainian conflict

Market share analysis:

The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

The report provides information on the following:

  • Market Penetration: Comprehensive market insights offered by major players

  • Market development: detailed information on lucrative emerging markets and penetration analysis in mature market segments

  • Market diversification: detailed information on new product launches, untapped geographies, recent developments and investments

  • Competitive assessment and intelligence: assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape and manufacturing capabilities of key players

  • Product development and innovation: intelligent information on future technologies, R&D activities and breakthrough product developments

The report answers questions such as:

  • What is the market size and forecast of the global drug discovery services market?

  • What are the inhibiting factors and impact of COVID-19 on the global drug discovery services market during the forecast period?

  • What are the products/segments/applications/areas to invest in during the forecast period in the global drug discovery services market?

  • What is the competitive strategic window for opportunities in the Global Drug Discovery Services Market?

  • What are the technology trends and regulatory frameworks in the global Drug Discovery Services market?

  • What is the market share of the top vendors in the global drug discovery services market?

  • What modes and strategic moves are considered suitable for entering the global drug discovery services market?

Main topics covered:

1. Preface

2. Research methodology

3. Executive Summary

4. Market Overview

5. Market Overview

6. Drug Discovery Services Market, By Type

6.1. Introduction

6.2. Biology services

6.3. Drug metabolism and pharmacokinetics

6.4. Medicinal Chemistry Services

7. Drug Discovery Services Market, By Drug Type

7.1. Introduction

7.2. Biological drugs

7.3. Small molecule drugs

8. Drug Discovery Services Market, By Process

8.1. Introduction

8.2. Validation of candidates

8.3. Hit-To-Lead Identification

8.4. Lead Optimization

8.5. Target selection

8.6. Target validation

9. Drug Discovery Services Market, By Therapeutic Area

9.1. Introduction

9.2. Cardiovascular illnesses

9.3. Diseases of the digestive system

9.4. Neurology

9.5. Oncology

10. Americas Drug Discovery Services Market

11. Asia Pacific Drug Discovery Services Market

12. Europe, Middle East and Africa Drug Discovery Services Market

13. Competitive Landscape

13.1. FPNV positioning matrix

13.2. Market Ranking Analysis

13.3. Market share analysis, by key player

13.4. Competitive scenario

14. Company Usability Profiles

  • Albany Molecular Research

  • Aurigen Discovery Technologies

  • Charles River Laboratories

  • Chempartner

  • Domains

  • Eurofins Scientific

  • Evotec

  • Facade

  • Genscript Biotech Corporation

  • Jubilant Life Sciences

  • Laboratory Corporation of America Holdings

  • Development of pharmaceutical products

  • Piramale Companies

  • Selvita

  • Shanghai Medicilon

  • Syngene International

  • TCG Lifesciences Pvt.

  • Thermo Fisher Scientific

  • Viva Biotech

  • Apptec Wuxi

For more information on this report, visit https://www.researchandmarkets.com/r/sjtbm2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

The Center for Natural Products celebrates the 20th Botanical Forum

James McChesney, CEO of Cloaked Therapeutics LLC, discusses his company’s development of new drugs to target cancer cells during the McChesney Inaugural Lecture at the 20th ICSB. Photo by Whitney Tarpy/UM School of Pharmacy

OXFORD, Mississippi — For the first time since 2019, the botany industry traveled to Oxford this spring for the International Conference on the Science of Botany.

The conference, hosted annually by the National Center for Natural Products Research within the University of Mississippi School of Pharmacy, brought together leading industry figures, government officials and academics for a week of discussion and sharing ideas about the old, but evolving, drug study. plants.

This year’s conference was the 20th edition of the ICSB, but has been on hiatus since 2020, due to COVID-19 creating travel difficulties. Being able to hold the conference in person after the delay only increased the excitement, said Ikhlas Khan, director of NCNPR and a distinguished professor of pharmacognosy.

“It was great to be together after a long break,” Khan said. “People were enthusiastic and energized on the level you can feel. Everyone felt that the agenda was filled with exciting discussions and that the discussions during the breaks were very stimulating. »

This enthusiasm showed as the conference was well attended with 238 in-person attendees. Presentations included speakers from companies and organizations such as the American Botanical Council, United Natural Products Alliance and the United States Food and Drug Administration.

Mahmoud ElSohly, professor of pharmacy and drug administration at UM and director of the Marijuana Project, receives the award for outstanding contribution to natural products during the 20th ICSB. Photo by Whitney Tarpy/UM School of Pharmacy

Tieraona LowDog, an internationally recognized figure in the botanical industry and founding member of the American Board of Integrative Medicine, delivered the keynote address.

In addition to lively discussions, the conference also provided an opportunity to recognize the achievements of participants.

One such individual was Mahmoud ElSohly, a research professor at NCNPR and professor of pharmacy and drug administration, who received the Waters Corp-sponsored Outstanding Contribution to Natural Products Award. Since 1981, ElSohly has led the UM Marijuana Project and is one of the world leaders. cannabis research authorities. His work has received wide recognition, including from mainstream media such as NBC’s “Today” show.

This year’s conference also saw the inaugural McChesney Lecture. Named for James D. McChesney, a former UM professor of pharmacy who was instrumental in founding NCNPR, the conference will serve as a platform for botanical industry players to share new research. innovative.

“I am very honored by this prestigious conference creating a conference in my name,” McChesney said. “I hope it can be a venue for communicating significant advances in research and development in botanical and natural product efforts.”

It was only fitting that the first speaker be McChesney himself, who is President and CEO of Cloaked Therapeutics LLC. His talk detailed his company’s efforts to improve the safety and effectiveness of cytotoxic chemotherapies, drugs that target cancer cells.

McChesney hopes future speakers will follow his lead in bringing new and innovative ideas to the table.

“I hope to see reports of innovative progress in understanding how plants and natural product substances can benefit humanity by thinking ‘outside the box,'” McChesney said.

As the conference reaches such a milestone, Khan reflected on how important the ICSB has become over the past two decades.

“It’s an important step to take,” Khan said. “ICSB has become a community of stakeholder meetings and plays an important role in bringing together academia, industry and government.”

The Belarusian economy in full structural transformation

MINSK, May 12 (BelTA) — The Belarusian economy is going through a structural transformation. Belarusian Economy Minister Aleksandr Chervyakov made the statement when asked about the performance of the economy in January-April 2022 after a session of the House of Representatives of the National Assembly, BelTA learned.

Aleksandr Chervyakov stressed that the economy was working steadily. The government analyzes the situation in all branches of the economy and all regions of the country 24 hours a day, 7 days a week. Issues are reviewed promptly and decisions are made. Particular attention is paid to large GDP-generating companies and local economic pillars.

The official said: “MAZ, MTZ, BelAZ, Gomselmash, Minsk Engine Plant and our other flagships are operating at full capacity. Their backlog will last at least 3-4 months. Apart from this, new data from the polls that our economic institute conducts every month indicate favorable changes in the dynamics of industrial optimism index, level of demand, workload and production figures. . This means that respondents see their short-term development in a positive light.

The Economy Minister went on to say, “Undoubtedly, the unprecedented sanctions are impacting the functioning of our businesses by limiting their access to target markets, limiting the acquisition of individual components and raw materials. Trade with Ukraine has been completely halted and Ukraine accounted for 11% of our exports last year. Our companies are busy redirecting exports to the markets of the Russian Federation, China and other friendly countries. New logistics routes are being built.

In January-April 2022, Belarus’ GDP is expected to slow down by no more than 2% from last year’s level. The industries affected by the sanctions make a substantial negative contribution. As for the manufacturing sector, the traditional earners are food producers, manufacturers of transport solutions, woodworking, pharmaceuticals, electronics and others.

According to the source, despite the late spring, Belarusian farmers are successfully carrying out sowing and planting. The amount of fertilizer applied will be increased by a third compared to last year. State-run agricultural enterprises are supplied with fuel and phytosanitary products, and their vehicles and machinery are well maintained. All this creates a basis for a good harvest and good annual performance figures, said Aleksandr Chervyakov. Housing construction is ahead of forecasts. Hard work is underway to export civil engineering services to the Russian Federation – export volume increased by 13% in the first quarter of 2022.

As for the sphere of services, the computer industry and the retail trade continue to grow. After the surge in demand for sugar, cereals, butter and other products in April, the situation in the consumer market has stabilized. Passenger turnover increased, in particular to the Russian Federation, after the lifting of restrictions related to COVID-19. New destinations in the south direction and southeast direction are explored.

Regarding foreign trade, in the first quarter of 2022, exports increased by $0.5 billion or 5%. The export surplus is at an all-time high – nearly $1 billion, including $1.2 billion from service exports. The main incomes were the food industry, transport manufacturers, the wood industry and the metallurgical industry. With regard to the sphere of services, the main incomes are the IT industry, transport and financial services.

Aleksandr Chervyakov said: “People should not feel the effect of sanctions. This is a priority task for the government. To do this, it is necessary to compensate underperforming industries, which are affected by external restrictions. A clear algorithm of our actions has been worked out. We understand that the Belarusian economy is going through a structural transformation. Supply chains are reworked as well as target markets and acquisition markets. The share of the US dollar and the euro is decreasing in the trading system while the share of the Russian ruble and the Belarusian ruble is increasing. Imported components and raw materials are replaced by domestic products from friendly countries. There are problems of underdeveloped infrastructure in new transport destinations, which prevent a drastic increase in transport volumes. All of this can be improved. It takes time to rethink the whole economic mechanism. What matters is that companies continue to work, keep people in employment, pay salaries while the State honors its social commitments”, underlined the Minister of Economy.

Stealth privatization of Medicare is a boon for Wall Street

The Joe Biden administration’s recent entrenchment and expansion of the Donald Trump administration’s efforts to privatize Medicare helps an obscure group of big business beneficiaries: private equity firms and large healthcare, including one that previously employed the government official overseeing the privatization plan, new analysis from us shows.

In April last year, the Biden administration contracted fifty-three third-party companies to mandate privatized health care plans through Medicare. The resulting healthcare options are effectively Medicare Advantage plans, or private coverage offered by National Health Insurance for the elderly and disabled – but with a twist: patients are assigned to these new plans without their consent.

The fifty-three participating companies — called “direct contracting entities,” or DCEs — are authorized to offer benefits beyond traditional health insurance, such as gym membership coverage. But as for-profit companies that receive a fixed payment from Medicare regardless of the amount of care they approve, these DCEs have an incentive to limit the care patients receive, especially when they are very sick. . The first DCEs were launched by President Donald Trump in 2019, and so far at least 350,000 seniors have already been transferred to these privatized health insurance plans.

However, a new analysis that we have made of the fifty-three DCEs has revealed an additional source of concern: fifteen of these entities, or just over a quarter, are backed by private equity firms, known to extract profits at the expense of workers, the environment, and even their own pension fund investors. Companies include well-known companies such as the Carlyle Group, General Atlantic, Clayton, Dubilier & Rice, Benchmark Capital and Warburg Pincus. Additionally, fifteen other DCEs are tied to major health care companies — including one with a direct link to the Biden appointee in charge of the new privatized Medicare plan.

Wall Street’s encroachment on Medicare is the latest example of the aggressive expansion of private equity into health care, which ranges from hospitals to emergency physician groups. In 2021, private equity managers deployed $172 billion in capital into the healthcare sector, nearly four times the total budget of the National Institutes of Health.

Biden himself lambasted the for-profit industry’s takeover of aged care services, noting during his State of the Union Address in March: “As Wall Street corporations take over more nursing homes, the quality of those homes has gone down and costs have gone up. It ends on my watch.

Biden apparently doesn’t have the same worries about Wall Street’s growing role in Medicare — a development that could lead to higher medical bills for patients. The financial industry has already demonstrated its willingness to take an aggressive approach to generating healthcare profits. private equity waged an aggressive campaign to derail legislation designed to stop so-called “surprise” medical bills, which were a significant part of their hospital staffing companies’ bottom line.

Now, as private equity strengthens in Medicare privatization, industry lobbyists are likely to push for more generous payment structures that benefit for-profit companies at the expense of Medicare patients. The Medicare Payment Advisory Commission, an independent body that advises Congress on Medicare, hinted at this scenario while discussing the role of private equity in the Medicare Advantage space during a hearing in April 2021.

“The end result might or might not be better for consumers, but I think it impacts Medicare payment policy,” Commissioner Pat Wang said.

Experts fear that the Medicare space is particularly vulnerable to Wall Street’s predatory approach.

“We have ample evidence of many other situations in which private equity puts profits ahead of patients,” said Eileen Appelbaum, co-director of the Center for Economic and Policy Research and co-author of Private Equity at Work: When Wall Street Runs Main Street. “They’re looking for a place where it’s easy to make money – and it’s easy to make money when the taxpayer pays the bill.”

While the ECD program was launched under President Trump, Biden expanded the effort in February under a new name: the Accountable Care Organization Realizing Equity, Access, and Community Health, or “ACO REACH” program. Now, for-profit, hospital-supported health benefit programs are also allowed to automatically enroll Medicare patients into their health care plans.

Like providers of Medicare Advantage plans, these new companies receive a fixed payment from Medicare for their offerings, supposedly to incentivize more holistic, higher-quality care. In exchange, these companies acquire Medicare patients into their plans — often without the patients realizing what’s going on.

In March, we reported how a Medicare beneficiary who was quietly assigned to an ELD initially misinterpreted a message she received about the change as a health-related communication from her doctor — though she is an experienced health policy expert.

In addition to the fifteen private equity-backed companies, the list of DCEs approved by the Biden administration published in April 2021 includes fifteen operations owned by healthcare giants, such as insurers Humana, UnitedHealth and Anthem, the pharmacy chain Walgreens and the dialysis provider. DaVita.

Experts say these connections raise serious questions about conflicts of interest. For example, the DCE program is run by a little-known federal entity, the Centers for Medicare & Medicaid Services (CMS) Innovation Center, headed by Liz Fowler — the former vice president of public policy at the now well-known insurer WellPoint. as Hymn.

In response to our request for comments, a CMS spokesperson said Fowler was not involved in the ELD approval process. They further claimed that many of the entities we have identified are not backed by private equity because they are public companies.

But several of these public companies have received substantial investments from private equity firms, also known as “private investments in public funds”. For example, while 1LifeHealthcare — a primary care provider that owns one of the DCEs, One Medical’s Iora Health — is publicly traded, leading private equity firm Carlyle Group owns more than 7% of its shares.

Critics say Fowler has a history of crafting politics to help his contacts in the private sector.

“Honestly, it just seems to add to the pattern we’ve seen with Liz Fowler,” said Fatou Ndiaye, research assistant at the Revolving Door Project, which monitors the revolving door between the public and private sectors.

Ndiaye pointed out that before lobbying for WellPoint, Fowler worked for Sen. Max Baucus (D-MT), where she helped draft Medicare Part D, a program that critics say was a huge giveaway for the state. pharmaceutical industry because it created massive new benefits for drugs without controlling prices.

After working for Wellpoint from 2006 to 2008, Fowler joined the staff of Baucus, where she helped draft a version of the Affordable Care Act (ACA) that excluded the public health insurance option promised by Democrats. , resulting in huge profits and no competition from the public sector to the private sector. insurers.

” One year later [ACA’s] passage, Wellpoint’s profits increased 91% to $2.3 billion,” Ndiaye said.

The fact that private equity now backs more than a quarter of all companies in the DCE space stands in stark contrast to the fact that private equity owns only 2% of all for-profit Medicare Advantage programs.

While Medicare Advantage options have been criticized by health advocates for their extremely high costs, the focus of private equity on this new type of non-voluntary, privatized Medicare plan suggests that Fowler and the Biden administration could pave the way for much larger projects. involvement of private equity in the national health insurance program.

Examples abound of the problems that arise when private equity supports healthcare operations. Just last month, News reported that BrightSpring, a group home operator acquired by mega-private equity firm KKR in 2019, has since been plagued by serious issues at its group homes for people with disabilities, resulting in serious injuries and in some cases , the death of residents.

The Carlyle Group, which owns a stake in OneMedical, the parent company of Iora Health, has a particularly troubling history in healthcare. After Carlyle acquired HCR Manorcare, a chain of nursing homes, the company was plagued with serious shortcomings in standards of care until it went bankrupt eleven years later.

Other private equity-backed deals approved for the new DCE program have major ties to the Democratic Party establishment. Private equity firm Warburg Pincus, which backs a DCE called Excelera, was co-founded by the current secretary of state’s father Antony Blinken and counts former Barack Obama Treasury Secretary Tim Geithner among its chairmen.

Laura Katz Olson, professor at Lehigh University and author of the recently published book Ethical Challenge: Private Equity Is Taking U.S. Health Care By Storm, said the role of private equity in Medicare privatization raises significant concerns.

“If you understand the private equity playbook, the dangers are pretty obvious,” Katz Olson said. “They borrow money to pay off their debts. They take money out of their pockets through fees. It would take a magician to maintain the quality of care by doing all of these things.

She added, “Private equity is bad for health care, period, so I can’t imagine it would be good for Medicare Advantage. I’m actually in a state of surprise that they even think about it.

Nigeria has yet to harness the power of herbal medicine

The Vice Chancellor of the University of Medical Sciences (UNIMED), Ondo City, Ondo State, Prof. Adesegun Fatusi said on Wednesday that Nigeria has yet to unlock and harness the potential of herbal medicine.

Fatusi said so at a one-day symposium titled ‘Phytotherapy: The Past, Present and Future’, hosted by the University’s Center for Herbal Medicine and Drug Development, which will is held at the school’s Laje campus.

Fatusi noted that Nigeria will have to make a deliberate effort to promote herbal medicine, saying the power of science and the potential of herbs can make a difference in the country’s health sector.

He said: “We haven’t tapped into our God given heritage in the fields of herbs and what our ancestors did, but UNIMED is starting to reverse history and this moment is that golden moment, this workshop opens up this opportunity to crystallize our vision and lead the Nigerian nation to understand the power of science fused with the power of herbs, making all the difference not only to health but also to the economy.

He said the University’s dream of starting a bachelor’s degree program in herbal medicine has been cut short by the absence of the National Universities Commission (NUC) Benchmark Minimum Academic Standard (BMAS), now known as Core Curriculum and Minimum Academic Standard (CCMAS) for the program.

“We have always had a big dream about herbal medicine in UNIMED since our foundation. UNIMED had even offered to start a B.Sc. program in herbal medicine, but the fact that there was no BMAS minimum standard with NUC has blocked the whole process, which shows you how passionate we are about the program,”

He said UNIMED was working with NUC and other stakeholders to get a CCMAS approved to launch the program and said “there are great days ahead for our Center for Plant and Drug Discovery, and with the imminent arrival of our faculty of pharmacy, they will be complementary to each other.

“So we’re driving the herbal medicine agenda like no one else has in this country, that’s one of the benefits of being a specialist medical university,”

The keynote speaker, Director of the Research and Development Center of the Federal University of Technology Akure (FUTA), Prof. Ganiyu Oboh said that the practice of herbal medicine is the oldest form of health care and that the human being had survived in nature until nourishing, treating and preventing diseases.

“The future of herbal medicine is an inevitable integration into modern medical practice and this can only be achieved when there is proper collaboration between government and all actors involved in the delivery of healthcare,” he said. -he declares.

Oboh noted that strict monitoring and implementation of regulatory guidelines to reduce the undue proliferation of natural products, the use and sale of herbal remedies must be put in place.

The Dean of the School of Public Health, UNIMED, Ondo, Professor Wasiu Adebimpe, while delivering an article titled “Public Health Concerns and Agenda for Integrating Herbal Medicine into the National Health System”, stressed the need to integrate phytotherapy and modern medicine. Medication.

He said: “The use of traditional medical knowledge for drug development without the consent of the customary knowledge holders is not acceptable under international law, hence the need to regulate the practice and practitioners, it must be able to distinguish qualified practitioners and practices. ”

The Director, Office of Strategy and Program Management, UNIMED, Ondo, Professor Adeduro Adegeye, in the last part of the symposium, spoke about “the economics of herbal medicine”.

He noted that countries like China and India are prospering economically through herbal medicine, saying that Nigeria has been blessed with many herbs that can improve the economic output of the country.


Earlier, the Acting Director of the Center for Herbal Medicine and Drug Development, UNIMED, Ondo, Dr. Babawale Olatunji, in his welcome speech, said that the vision of the center is to be a center of study serving as reference center and standard place to study. traditional medicine in Nigeria and around the world, which will be an effective bridge between orthodox medicine and herbal medicine in the delivery of health services to the majority of the population.

“Our goal is to provide rudimentary knowledge through training in herbal medicine to a wide range of people who will be able to provide health care services in collaboration with orthodox medicine providers or alone,” said Dr. Olatunji .

Dignitaries present at the event included DVC, Administration and Clinical Services, UNIMED, Ondo, Prof. Adolphus Loto; DVC, Academic, UNIMED, Ondo, Prof. Roseangela Nwuba; the Registrar, represented by the Deputy Registrar, Ms. Bola Arowosegbe and the University Librarian, Mr. Femi Folorunso.

Others who joined virtually included Steward, UNIMED, Ondo, Mr. MSO Shittu; Former member of the UNIMED Board of Directors, Prof. Tolu Odugbemi; Professor Anthony Elujoba; Professor Olukemi A. Odukoya; Professor Yemisi Kunle; and a professor of pharmacognosy, Professor Jones Moody among others.


Revealed! Details of APC South West leaders’ meeting with presidential candidates

Sprint Bioscience Appoints Scientific Advisory Board

“We are very pleased to have succeeded in attracting some of the world’s leading cancer experts. Their strong academic and industry experience as well as their deep expertise in preclinical research will be a great asset to us, both in projects specific that in terms of alongside the work of our newly formed Scientific Advisory Board, our collaborations with the academy continue, including the collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet,” said Erik KinmanCEO of Sprint Biosciences.

The Scientific Council consists of:

Gunilla Enblad – Professor of Oncology at Uppsala University since 2013 and Chief Medical Officer at Uppsala University Hospital. Her research areas include clinical and tumor biological studies of malignant lymphomas, as well as immunotherapy, including clinical studies of CAR T-cells. XNK-therapeutics and Elicera Therapeutics. She is a member of the board of directors of cancer foundation and the Department of Immunology, Genetics and Pathology to Uppsala University. Since 2017, she is also a member of the Royal Swedish Society of Sciences in Upsala.

Robert J De Vita – Principal consultant of RJD Med Chem and Drug Discovery Consulting LLC since 2013. He has over 30 years of experience in drug discovery and development in biotechnology, pharmaceutical industry and academia. To Merck Research Laboratories, he served as Director of Medicinal Chemistry and led 6 different programs that delivered drug candidates for further clinical development, several of which reached human clinical trials. He was also Vice President, Chemistry at Agios, a company focused on early oncology drug development. For the past 10 years, he has led a medicinal chemistry consulting firm and supported other corporate clients in all phases of drug development, including intellectual property strategy and due diligence as part of license agreements. He is also a member of the medicinal chemistry division of the American chemical societyserving in a variety of leadership roles.

Lewis C. Cantley – Professor at the Dana Farber Cancer Institute. A cell biologist and biochemist, he made groundbreaking discoveries in the field of cancer metabolism. Among his most notable contributions is the discovery and study of the enzyme PI-3 kinase, which is important in diseases such as cancer and diabetes. He was previously Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He has also held professorships in the departments of systems biology and medicine at Harvard Medical School and director of Research against cancer to Beth Israel Deaconess Medical Center in Boston. Professor Cantley is also a co-founder of several oncology-focused biotechnology companies, including Agios Pharmaceuticals, Petra Pharma and Volastra Therapeutics. In 2016, he was elected Chairman of the Board of Directors of Cancer Research Hope Fund and has received several scientific awards for his research over the years.

Raman Spectroscopy Market Size and Forecast

New Jersey, United States – Comprehensive analyzes of the fastest growing companies Raman Spectroscopy Market provide information that helps stakeholders identify opportunities and challenges. The 2022 markets could be another big year for Raman spectroscopy. This report provides an overview of the company’s activities and financial situation (a company profile is required if you want to raise capital or attract investors), recent developments (mergers and acquisitions) and recent SWOT analyses. This report focuses on the Raman spectroscopy market over the assessment period 2029. The report also provides an analysis of the growth of the Raman spectroscopy market which includes Porter’s five factor analysis and analysis of the supply chain.

It describes the behavior of the industry. It also outlines a future direction that will help companies and other stakeholders make informed decisions that will ensure strong returns for years to come. The report provides a practical overview of the global market and its changing environment to help readers make informed decisions about market projects. This report focuses on growth opportunities that allow the market to expand its operations in existing markets.

For more information or query or customization before buying, visit @ https://www.verifiedmarketreports.com/product/global-raman-spectroscopy-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024/

(Use company email id to get higher priority)

The report helps both major players and new entrants to analyze the market in depth. This helps key players determine their business strategy and set goals. The report provides key market insights including niche growth opportunities along with market size, growth rate and forecast in key regions and countries.

The Raman Spectroscopy report contains data based on rigorous studies in primary and secondary schools using the best research practices. The report contains exhaustive information which will enable you to evaluate each segment of the Raman Spectroscopy market. This report has been prepared considering various aspects of market research and analysis. It includes market size estimates, market dynamics, and company and market best practices. Entry marketing strategy, positioning, segmentation, competitive landscape and economic forecasts. Industry-specific technology solutions, roadmap analysis, alignment to key buying criteria, in-depth vendor product benchmarking

Key Players Mentioned in the Raman Spectroscopy Market Research Report:

Horiba Jobin Yvon, Renishaw, Thermo, B&W Tek, Bruker, Kaiser Optical, Ocean Optics, Smiths Detection, JASCO, Sciaps, TSI, Agilent Technologies, Zolix, GangDong

Raman Spectroscopy Market Segmentation:

By Product Type, the market is primarily split into:

• Benchtop Raman spectroscopy
• Portable Raman spectroscopy

By application, this report covers the following segments:

• Pharmaceutical
• R&D in academia
• Industrial sector
• Others

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketreports.com/download-sample/?rid=46412

Scope of Raman Spectroscopy Market Report

UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Geographic segment covered in the report:

The Raman Spectroscopy report provides information about the market area, which is sub-divided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country and sub-region over the estimated period.

• North America (USA and Canada)
• Europe (UK, Germany, France and rest of Europe)
• Asia-Pacific (China, Japan, India and the rest of the Asia-Pacific region)
• Latin America (Brazil, Mexico and rest of Latin America)
• Middle East and Africa (GCC and Rest of Middle East and Africa)

Key questions answered in this Raman Spectroscopy Market report

  1. How much revenue will the Raman Spectroscopy market generate by the end of the forecast period?
  2. Which market segment is expected to have the maximum market share?
  3. What are the influencing factors and their impact on the Raman Spectroscopy market?
  4. Which regions are currently contributing the maximum share of the global Raman spectroscopy market?
  5. Which indicators are likely to drive the Raman Spectroscopy market?
  6. What are the key strategies of the major Raman Spectroscopy market players to expand their geographical presence?
  7. What are the key advancements in the Raman Spectroscopy market?
  8. How are regulatory standards affecting the Raman spectroscopy market?

Get a discount on the purchase of this report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=46412

Visualize Raman Spectroscopy Market Using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and results with built-in presentation functionality that saves you over 70% of your time and resources for presentations to investors, sales and marketing, R&D, and product development. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the Raman Spectroscopy Market Using [email protected] https://www.verifiedmarketresearch.com/vmintelligence/

Most Popular Reports

Global Fully Automatic Inserting Market Size and Forecast

Global Radome Market Size and Forecast

Global 3D Metrology System Market Size and Forecast

Global Digital Microscope Market Size and Forecast

Global Microscope Lighting Market Size and Forecast

Global Counter-UAV Market Size and Forecast

Global Raman Spectroscopy Market Size and Forecast

Global Industrial Monitors Market Size and Forecast

Global Gas Pipe Fittings Market Size and Forecast

Global Cloud Robotics Market Size and Forecast

About Us: Verified Market Reports

Verified Market Reports is a leading global research and advisory company serving over 5000 global clients. We provide advanced analytical research solutions while delivering information-enriched research studies.

We also provide insight into the strategic and growth analytics and data needed to achieve business goals and critical revenue decisions.

Our 250 analysts and SMEs offer a high level of expertise in data collection and governance using industry techniques to collect and analyze data on over 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Our research spans a multitude of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage, and more. Having served many Fortune 2000 organizations, we bring a wealth of reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

E-mail: [email protected]

Website: – https://www.verifiedmarketreports.com/

editorial | New York must protect safety net services to end the HIV/AIDS crisis

The HIV/AIDS crisis is not over in New York City, and efforts to eradicate new infections – already delayed by the coronavirus pandemic – are jeopardized by an outdated plan to starve community providers who care for vulnerable patients from an essential funding stream.

Early in the pandemic, disgraced former Governor Andrew Cuomo proposed a plan to remove prescription drug coverage from the Medicaid drug benefit program. If this plan is implemented, the social safety net mechanisms supporting 2.3 million New Yorkersof which 71% are people of color and 89% are low-income, will be forced to reduce services and possibly close altogether.

This will have a devastating impact on people living with HIV/AIDS – a virus that disproportionately affects people of color. According to data from the New York City Department of Health and Mental Hygiene, rates of new HIV diagnoses among blacks and Latinos were 8.1 and 3.9 times higher, respectively, that the rate for whites.

For 30 years, the Medicaid Pharmacy Program, known as 340B, has enabled safety net providers to purchase medicines at discounted prices and use the savings to fund other programs for vulnerable patients, such as the provision of food, housing assistance and transportation, to to name a few. The 340B program enables safety net providers to provide vital support to patients, the majority of whom are low-income and people of color, at no cost to taxpayers.

If Cuomo’s exclusion goes into effect, safety net clinics would lose access to more than $100 million in annual funding, nearly 80% of health centers would lay off or lay off staff and at least 32 community clinics would be forced to close entirely, according to a survey by the Community Health Care Association of New York.

The recently passed state budget was a missed opportunity to permanently repeal Cuomo’s exclusion. But there is still time to right this wrong by passing and signing the legislation we have introduced in our respective chambers to protect the funding of safety net providers.

We both know these changes would be devastating to many people in the communities we represent as well as thousands of others across the state, including the health clinics that are critical to reducing new HIV cases. . Governor Kathy Hochul has committed to end the HIV epidemic by 2024 – the deadline 2020 already delayed by two years due to the challenges created by the COVID-19 crisis. She certainly won’t be able to achieve that goal if she allows Cuomo’s carve-out to go ahead.

One of the first rules of good government and good health care policy is that when you find something that works, don’t do it. Cuomo’s exclusion is a good example of bad policy that shouldn’t happen. Governor Hochul must work with state lawmakers to end this repeal before the end of the legislative session next month.

Linda B. Rosenthal, Member of the Assembly, is Chair of the Committee on Social Services. She represents the 67and Assembly District, which includes the Upper West Side and Hell’s Kitchen. State Senator Cordell Cleare represents District 30, which includes Harlem, Morningside Heights and Washington Heights.

Federal Litigation Update and Pharmacy Benefits Managers Proposed Rule – Employee Benefits and Compensation

To print this article, all you need to do is be registered or log in to Mondaq.com.

Court strikes down CMS Hospital salary level settlement

On March 2, 2022, the United States District Court for the District of Columbia ruled in favor of a hospital group challenging the 2019 “Low Wage Index Hospital Policy” adopted by Health and Human Services (“ HHS”). The settlement was intended to address wage disparities among hospitals by increasing the amount that hospitals in certain low-wage geographic areas receive in Medicare reimbursement while offsetting that increase by reducing reimbursements for all hospitals.

The hospital group alleged that this policy would ultimately result in reduced Medicare reimbursement for hospitals and that HHS had no legal authority to adjust Medicare reimbursement for low-wage hospitals in the way that He did it. In summary, the Court concluded that “because HHS must use salary data to calculate the relative salary levels of hospitals in particular geographic areas relative to the national average, the agency exceeded its statutory authority when it changed the salary index for hospitals in the bottom quartile, so that the salary index values ​​for these hospitals were based neither on survey data nor on rough approximations of the relative levels of hospital salaries.

As a result, the Court ultimately concluded that the hospitals had discharged “the burden of demonstrating that the salary indices violated the Medicare Act” and therefore “that the [low wage index hospital
policy] must be struck down as contrary to the statutory directive of Congress.”

Court upholds Hospital Medicare’s denial of resident education reimbursement

On March 7, 2022, the Tenth Circuit Court of Appeals upheld a decision of the United States District Court for the District of Oklahoma denying the challenge of three teaching hospitals appealing Medicare’s denial of reimbursement despite news rules under the Affordable Care Act (“ACA”) that would allow reimbursement if applied retroactively.

In that case, the suing hospitals shared the cost of offsite resident education from 2001 to 2006 despite the fact that at that time a teaching hospital could only obtain reimbursement by incurring “the substantially all” of a resident’s training costs under the Omnibus Reconciliation Act of 1986, Pub. L. no. 99-509, § 9314, 100 Stat. 1874, 2005. Because of these costs shared by the hospitals, the government refused reimbursement and the hospitals filed their administrative appeal. However, while the appeal was pending, Congress enacted the ACA, which created a new reimbursement standard that allowed costs to be shared on a proportional basis.

The hospitals argued that the ACA’s changes to resident education cost sharing should be retroactive and that their appeal of Medicare’s denial of reimbursement should therefore be upheld in their favor. The Court disagreed and concluded that “[w]When the teaching hospitals incurred the training costs, Medicare statutes did not allow reimbursement of shared costs.”

As such, the Court found that although the ACA “relaxed” the disputed restrictions when it was passed in 2010, these changes were not to be made retroactively and hospitals were therefore not entitled to reimbursement of their shared residency training costs from 2001. to 2006.

CMS seeks to reduce cost sharing with beneficiaries by limiting PBM recoveries

On January 6, 2022, the Centers for Medicare and Medicaid Services (“CMS”) issued a proposed rule, 87 FR 1842, that would require, in part, Medicare Part D plans to apply all “price concessions” that they receive from network pharmacies at the point of sale in order to reduce the beneficiary’s participation in the costs.

This proposed rule, which will come into effect on January 1, 2023 if it becomes final, responds to a practice of Pharmacy Benefit Managers (“PBMs”) whereby they enter into agreements with pharmacies called “price concessions” whereby the PBM can “claw back” payments to pharmacies if certain measures are not followed.

Currently, the rules require “negotiated prices” for drugs to include all network pharmacy price concessions, except for contingent amounts that cannot “reasonably be determined” at the point of sale. This exception ultimately allows negotiated prices to not reflect these performance-based pharmacy price concessions.

The new rule would eliminate this exception and redefine “negotiated price” as “the lowest amount that a pharmacy could receive in reimbursement for a covered Part D drug under its contract with the plan sponsor of the Party D or the promoter’s intermediary’. CMS further proposes that a definition be added for “price concession” “broadly to include all forms of direct or indirect discounts and subsidies or rebates which serve to reduce costs incurred under the plans of the party D by the sponsors of part D”.

CMS has released an information sheet for the proposed rule.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Employment and HR in the United States

Employee layoffs: breaking up is hard to do

Akerman LLP

Firing an employee can be a lot like breaking up with a significant other – stressful, messy, and awkward. Nobody wants to be the “bad guy”, and often it’s nicer to sugar coat…

Amended Maine law will require vacation payout upon termination of employment

Little Mendelson

The Governor of Maine recently signed HP 160 – LD 225, amending the state’s final wages law to require that “[a]All unused paid leave accrued in accordance with the employer’s leave policy on or after January 1, 2023 must be paid to the employee upon termination of employment.

The University of Dayton celebrates 2020 graduates with a special weekend: University of Dayton, Ohio

It’s been a long wait for the University of Dayton’s Class of 2020, whose on-campus commencement ceremony was canceled two years ago due to the COVID-19 pandemic. Now it’s finally their turn.

This weekend, 421 2020 graduates and 805 families and friends will return to campus to reconnect with faculty, celebrate their accomplishments, and complete their UD campus experience.

The University will celebrate its 2020 graduates at noon on Saturday, May 14 at the Marycrest Amphitheater located at the east end of Central Mall across from Kennedy Union. The celebration is part of a weekend of events, which will include a welcome reception on Friday, May 13 at UD Arena’s Connor Flight Deck, a Dean’s Open House before the ceremony on Saturday morning, and a party under the porch later in the afternoon.

“I’ve always been excited about the idea of ​​a graduation ceremony,” said Chloe Voelker, a double major in management information systems and entrepreneurship who now works for tech company VNDLY in Cincinnati. . “Having the ceremony not only means a lot to me and my peers, but also to my parents who sacrificed so much for me to go to UD. I am thrilled to see this come to fruition.”

Although UD has held a virtual graduation ceremony for the Class of 2020, the University has promised to also hold an official on-campus start for 2020 graduates when public health restrictions are lifted. With logistical considerations and last year’s public health restrictions, UD could only hold separate undergraduate ceremonies with limited seating for the class of 2021. It still wasn’t safe enough to invite the class. of 2020 to return for a full group experience.

But UD never gave up on celebrating the Class of 2020 in person.

“I’ve been waiting to say ‘welcome home’ to the class of 2020 for two years,” UD President Eric F. Spina said. “Today is more than just a long-awaited in-person ceremony on a spring day in the heart of campus – it’s a joyful reunion of classmates. It’s a time to thank a favorite teacher and a time for graduates to step back and savor all they have accomplished in the past two years. It is a day we have all dreamed of, worried about if it would ever happen, and one we will never forget.

December Lee, a graduate in medicinal chemistry, will be driving from Columbus to participate. She said she was delighted to reunite with friends and thrilled that her class was getting the long-awaited public recognition for a job well done.

“We couldn’t say goodbye,” said Lee, who is currently in a pharmacy graduate program at Ohio State University. “We left for spring break and thought we’d be back in three weeks, so it took us a while to get over the fact that we weren’t going to have a graduation ceremony. We didn’t get some of the things we should have gotten, and UD recognized that. There’s no way I’m missing this.

In March 2020, students were days away from leaving for spring break when the University announced the suspension of in-person instruction following the advice of Ohio Governor Mike DeWine. The initial announcement, dated March 10, 2020, provided that students would stay off campus for at least two weeks after spring break and continue their classes virtually.

“At the time, most of us thought it would be temporary because the school was closed for two weeks,” said Sean Newhouse, a political science and communications graduate. “My bold opinion at the time was, ‘I think it’s going to be three weeks.’ It turned out to be wrong – it wasn’t inaccurate but it was just over three weeks. Much longer.”

The 2020 graduates never had a chance to return, except for a window during the summer when they were allowed to return to get their belongings out of student accommodation.

Now a reporter for congressional committees for CQ roll call in Washington, DC, Newhouse said he was ready to return to Dayton.

“It’s kind of unique because in an alternate universe that probably would have been the last time I would have seen everyone, but now I’ll see them two years later and see if we’ve changed or if we’re all the same,” Newhouse said. “I consider this a celebration. A time to reflect on our time at college, how long since we left college, and how events have affected I think it definitely made me appreciate the big times like graduations more.

The University Advancement Division contacted student leaders like Voelker, Lee, Newhouse and others shortly after the end of the 2020 academic year to ask if they would like to join a committee to help plan a celebration in the future. They were asked to imagine what the “return” would look like – would it be a graduation ceremony? Maybe a meeting?

“It’s a bit of both,” said Ummiya Chaudhary, a civil engineering graduate who is now an engineer at Wright-Patterson Air Force Base. “Just having a celebration is important – it means something. It provides closure.

Like many 2020 graduates, Chaudhary is thrilled to see old friends again, but also former professors, helpful staff members she met regularly, and even acquaintances who have become part of her college experience. Several students said they looked forward to thanking them all for their support and help in making their UD trip special.

Although Morgan Eifert regularly visits the UD campus to visit his sister, a senior, and his brother, a junior, coming back this weekend will be special.

“I’m really looking forward to it,” said Eifert, an accounting and finance graduate who works in auditing for PricewaterhouseCoopers in Cincinnati. “All of my friends, former roommates – we all can’t wait to stay together at the Marriott, see each other again, and get back to doing all the things we haven’t been able to do together for the past few weeks.”

Gabriella Rice, who majored in international business and minored in Chinese and Asian studies, hated leaving behind the many organizations she was involved with as a UD student, including the Asian American Association she helped get started on campus. Now an executive assistant in the office of the CEO of Tectronic Industries in Fort Lauderdale, Florida, Rice is looking forward to returning for the event.

“I’m so excited to go back,” Rice said. “We know it’s not the same as a graduation ceremony in the traditional sense, but I can’t wait to walk across the stage, see my old friends again, and shake hands with President Spina. It may only be a handshake, but it means so much more.

Two UM Faculty Members Named Distinguished Professors – The Oxford Eagle

Two respected University of Mississippi professors with a combined 50 years of teaching, research, and service have been named professors emeritus by the university.

Kenneth J. Sufka, professor of psychology and pharmacology, and Robert Van Ness, holder of the Bruce Moore professorship in finance, received the honorary title Friday, May 6, during the spring meeting of professors.

Created in 2018, the title of Professor Emeritus recognizes top faculty members with sustained excellence at the university. The award was created in response to the university’s strategic initiative to develop post-professional recognition.

“The Professor Emeritus Award recognizes individuals for sustained careers of achievement that have had a significant influence on their disciplines,” Provost Noel Wilkin said. “This year’s two winners, Dr. Sufka and Dr. Van Ness, are no exception.

“They both had productive careers that helped transform their research fields and enhanced their students’ educational experiences.”

A leading international researcher in behavioral neuroscience and psychopharmacology, Sufka joined the UM faculty in 1992. He has ongoing collaborative projects with Mahmoud ElSohly, professor of pharmacy and drug administration at UM and director of the university’s Marijuana Project; Kevin Freeman, associate professor of psychiatry at UM Medical Center; Stephen White, a former Ole Miss doctoral student working at Sam Houston State University; and Johnny Roughan, at Newcastle University.

“During his career, he has produced an impressive body of work in the field of behavioral neuroscience and psychopharmacology, which has led to incredible breakthroughs in the treatment of depression, chronic pain and addiction”, wrote ElSohly in support of Sufka’s nomination. . “Most notably, his research led to the discovery of the first and still only drug-effectiveness screening procedure for treatment-resistant depression, for which he was granted a patent in 2015.”

In collaboration with ElSohly and others, Sufka received a second patent in 2020 for a new cannabidiol analog that shows analgesic activity on par with opioids but without the side effect profile or abuse liability typical of this class of analgesics. This compound, which has the potential to solve the current crisis of opioid abuse, is licensed to a biotechnology company and is moving towards clinical trials.

Sufka’s work is transforming research to help fight chronic pain, ElSohly said.

“Dr. Sufka’s lab developed an innovative method to quantify the effects of analgesic drugs in animal models of chronic pain that is now routinely used in leading pain laboratories in the United States and abroad,” said he declared.

Sufka was often ahead of his time, said Jeffrey Mogill, EP Taylor professor of pain studies at McGill University in Montreal, citing a 1994 study in which Sufka found that conditioned place preference could be used as an indirect measure of chronic pain to assess potential analgesics.

“This idea was so ahead of its time that the article only garnered 17 citations in the first decade after publication,” Mogill noted.

“In the past five years alone, Sufka, 1994 has been cited 40 times,” he continued. “I should point out that at present, CPP is the most commonly used technique in the pain field to measure spontaneous (or ongoing) chronic pain, and it is now widely accepted that this symptom of pain is the #1 priority for preclinical pain research.

“More and more people in the field are using a technique that Ken single-handedly invented in 1994.”

Widely hailed as a talented, dedicated and effective teacher who is passionate about student success, Sufka is the first UM professor to be named Case-Carnegie American Professor of the Year. His other awards include the 2006 Thomas F. Frist Student Service Award, the 2005 Outstanding Faculty Award, and the 1996 Elsie M. Hood Outstanding Teacher Award.

He has turned his passion for student success into a widely used book for undergraduates, “The A Game,” now in its second edition and translated into Spanish and Arabic. With over 250,000 copies in print, his book has been adopted by a number of colleges and universities for distribution to their freshman classes.

Van Ness came to UM in 2002 after serving on the faculty at Marshall University and Kansas State University.

Promoted to the rank of professor in 2009, he has held the Moore Professorship since 2013. He co-edited, with Bonnie Van Ness, The Financial Review from 2009 to 2015. Widely recognized as one of the most eminent scholars in his field, its main The research area examines financial markets and securities trading, commonly referred to as market microstructure research.

“His work has always been excellent, and I have no doubt that his future work will continue to meet the very high standards he has set for himself,” wrote Michael Pagano, professor of finance at the Villanova School of Business. “As his CV attests, Dr. Van Ness is an excellent teacher as well as an academic, having received numerous awards for both teaching and research.

“He has also given back to the profession as a successful editor of The Financial Review as well as associate editor of the Journal of Banking and Finance and other respected financial journals.

“Indeed, Dr. Van Ness’s reputation has been critical in putting the University of Mississippi on the map in the area of ​​finance and the subfield of market microstructure: when we in the profession think about the University of Mississippi, we think of Dr. Van Ness.

Van Ness’ expertise was also cited by other colleagues in support of his nomination.

“Within financial markets, market microstructure is how different trading mechanisms affect price formation and discovery and how transaction costs affect investor behavior,” wrote Daniel Bradley, Professor Lykes in finance and sustainability at the University of South Florida.

“Recently, the GameStop trade event in January 2021 underscored the importance of this area of ​​research, as payment for order flow was heavily debated across all mainstream media and ultimately led to congressional hearings (the debate is still ongoing).

“When I think of the microstructure of the market, the first person I think of is Dr. Van Ness. He has been and continues to be at the forefront of this field.

One of the most prolific researchers and scholars in his field, Van Ness has published over 100 peer-reviewed articles, has nearly 4,000 Google Scholar citations, and received 10 best paper awards at professional academic conferences, which further indicates his position as a researcher.

Primarily teaching MBA and PhD courses, he was highly regarded by students and won five teaching awards in the MBA program. The Director of Doctoral Programs, Van Ness has mentored numerous doctoral students, chaired or co-chaired 18 theses, and published with more than a dozen PhDs. students since arriving at Ole Miss.

No more than two eligible professors may be named emeritus professors in any given year.

Each school and college has its guidelines for nominations, but the university requires nominated faculty to have at least six years of service at the highest faculty rank, as well as exemplary achievements in research and creative achievement, teaching and service. In addition, winners are expected to have achieved a significant degree of national or international recognition.

The first distinguished professors in 2018 were John Daigle, Donald Dyer and Ikhlas Khan. Other faculty members who have earned the title are Alan Gross, Charles Hussey, Karen Raber, Arunachalam Rajendran, Michael Repka, Ron Rychlak, and Jay Watson.

New Zealand mother denounces pressure to send children back to school

the World Socialist Website recently spoke with a single mother from South Auckland, as part of the global workers’ inquiry into the COVID-19 pandemic, about the growing pressure she is facing to send back her two primary school-aged children at school, as the pandemic rages out of control.

COVID-19 has spread like wildfire across New Zealand, which has just experienced its deadliest month of the pandemic so far. COVID deaths have risen from 59 at the end of last year to more than 845 as of May 5. At least one in five people have been infected and hospitals are overwhelmed with COVID patients.

New Zealand has officially recorded nearly one million cases of COVID. The vast majority had been since March 2022. (Source: Our World in Data, CC BY 4.0)

The disaster is a direct result of the Labor-led government’s decision last October to abandon its previous policy of elimination, which used border closures and quarantine to reduce cases to zero. At the behest of big business and the financial elite, these measures were removed and schools and businesses were reopened with the help of unions.

The mother, whom we will call Jennifer, is in her 40s and suffers from asthma. She fears that her children will contract COVID and pass it on to her. She pointed out that the Department of Health’s website lists “chronic diseases of the lungs or airways” (which includes asthma) among the conditions that put people at “a higher risk of more serious disease if they contract COVID-19”. Jennifer said the ministry “also gives advice to vulnerable groups, and advice number one is: avoid getting COVID.”

Despite the government telling people to take responsibility for their own safety, the Department of Education and school administrators are pushing parents to send their children back to unsafe classrooms. The government has announced a crackdown on “school truancy,” with $88 million earmarked for tackling the problem in this year’s budget.

Jennifer said she tried several times to get her children’s school to send learning materials so they could study at home, but she refused to do so. At the start of the second term in May, she emailed the school again asking for the learning kits. The principal responded by saying that the children should attend “in person” and that the school had asked the Department of Education to “have a discussion” about this with Jennifer. She’s still waiting for the ministry to call her.

“Is it acceptable that they force me to expose myself to medical risks because of absenteeism problems?” asked Jennifer. “Isn’t it okay that I want learning packs so I can educate my kids at home where I know we’re safe?” I am their sole caregiver. If I die, then what? Will the director adopt them? Catching COVID is not a risk or an ordeal I am willing to go through for myself or my children.

She wondered what the ministry could say to justify sending her children back to school. “They’re not going to change my mind about vulnerability and insecure school and remote learning. They can’t change my mind about asthma and the need to avoid COVID. What do they think they will change?

Jennifer explained: “The government has dismantled all of our COVID regulations. So the only logical thing for me and people with other vulnerabilities to do is to move further away from the public. We are not given any other options.

After schools reopened across the country in February, the highly contagious variant of Omicron quickly spread across New Zealand. South Auckland, a working-class area, is one of the worst affected areas in the country, with Middlemore Hospital often overwhelmed with patients.

Manurewa High School Principal Pete Jones said A news that in the first quarter of 2022, attendance fell to just 35% “because we had so many cases of COVID in the community”. Nationally, the Federation of Head Teachers reports that 67% of students attend school “regularly”, which is more than 90% of the time.

Jennifer said these out-of-school children were likely living with vulnerable family members, like her.

Contrary to repeated misrepresentations by politicians and the media, children are at significant risk from COVID. On May 4, the Ministry of Health reported the deaths of a child under 10 and an elderly teenager who had the virus. Jennifer stressed that vaccines don’t make people ‘invincible’ and that ‘everything is uncertain and still being researched. Long COVID is still being researched. How can we put our children at risk without having fully researched this? »

On April 13, the government lifted a mask mandate that covered most but not all students. The removal of the mandate was disputed by experts, who also criticized the lack of ventilation in schools. Disability Rights Commissioner Paula Tesoriero is also calling for the reintroduction of masks in schools.

Many children are unvaccinated or not fully vaccinated, making schools ideal for spreading the virus. Vaccination mandates for school personnel have also been removed.

Jennifer said the real issue was that schools shouldn’t be open in the first place. “When the school’s enrollment administrator called me, they said, ‘We have masks and we keep the kids away from each other in the classroom. I said, ‘Well, my son won’t be wearing a mask for more than two minutes. He just won’t. Teachers, who are stressed and overworked, are unable to enforce proper mask-wearing, especially with young children.

As a recent immigrant from the United States, who came to New Zealand to study, Jennifer said she was shocked by the flip-flop in the Labor government’s handling of the pandemic and the complacency that is now being encouraged.

“I had to go get my shot at the pharmacy and everyone was walking around as usual, queuing next to each other, no one wearing a mask,” she said. “I think another thing that people always forget about COVID is that you don’t recover like the flu. Some people become permanently disabled, if you don’t die.

Jennifer told the WSWS that a childhood friend of hers died of COVID last year in the United States, aged in her 30s. “We grew up together as kids in the 90s, played video games together, went to school together and got into trouble together. Now he’s dead.

She felt “very disappointed” that New Zealand had taken the “every man for himself” approach from the United States. “I would make the connection with the Republican [Party] ideal, which is really sad, because Labor is supposed to be left of centre, I thought.

Prime Minister Jacinda Ardern at the October 4, 2021 press conference announcing that the government will begin to move away from its previous policy of eliminating COVID-19. (Source: Jacinda Ardern’s Facebook page) [Photo / CC BY 4.0]

When Prime Minister Jacinda Ardern announced the end of the zero COVID policy, during New Zealand’s Delta outbreak last year, Jennifer said “my heart sank immediately” even though she had it. seen coming. “They couldn’t go on forever, I could tell they were breaking just the way they were reporting [on the cases]. I knew that because of what other countries were doing, they were going to do it too. For some reason, New Zealand likes to copy Australia, and Australia copies America: it’s a bad line of dominoes.

Ahead of the policy change in October, former Prime Minister John Key and many pro-business commentators had demanded New Zealand reopen its border and ‘live with’ the virus, saying the policy of elimination had transformed the country into a “hermit kingdom”.

Commenting on this propaganda, Jennifer said, “What I feel about this is: What if we were a hermit kingdom, if it’s going to keep people safe? I come from a place where there are a lot of tornadoes, and during a tornado, we take shelter. When the tornado is gone, you exit the shelter. You don’t come out of the shelter in the middle of a tornado.

She said New Zealand’s public health response was “retreating and it made no sense. It seems that whenever they have the opportunity to listen to real microbiologists or epidemiologists about what should happen, [the government] completely ignores” expert advice.

Cannabis License Approved for Michigan’s Hoxeyville Music Festival | A batter | Detroit

Click to enlarge

Courtesy picture

Revelers at Michigan’s Hoxeyville Music Festival.

The long-running Hoxeyville Music Festival in northern Michigan announces for the first time that it will have an official cannabis partner this year.

The Americana and roots music festival, held on 150 acres of farmland near the Manistee National Forest in Wellston, celebrates its 20th anniversary in August.

Festival operator Hoxeyville Enterprises said it has reached an agreement with Dunegrass Co. to offer on-site cannabis sales and has partnered with event organizer and cannabis grower Tom Beller of Real Leaf Solutions to offer a consumption on the spot.

Fittingly, approval for the license was granted at the Wellston Township board meeting on April 20.

Hoxeyville Enterprises says Dunegrass Co. will be the festival’s cannabis partner in 2022 and 2023.

“We are very pleased to offer this option to our attendees and look forward to growing both this experience within the event as well as our partnership with Dunegrass,” Jake Robinson of Hoxeyville Productions said in a statement.

“Dunegrass is beyond excited to be working on the first music festival-turned-cannabis event in the state,” Dunegrass COO Eric Piedmonte said in a statement. “So far, all of the on-site cannabis events have been cannabis first, entertainment second. We’re flipping the model by partnering with a long-running festival like Hoxey and adding to it.”

“This event is going to set the new standard for cannabis events,” said Beller, who also owns the state’s first licensed cannabis event organizer.

Scheduled for August 19-21, Hoxeyville features two stages with national and local acts. The festival has a capacity of 4,000 people.

This year’s lineup includes Trampled by Turtles, Railroad Earth, the Infamous Stringdusters and more. The complete program is available on hoxeyville.com.

In Lansing, a 420 music festival featuring a lineup of mostly hip-hop acts took place last month. In Metro Detroit, a planned “Spark in the Park” event in Hazel Park was rejected by the city council due to parking issues, with programming that was expected to mix rock, funk and hip-hop.

In Michigan’s Upper Peninsula, cannabis chain Fire Station is planning a “Camp Cannabis” event in Marquette for October 7-9. Although a lineup has yet to be announced, he says he is looking to book national and local acts.

Stay connected with Detroit Metro Times. Subscribe to our newsletters, and follow us on Google News, Apple News, TwitterFacebook, Instagram, Reddit or TikTok.

Chair in Biomolecular Sciences shares expertise in toxicology and receives top research award – The Oxford Eagle

Sometimes parents are the best role models. Kristie Willett is perhaps an example.

Lynn B. Willett, now a retired Ohio State University animal science and toxicology professor, introduced her daughter, Kristie, to the world of toxicology from an early age. Kristie attended her first Society of Toxicology, or SOT, meeting in 1978, and her first publication was with him when she was in high school in 1989 on the topic of polychlorinated biphenyl metabolism by rumen microorganisms.

But her father didn’t point her towards a certain career path in toxicology, and she didn’t plan a life around academics. Instead, she had to go into industry or government.

“When I came to Texas A&M graduate school in Stephen Safe’s lab, the environment was such that I could pursue my own questions, write my own proposals, and the academic freedom associated with the academic stream appealed to me. really,” Kristie Willett said.

“Toxicology is such an interdisciplinary field. You need expertise in chemistry, ecology, physiology, and politics, so academia really provides those collaborative relationships.

It is these partnerships within research, communities, and academia where Willett has thrived at the University of Mississippi, and it has earned him the university’s 2022 Distinguished Research and Creative Achievement Award.

The annual honor recognizes a faculty member who has demonstrated outstanding achievement in research, scholarship, and creative activity.

“It’s a huge honor,” said Willett, chair of the Department of Biomolecular Sciences and professor of pharmacology and environmental toxicology at the School of Pharmacy. “My mentor since coming to college has been Dr. Alice Clark (Vice Chancellor Emeritus of UM and Professor Emeritus of Pharmacognosy at FAP Barnard), and to be on a list of honorees with her is really neat.

“I’ll never accomplish everything she did when she was at UM, but it’s nice to be recognized in the same way.”

A 1993 graduate in chemistry from the University of North Carolina, Willett focused on marine environments while pursuing her doctorate at Texas A&M. She then completed postdoctoral fellowships at Indiana University and Duke University, learning mass spectrometry and polycyclic aromatic hydrocarbon metabolism, respectively.

Willett has since become an international leader in environmental toxicology and an authority on the use of zebrafish as a model organism to study the developmental, reproductive, and multigenerational effects of exposure to pollutants and cannabinoids. She has been instrumental in working on the environmental consequences and policies following disasters, including Hurricane Katrina and the Deepwater Horizon oil spill.

In collaboration with scientists from the National Center for Natural Products Research, she studies the restoration of oysters in the face of climate change and environmental stressors.

She is also part of a multidisciplinary team of researchers helping to mobilize Mississippi communities on the issue of lead in drinking water. This community-based research has his department collaborate with the National Sea Grant Law Center and the UM School of Engineering.

Willett’s role in the project is to help test participants’ water samples so they are empowered to know how to limit their exposure to the toxic metal.

“I think it’s really important to have diverse perspectives on every research project,” Willett said. “The team approach is essential, I believe, to better understand and therefore help solve environmental and human health problems.

“My career and my ability to serve as a good mentor have been enriched through my collaborations both at UM and with off-campus colleagues.”

Willett has received over $6 million in external funding from various sources, including the National Institutes of Health, the U.S. Army Engineering Research and Development Center, the Mississippi Water Resources Research Institute, and the Mississippi Based RESTORE Act Center of Excellence.

She is an active leader of the Society of Environmental Toxicology and Chemistry as well as the SOT, and is associate editor of the society’s journal, Toxicological Sciences. Willett has authored or co-authored over 80 peer-reviewed publications, four book chapters, and co-edited a book titled “The Toxicology of Fishes.”

“Selecting the Distinguished Research and Creative Achievement award is tough every year,” said Josh Gladden, UM’s vice chancellor for research and sponsored programs. “The university is fortunate to have so many faculty creating so much positive impact in our world.

“Dr. Willett has developed an international reputation and truly embodies excellence in research, mentorship, and service to both his community and his discipline. The university is delighted to recognize his many accomplishments.

His teaching efforts have been recognized with the 2020 American Association of Colleges of Pharmacy Higher Education Special Interest Group Achievement Award, the 2017 UM Faculty Achievement Award, and the School of Pharmacy Faculty 2017 Educational Innovation Award.

Willett has supervised the research of nine master’s students, nine doctoral students. students and five postdoctoral fellows, and has been part of numerous student committees since joining the BMS faculty, of which she has been president since 2017.

His passion and enthusiasm for teaching and mentoring was recently recognized with the SOT Undergraduate Educator Award. Willett noted that the best way to gain student interest is to show that toxicology is all around them, from why you have to boil water, to why drugs have a certain dosage, to why water bottles say “BPA free”.

Since joining the Ole Miss faculty in 2000, Willett’s lab has hosted more than 60 undergraduate and high school students conducting independent research. Many of them are using the research for their Sally McDonnell Barksdale Honors College thesis, and she was named the college’s 2016 faculty member of the year.

Students also use this work for posters and presentations at conferences as well as being co-authors on some of Willett’s publications.

“I hope these experiences provided them with an understanding of the scientific method, confidence in their communication skills, but most importantly, that lifelong curiosity,” Willett said. “I hope I inspire students to embark on this career choice and in doing so I contribute to the future, which is one of my favorite aspects of my job. »

Established in 2008, the School of Pharmacy is home to six former Distinguished Research and Creative Achievement Award winners: Larry Walker, Mahmoud ElSohly, Ikhlas Khan, Alice Clark, Marc Slattery and Michael Repka. Other winners include Sam Wang, Charles Reagan Wilson, Dale Flesher, Atef Elsherbeni, Robert Van Ness, Charles Hussey and Ron Rychlak.

The recipient of the award is selected from a pool of applicants by the last 10 winners.

For Donna Strum, Dean of Pharmacy at UM, these recognitions show the caliber of research and education coming out of the school and its research enterprises.

“I am thrilled for Dr. Willett, as his enthusiasm for environmental toxicology and his exemplary efforts in scholarship, research and mentorship deserve recognition,” Strum said. “She is collaborative and works continuously to advance science for the betterment of communities in the state and nation.

“We are fortunate at the School of Pharmacy to have incredible professors and scientists who are dedicated to their disciplines like Dr. Willett.”

As much as she is committed to her lab and classroom work, Willett is equally dedicated to her life at home. Willett and her husband, UM chemistry professor Jason Ritchie, try to keep up with their children’s activities and attend many Ole Miss sporting events as a family.

While her dad provided a strong toxicology model, Willett is clearly doing the same for her 15-year-old daughter Alex and 10-year-old son Cody. However, their current career plans lean towards environmental engineering and professional baseball playing, respectively.

“They’re still young, so there’s plenty of time for them to change their minds,” Willett said.

Kristie Willett receives university’s best research award

Kristie Willett (left), chair of the Department of Biomolecular Sciences and professor of environmental pharmacology and toxicology, has won numerous teaching awards and mentored many graduate students while at the university. Photo by Kevin Bain/Ole Miss Digital Imaging Services

OXFORD, Miss. – Sometimes parents are the best role models. Kristie Willett is perhaps an example.

Lynn B. Willett, now a retired Ohio State University animal science and toxicology professor, introduced her daughter, Kristie, to the world of toxicology from an early age. Kristie attended her first Society of Toxicology, or SOT, meeting in 1978, and her first publication was with him when she was in high school in 1989 on the topic of polychlorinated biphenyl metabolism by rumen microorganisms.

But her father didn’t point her towards a certain career path in toxicology, and she didn’t plan a life around academics. Instead, she had to go into industry or government.

Kristie Willett

“When I came to Texas A&M graduate school in Stephen Safe’s lab, the environment was such that I could pursue my own questions, write my own proposals, and the academic freedom associated with the academic stream appealed to me. really,” Kristie Willett said.

“Toxicology is such an interdisciplinary field. You need expertise in chemistry, ecology, physiology, and politics, so academia really provides those collaborative relationships.

It is these partnerships within research, communities, and academia where Willett has thrived at the University of Mississippi, and it has earned him the university’s 2022 Distinguished Research and Creative Achievement Award.

The annual honor recognizes a faculty member who has demonstrated outstanding achievement in research, scholarship, and creative activity.

“It’s a huge honor,” said Willett, chair of the Department of Biomolecular Sciences and professor of pharmacology and environmental toxicology at the School of Pharmacy. “My mentor since coming to college has been Dr. Alice Clark (Vice Chancellor Emeritus of UM and Professor Emeritus of Pharmacognosy at FAP Barnard), and to be on a list of honorees with her is really neat.

“I’ll never accomplish everything she did when she was at UM, but it’s nice to be recognized in the same way.”

A 1993 graduate in chemistry from the University of North Carolina, Willett focused on marine environments while pursuing her doctorate at Texas A&M. She then completed postdoctoral fellowships at Indiana University and Duke University, learning mass spectrometry and polycyclic aromatic hydrocarbon metabolism, respectively.

Willett has since become an international leader in environmental toxicology and an authority on the use of zebrafish as a model organism to study the developmental, reproductive, and multigenerational effects of exposure to pollutants and cannabinoids. She has been instrumental in working on the environmental consequences and policies following disasters, including Hurricane Katrina and the Deepwater Horizon oil spill.

In collaboration with scientists from the National Center for Natural Products Research, she studies the restoration of oysters in the face of climate change and environmental stressors.

She is also part of a multidisciplinary team of researchers helping to mobilize Mississippi communities on the issue of lead in drinking water. This community-based research has his department collaborate with the National Sea Grant Law Center and the UM School of Engineering.

Willett’s role in the project is to help test participants’ water samples so they are empowered to know how to limit their exposure to the toxic metal.

“I think it’s really important to have diverse perspectives on every research project,” Willett said. “The team approach is essential, I believe, to better understand and therefore help solve environmental and human health problems.

“My career and my ability to serve as a good mentor have been enriched through my collaborations both at UM and with off-campus colleagues.”

Willett has received over $6 million in external funding from various sources, including the National Institutes of Health, the U.S. Army Engineering Research and Development Center, the Mississippi Water Resources Research Institute, and the Mississippi Based RESTORE Act Center of Excellence.

She is an active leader of the Society of Environmental Toxicology and Chemistry as well as the SOT, and is associate editor of the society’s journal, Toxicological Sciences. Willett has authored or co-authored over 80 peer-reviewed publications, four book chapters, and co-edited a book titled “The Toxicology of Fishes.”

“Selecting the Distinguished Research and Creative Achievement award is tough every year,” said Josh Gladden, UM’s vice chancellor for research and sponsored programs. “The university is fortunate to have so many faculty creating so much positive impact in our world.

Kristie Willett, recipient of the 2022 UM Distinguished Research and Creative Achievement Award, is an international authority on the use of zebrafish as a model organism to study the effects of exposure to pollutants and cannabinoids. Photo by Robert Jordan/Ole Miss Digital Imaging Services

“Dr. Willett has developed an international reputation and truly embodies excellence in research, mentorship, and service to both his community and his discipline. The university is delighted to recognize his many accomplishments.

His teaching efforts have been recognized with the 2020 American Association of Colleges of Pharmacy Higher Education Special Interest Group Achievement Award, the 2017 UM Faculty Achievement Award, and the School of Pharmacy Faculty 2017 Educational Innovation Award.

Willett has supervised the research of nine master’s students, nine doctoral students. students and five postdoctoral fellows, and has been part of numerous student committees since joining the BMS faculty, of which she has been president since 2017.

His passion and enthusiasm for teaching and mentoring was recently recognized with the SOT Undergraduate Educator Award. Willett noted that the best way to engage students is to show that toxicology is all around them, from why you have to boil water, to why drugs have a certain dosage, to why water bottles say “BPA free”.

Since joining the Ole Miss faculty in 2000, Willett’s lab has hosted more than 60 undergraduate and high school students conducting independent research. Many of them are using the research for their Sally McDonnell Barksdale Honors College thesis, and she was named the college’s 2016 faculty member of the year.

Students also use this work for posters and presentations at conferences as well as being co-authors on some of Willett’s publications.

“I hope these experiences provided them with an understanding of the scientific method, confidence in their communication skills, but most importantly, that lifelong curiosity,” Willett said. “I hope I inspire students to embark on this career choice and in doing so I contribute to the future, which is one of my favorite aspects of my job. »

Established in 2008, the School of Pharmacy is home to six former Distinguished Research and Creative Achievement Award winners: Larry Walker, Mahmoud ElSohly, Ikhlas Khan, Alice Clark, Marc Slattery and Michael Repka. Other winners include Sam Wang, Charles Reagan Wilson, Dale Flesher, Atef Elsherbeni, Robert Van Ness, Charles Hussey and Ron Rychlak.

Kristie Willett (left) helps visitors understand environmental toxicology concepts at a School of Pharmacy booth during Mississippi Day activities in April. Photo by Whitney Tarpy/UM School of Pharmacy

The recipient of the award is selected from a pool of applicants by the last 10 winners.

For Donna Strum, Dean of Pharmacy at UM, these recognitions show the caliber of research and education coming out of the school and its research enterprises.

“I am thrilled for Dr. Willett, as his enthusiasm for environmental toxicology and his exemplary efforts in scholarship, research and mentorship deserve recognition,” Strum said. “She is collaborative and works continuously to advance science for the betterment of communities in the state and nation.

“We are fortunate at the School of Pharmacy to have incredible professors and scientists who are dedicated to their disciplines like Dr. Willett.”

As much as she is committed to her lab and classroom work, Willett is equally dedicated to her life at home. Willett and her husband, UM chemistry professor Jason Ritchie, try to keep up with their children’s activities and attend many Ole Miss sporting events as a family.

While her dad provided a strong toxicology model, Willett is clearly doing the same for her 15-year-old daughter Alex and 10-year-old son Cody. However, their current career plans lean towards environmental engineering and professional baseball playing, respectively.

“They’re still young, so there’s plenty of time for them to change their minds,” Willett said.

How This Trinity Scientist Opens Nature’s Pharmacy

Dr Helen Sheridan, from Trinity College Dublin, talks about her work harnessing the medicinal power of Irish peatlands and explains the importance of citizen science.

In February, leading researchers and innovators from Trinity College Dublin (TCD) were recognized for their contributions to their fields at the Trinity Innovation Awards 2021.

One of the winners in the Societal Impact category was Dr. Helen Sheridan, associate professor at Trinity and founder of NatPro, the Trinity Center for Natural Products Research, based in the School of Pharmacy and Pharmaceutical Sciences.

Speaking to SiliconRepublic.com after the awards, Sheridan said the accolade was related to the work she was doing in the bogs of Ireland.

“My mandate here is to look at peatlands, look at biodiversity, look at the environment, and then look at what may be hidden in what I would consider a high value ecosystem in this country.”

“Ireland’s peatlands are an enormous national resource”

Sheridan said she was born to be a scientist, conducting her first experiments as a young child in the back garden. “I collected caterpillars, old animal skeletons and stones. I had a notebook that I used as my first lab book! »

She was the first in her extended family to go to university, undertaking a Bachelor of Science degree at University College Dublin. She was quickly drawn to the chemical sciences, microbiology and zoology, and later completed a doctorate in natural product chemistry.

“I studied biological systems, mainly the chemistry of fungi at that time. So from the early stages, I saw biology through a chemical lens. I looked to nature for bioactive molecules, drugs and agrochemicals,” she said.

“It was in the early 1980s, before biodiversity and the bioeconomy were scientific priorities. At that time in Ireland, all researchers had to be nimble and change their vocabulary and direction of research to keep up with funding.

nature’s pharmacy

Sheridan then focused on natural products from terrestrial and marine plants and organisms, and her research included work on aspects of penicillin biosynthesis.

“It was in 1983 and 1984 when I learned about the importance of enzymes in transforming substances into new natural products. These are the sources of knowledge that I still draw on, as we examine the challenges of the bioeconomy and use old science to solve new problems and challenges and innovate by applying these technologies to natural “waste streams” and making new valuable substances, thus closing the circle economically.

Sheridan’s work continued to make waves throughout his career. She recently led a project titled “Unlocking Nature’s Pharmacy from Bogland Species”, which received €6 million in funding in November 2020.

“All science must be examined through an objective lens”

The project aims to identify potential therapeutic and commercial uses of Irish native bog plants, bog waters and the microbiome of unique bog species.

“Ireland’s peatlands are an enormous national resource. The need to cease industrial exploitation of peatlands has provided a unique opportunity to examine new uses of peatlands and to develop a deeper understanding of the cultural use and chemical potential of the biodiverse species found in these unique ecosystems,” said she declared.

“Plant species, native to these environments, can provide environmental and economic solutions based on these resources for the benefit of communities that have traditionally worked on peatlands.”

While Ireland’s bogs could be a treasure trove for drug discovery, Sheridan said a common misconception about his work is that all things that are natural must also be safe.

“This applies to most ‘natural products’, including foods, supplements and natural ingredients, and it is not true. All science must be examined through an objective lens. Things you can eat can kill you. Things that can kill you can also heal you. It all depends on the dose. »

Citizen science

A major component of Sheridan’s work involves citizen scientists. This includes launching a new transition year module on peatlands and biodiversity, supporting engagement in national science competitions and collecting samples and generating data for its research program by people from all over the country.

“More recently, we have worked with groups of farmers in the Comeragh Mountains, connecting them to medicinal plants growing on their land and linking them to their cultural use by their ancestors. We use this civic engagement to gain knowledge that will in turn explain why certain practices, such as fern burning, need to change,” she explained.

“The company is full of very capable people. Many have not had the privilege of going to higher education. Many are experienced in different areas of life and have interesting opinions and experiences that can fuel scientific and social debates. I think engaging people in citizen science, where possible and appropriate, should be a requirement for scientists.

10 things you need to know straight to your inbox every weekday. Sign up for the brief dailythe summary of essential science and technology news from Silicon Republic.

Pharmacists play a vital role in patient access to contraception

Legislation allowing pharmacists to prescribe contraceptives is becoming widespread.

Until recently, a pharmacist’s responsibilities were almost exclusively limited to counting pills, affixing a label to the prescription bottle, and dispensing medications. At most they would advise patients whose prescriptions were a bit complicated.

However, as healthcare in the United States has progressed, pharmacists have taken on a more active role. Some of their new responsibilities include providing comprehensive drug reviews to patients, conducting research, and administering vaccines.

Idaho is the most progressive jurisdiction in the United States in terms of scope of practice for a pharmacist. State practitioners can prescribe low-risk drugs like contraceptives as long as the circumstances and agents in question fall within the parameters set by the Idaho legislature.1 And other states have followed suit.

In New Jersey, for example, Assembly Bill A5810 was passed by the Senate in June 2021 and referred to the Assembly Health Committee. This bill would allow pharmacists to dispense self-administered oral contraceptives under a standing prescription and in accordance with protocols of the New Jersey Board of Pharmacy and Board of Medical Examiners.2 If passed, the bill would require pharmacists to undergo a training program run by councils, and women would have to take a self-screening test before receiving contraceptives.2 If, after the self-screening, the pharmacist decides that the drug is inappropriate for the patient, he can refer the woman to her primary care physician.

Currently, 15 states allow pharmacists to prescribe oral contraceptives.3 The extent of their authority in the matter (the type of contraceptive and the circumstances in which they can provide it) varies by state. In addition to expanding the role of pharmacists, passing more such laws could improve access to birth control for large numbers of women, including the estimated 435,000 women aged 13 to 44 years old in New Jersey who need publicly funded contraceptive services and supplies.4

Research also shows that access to birth control significantly improves women’s quality of life. Such access has dramatically increased the number of women enrolling and graduating from college.5 These women also have the opportunity to delay childbirth and invest in themselves by pursuing a career.5 This is not only liberating for women, but it can also help the economy by increasing the number of people employed. In the 1970s, women began to make up a larger percentage of the workforce, especially in fields like medicine and law,5 and part of this increase can be attributed to the greater access to oral contraceptives they had at the time.

Unwanted pregnancies are higher in the United States than in other developed countries, and this problem disproportionately affects low-income women.6 Although, as currently written, New Jersey’s Bill A5810 would not reduce the cost of contraceptive coverage, it would spare patients a trip to the doctor and the associated costs. It would also be much easier for people living in rural areas and lower socio-economic groups to obtain contraceptives, as they can get to their local pharmacy much more easily than the nearest doctor’s office. Patients would also experience shorter wait times and their health care would be more cost effective.1

Making contraceptives more accessible has many benefits, but it is not without risks. Primarily, easier access to contraception could increase the incidence of certain adverse effects associated with it, including blood clots and depression. Pharmacists should be vigilant in advising patients about the risks as well as the benefits. As with most prescriptions, pharmacists should also monitor potential interactions between all patient medications. Given the heavier workload that community pharmacists have faced since the onset of the COVID-19 pandemic, some may feel overwhelmed by the prospect of yet another responsibility, and the quality of care may suffer.

However, legislation like A5810 could also have a positive impact on pharmacy students. New positions — specifically to prescribe oral contraceptives — could become available for pharmacists at publicly funded institutions like Planned Parenthood. Pharmacists would be needed
take additional training, but as the practice becomes more common, schools of pharmacy may begin to offer this training as part of the program. Overall, enabling pharmacists to prescribe these drugs will be beneficial not only for women but for society as a whole, and it can also allow pharmacy students to grow in a field that was previously limited to a single brief courses during their university years.

Adrian Michelet is a P3 student at the Ernest Mario School of Pharmacy at Rutgers University.


1. Broughel J, Amez-Droz E. Extending pharmacists’ prescribing power: options for reform. Mercatus Center. December 15, 2021. Accessed February 5, 2022. https://www.mercatus.org/publications/healthcare/expanding-pharmacists%E2%80%99-prescriptive-authority-options-reform

2. S404 (2020-2021). Accessed October 15, 2021. https://www.njleg.state.nj.us/bill-search/2020/S404

3. Contraceptives prescribed by the pharmacist. Guttmacher Institute. Published October 6, 2021. Accessed October 26, 2021. https://www.guttmacher.org/state-policy/explore/pharmacist-prepressed-contraceptives

4. Access to birth control 2021. Power to decide. Accessed October 26, 2021. https://powertodecide.org/what-we-do/access/birth-control-access

5. Center for the Economics of Reproductive Health at the Institute for Women’s Policy Research (IWPR). The economic effects of access to contraception: a review of the evidence. 2019:1-44. https://iwpr.org/iwpr-issues/reproductive-health/the-economic-effects-of-contraceptive-access-a-re-view-of-the-evidence Committee Opinion no. 615: access to contraception.

6. Obstet Gynecol. 2015;125(1):250-255. doi:10.1097/01.aog.0000459866.14114.33

The global drug discovery and development solutions market will be driven by increasing R&D spending and research initiatives on rare diseases and orphan drugs during the forecast period 2021-2026

Expert Market Research’s new report titled “Global Drug Discovery and Development Solutions Market Size, Share, Price, Trends, Growth, Report and Forecast 2021-2026‘, gives an in-depth analysis of the global drug discovery and development solutions market, assessing the market based on its segments such as service type, process type, technology type, therapeutic area, and main regions. The report tracks the latest industry trends and studies their impact on the overall market. It also assesses market dynamics, covering key demand and price indicators, as well as market analysis based on SWOT and Porter’s Five Forces models.

Get Free Sample Report with Table of Contents – https://www.expertmarketresearch.com/reports/drug-discovery-and-development-solutions-market/requestsample

Key highlights of the report include:

Market Overview (2016-2026)

• Forecast CAGR (2021-2026): 13%

The global market for drug discovery and production solutions is supported by the growth of the industry in North America. The growth of the drug discovery outsourcing industry in the region might be due to increased focus on drug discovery for the treatment of COVID-19, driving the outsourcing of drug discovery to companies equipped with AI technology. Additionally, increasing R&D spending by large pharma and biotech companies and their focus on rationalizing the internal costs of drug discovery outsourcing is fueling the growth of the drug discovery and development solutions industry. .

Industry definition and major segments

Drug discovery refers to the discovery of new drugs and the method of producing a therapeutically active substance for a specific target molecule or pathway. Drug research includes hit screening, medicinal chemistry, and hit optimization to reduce potential drug side effects. Together, the discovery and production of drug solutions constitute a complete mechanism for detecting and bringing a new product to market.

Read the full report with table of contents – https://www.expertmarketresearch.com/reports/drug-discovery-and-development-solutions-market

The types of services in the market can be divided as follows:

• Medical chemistry
• Biology services
• Drug metabolism
• Pharmaceutical Services
• Pharmacokinetics
• Others

The types of drugs on the market can be divided into:

• Small molecules
• Organic Products.

Process types can be segmented into:

• Target selection
• Target validation
• Track access identification
• Lead Optimization
• Validation of candidates
• Others

Types of technology in industry can be segmented as follows:

• High throughput screening
• Biochips
• Pharmacogenetics
• Nanotechnology
• Spectroscopy
• Others

On the basis of therapeutic area, the market can be segmented into:

• Oncology
• Neurology
• Infectious and immune system diseases
• Diseases of the digestive system
• Cardiovascular illnesses
• Others

Regional markets for drug discovery and development solutions include:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Market trends

The rise in demand for drug discovery outsourcing can be attributed to the focus on drug discovery for the treatment of the growing COVID-19 pandemic, which has led to drug discovery outsourcing. medicines to companies equipped with AI technology. Additionally, growing investment in research and development (R&D) by major pharmaceutical and biotech companies and their emphasis on rationalizing the internal costs of drug discovery outsourcing are fueling the growth of the market. In computational information processing for predictive chemistry, developments in fundamental algorithms are used, leading to improvements in scientific innovation and in laboratory computing. In the coming years, this is expected to increase the demand in the market.

Main market players

Major market players include Abbott Laboratories Inc., AstraZeneca plc, Genentech, USA Inc, Charles River Laboratories International, Inc., Gilead Sciences, Inc., Pfizer Inc., Jubilant Biosys Ltd., Sanofi SA, F. Hoffmann-La Roche Ltd, et al. The report covers market shares, capacities, plant rotations, expansions, investments, and mergers and acquisitions, among other latest developments of these market players.

Related reports:

United States Fire Sprinkler Market: https://www.expertmarketresearch.com/reports/united-states-fire-sprinklers-market

Global Calcium Chloride Market: https://www.expertmarketresearch.com/reports/calcium-chloride-market

Global dental insurance market: https://www.expertmarketresearch.com/reports/dental-insurance-market

Global plastic waste management market: https://www.expertmarketresearch.com/reports/plastic-waste-management-market-report

Global nisin market: https://www.expertmarketresearch.com/reports/nisin-market

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports and advisory services to our clients. We serve a wide clientele ranging from Fortune 1000 companies to small and medium-sized businesses. Our reports cover over 100 industries in established and emerging markets researched by our trained analysts who track the latest economic, demographic, business and market data globally.

At Expert Market Research, we tailor our approach based on the needs and preferences of our clients, providing them with valuable, actionable and up-to-date market insights, helping them realize their optimal growth potential. We offer market intelligence across a range of verticals including Pharmaceuticals, Food & Beverage, Technology, Retail, Chemicals & Materials, Energy & Mining, Packaging and agriculture.

We also provide state-of-the-art shopping insights through our platform, https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market insights, supply chain insights, sourcing analytics, and procurement insights. categories with our in-depth and infallible market reports, cost of production reports, price analysis and benchmarking.

Expert information (https://informedeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consulting services to a large clientele in Spanish-speaking countries. Focusing primarily on the Latin American and Spanish markets, our research experts provide relevant and actionable market insights and track key trends, economic developments and global trade data.

Determined to bring client satisfaction, we ensure that our tailored approach meets the client’s unique market intelligence requirements. Our syndicated and custom research reports cover a wide range of industries from pharmaceuticals and food and beverages to packaging, logistics and transportation.

Media Contact

Company name: EMR Inc.
Contact: Eliana Grace, Business Consultant
Email: [email protected]
Toll Free: USA +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
City: Sheridan
State: Wyoming
Country: United States
Website: https://www.expertmarketresearch.com

To learn more about this topic, click here: https://expertmarketresearch-emr.blogspot.com/

Also check Purchasing Information that provides you with infallible research solutions.

* At Expert Market Research, we always strive to give you the latest information. The figures in the article are only indicative and may differ from the actual report.

Pharmacy Guild welcomes bipartisan support for reduction of general PBS co-payment

Leading community pharmacy body, the Pharmacy Guild of Australia, patient advocacy body the Australian Patients Association, Chronic Pain Australia and Musculoskeletal Australia today welcomed the Labor Party’s announcement that it would reduce also the maximum general co-payment of the Pharmaceutical Benefit Scheme (PBS).

National chair of the Pharmacy Guild of Australia, Professor Trent Twomey, said community pharmacies were working hard with other patient representative bodies to advocate for more affordable medicines for patients.

“On behalf of patients, we and our partners the Australian Patients Association, Chronic Pain Australia and Musculoskeletal Australia are delighted that both major parties have now pledged to make medicines more affordable if elected.

“A bipartisan commitment to tackle the cost of prescription drugs is a victory for patients across the country who have fought hard and is a step in the right direction to restore universal access to PBS.

“Community pharmacies see patients struggling to afford medication from prescription to prescription and paycheck to paycheque. As the cost of living rises, patients are increasingly forced to choose between putting food on the table or buying the medicine they and their families need.

“We don’t want to see Australians ending up in the ER, in hospital or with long-term damage to their health because they’ve been forced to delay or skip taking essential medicines because of the cost.

“This announcement is a recognition of the importance of affordability of medicines at a time when Australians are struggling with the cost of living.”

The cost of drugs has become a key issue for voters, with 30% saying they struggle to afford drugs on the PBS, a 6-point jump since January this year, according to new research from the company. Independent Survey Insightfully. The number of voters skipping medication altogether has also increased, with 17% of voters now saying they or their family were unable to purchase medication due to cost. This is a three-point jump since January, when the price of drugs on the PBS rose again.

Australian Patients Association CEO Stephen Mason said the issue of prescription drug affordability is an ongoing concern for many Australians.

“Our research found that nearly 36% of people believe prescription drugs are too expensive and 20% of people say it’s beyond their usual budget.

Chair of Chronic Pain Australia, Fiona Hodson advocates that all Australians living with chronic pain receive Triple A standards of care – Awareness, Accessibility and Affordability.

“Reducing co-payments will be good news for one in five Australians living with chronic pain. Medication affordability is a key issue for these patients as they manage their complex and chronic conditions.

Musculoskeletal Australia CEO Rob Anderson said consumers were struggling to afford drugs to manage their own health and feared their weekly budgets would become increasingly tight.

“A recent survey we conducted found that 62% of respondents had experienced financial hardship due to a musculoskeletal disorder. 39% said the cost of medication was the source of this financial burden. We urge Canberra to take this issue seriously so that the many Australians living with musculoskeletal disease can access their lifesaving medicines. »

/Public release. This material from the original organization/authors may be ad hoc in nature, edited for clarity, style and length. The views and opinions expressed are those of the author or authors. See in full here.

Dr. Eric Tichy explains why more state biosimilar bills are needed

Eric Tichy, PharmD, MBA, vice president of pharmacy formulary at Mayo Clinic Health System, discusses the importance of state legislation to drive access and uptake of biosimilars.


You had the opportunity to provide feedback to Minnesota congressional leaders on HF 1516, a bill to increase patient access to biosimilars. Could you explain what this bill is and why more bills like this are needed?


So one of the reasons for this bill is that we found that there were barriers to the implementation of biosimilars. We’ve seen it in our experience, and it’s been noted by other organizations and other healthcare leaders. One of the biggest hurdles is actually that sometimes you come across health plans that will prefer an innovative product. And it may be because they have some kind of discount or some other situation that makes them prefer the innovator product.

We have actually encountered scenarios where this innovative product is 3 times more expensive than the biosimilar product. We felt that we needed incentives to push the practice to be able to use biosimilars, as our providers wanted to use biosimilars, our patients wanted to use a biosimilar, and we had payers who wouldn’t let us do that.

There are also some of these logistical issues related to product storage. This bill would help ensure that biosimilars are treated more similarly to how we treat generic drugs, where the distributing organization decides which product is used. Payers don’t micromanage the generic drug we use, and payors do a lot of important things to reduce costs. And we would just say, trust us to kind of drive at the lowest cost, we’ll pass it on. And you can focus on other things where you can bring value to healthcare and reduce overall healthcare costs.

CET obtains a patent for a compound with anti-cancer properties

The College of Engineering Thiruvananthapuram (CET) has filed a patent for the invention of a pharmaceutical agent which is expected to have immense potential in the treatment of cancer.

The newly synthesized compound, 3-([4-Chloro-3(Trifluoromethyl) Phenyl] Amino)-5-Hydroxy-2-Methyl-1,4-Dihydronaphthalene-1,4-Dione, is the result of five-year research undertaken jointly by Shyni P. Laila and Arunkumar B.

The researchers were guided by Annette Fernandez, the former head of the chemistry department at CET who had retired as principal of the Government College of Arts and Science, Pathirippala, in Palakkad a few years ago.

Arunkumar B. (center) and Shyni P. Laila (right), who obtained a patent for the compound at the College of Engineering in Thiruvananthapuram, with their research guide Annette Fernandez.

Arunkumar B. (center) and Shyni P. Laila (right), who obtained a patent for the compound at the College of Engineering in Thiruvananthapuram, with their research guide Annette Fernandez. | Photo credit: special arrangement

They pointed out that the pharmaceutical agent is a fluorinated derivative (a derivative compound obtained by reaction with a fluorinated compound) which was derived by structural modification from a hydroxyquinone, Plumbagin, which was isolated from the roots of Plumbago zeylanicaa medicinal plant known as Koduveli in the local parlance.

While subject to silicone and in vitro In colon cancer and melanoma cell line studies, the new compound showed cytotoxicity results comparable to the standard anti-cancer drugs doxorubicin and vemurafenib.

Fewer side effects

“Since this compound is a derivative of a phytocompound (produced by plants), we expect fewer side effects than standard drugs. Thus, the compound can be used as a lead molecule as an anti-cancer agent,” they said.

The group continues research on other phytocompounds such as embelia ribs (known in Malayalam as Vizhalari).

While Dr. Laila is currently an Associate Professor in the Department of Chemistry, University College, Thiruvananthapuram, Dr. Arunkumar is a Research Assistant in the Department of Computational Biology and Bioinformatics, University of Kerala.

The particular research had been published in the “Journal of Biomolecular Structure and Dynamics” in 2020. The patent, which was applied for in 2015, was granted for 20 years (from the date of filing). This is the third patent obtained by CET and the first for its Chemistry department.

Critical contrast: UPM-Kymmene (OTCMKTS:UPMKY) and Infinya (OTCMKTS:HAIPF)


UPM-Kymmene (OTCMKTS:UPMKYGet a rating) and Infinia (OTCMKTS:HAIPFGet a rating) are both commodity companies, but which is the better investment? We’ll compare the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability, and analyst recommendations.

Volatility and risk

UPM-Kymmene has a beta of 1.23, which means its stock price is 23% more volatile than the S&P 500. In comparison, Infinya has a beta of 1.33, which means its stock price is 33% more volatile than the S&P 500.


This table compares the net margins, return on equity and return on assets of UPM-Kymmene and Infinya.

Net margins Return on equity return on assets
UPM-Kymmene 13.76% 12.57% 8.65%
Infinity N / A N / A N / A

Institutional and insider ownership

0.6% of UPM-Kymmene shares are held by institutional investors. 1.0% of UPM-Kymmene shares are held by insiders of the company. By comparison, 11.5% of Infinya’s stock is held by company insiders. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a stock is poised for long-term growth.

Valuation and benefits

This table compares gross revenue, earnings per share (EPS) and valuation of UPM-Kymmene and Infinya.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
UPM-Kymmene $12.38 billion 1.14 $1.77 billion $2.65 9.98
Infinity N / A N / A N / A N / A N / A

UPM-Kymmene has higher revenues and profits than Infinya.

Analyst Recommendations

This is a breakdown of the current ratings and recommendations for UPM-Kymmene and Infinya, as reported by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
UPM-Kymmene 0 1 0 0 2.00
Infinity 0 0 0 0 N / A

UPM-Kymmene currently has a consensus price target of $39.00, suggesting a potential upside of 47.45%. Given the higher possible upside of UPM-Kymmene, equity research analysts clearly believe that UPM-Kymmene is more favorable than Infinya.


UPM-Kymmene beats Infinya on 6 of the 8 factors compared between the two stocks.

UPM-Kymmene Company Profile (Get a rating)

UPM-Kymmene Oyj operates in the forest-based organic industry. It operates through UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers, UPM Plywood and other operating segments. The company supplies eucalyptus, birch and softwood pulp grades for tissue, specialty and graphic papers, boards and packaging; sawn timber for construction, packaging, distribution, carpentry and furniture; and renewable wood-based diesel and renewable naphtha for fuel distributors, transportation, and the petroleum and petrochemical industries. It is also involved in the generation of electricity through hydroelectric, nuclear and condensing power plants. In addition, the company offers self-adhesive papers and film label stocks for product and information labeling to label printers and brand owners in the food, beverage, personal care, pharmaceuticals and retail; release papers for labels and liners, fine papers and flexible packaging, as well as production lines for label and packaging papers for retailers, printers, publishers, distributors and paper converters; and graphic papers for advertising, magazines, newspapers, home and office to publishers, cataloguers, retailers, printers and merchants. In addition, it provides plywood and veneer products for construction, vehicle flooring, liquefied natural gas shipbuilding and other manufacturing industries; wood and wood-derived biomass, and forest services for woods and forest owners; outdoor building products and aggregates for injection molding and extrusion; wood-based lignin products for industrial use and cell culture hydrogel products for biomedical applications; and biomedical products. The company mainly operates in Europe, North America and Asia. UPM-Kymmene Oyj was founded in 1995 and is based in Helsinki, Finland.

Infinya Company Profile (Get a rating)

Infinya Ltd, through its subsidiaries, manufactures and sells writing and printing paper, wrapping paper, cardboard and corrugated board, and recycled paper products in Israel and the foreign. It offers collection and recycling services for waste paper, cardboard and plastic waste, electronic waste and other recyclable materials; and offers cardboard packaging solutions for food, cosmetics, pharmaceuticals, textiles, high-tech, games, plastics and metals. The company also offers office supplies, paper and paper products, technology and peripherals, hobbies and crafts, furniture, food and cleaning products. The company was previously known as Hadera Paper Ltd. and changed its name to Infinya Ltd in February 2022. Infinya Ltd was incorporated in 1951 and is based in Hadera, Israel.

Get news and reviews for UPM-Kymmene Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for UPM-Kymmene and related companies with MarketBeat.com’s free daily email newsletter.

The Value of Human Life — Waterbury Roundabout

April 29, 2022 | By Rev. Matthew Rensch

Without value. Without meaning. Useless. These are some of the most scathing insults possible. Three weeks ago, an opinion piece raised this theme in my mind. The article explained proposed updates to Bill 39, the 2013 law regarding physician-assisted dying, also known as physician-assisted suicide. Updates (invoice S.74 signed into law last week by Governor Phil Scott) need not delay us here. My grave apprehensions and objections relate to the general approval of the practice.

Of course, I understand the call. I understand where legislators come from. Assisted suicide can prevent suffering. In the absence of coercion, he dictates the patient’s choice. The number of patients choosing suicide is rather small. Overall, he seems to put on a human and compassionate face. Nevertheless, my apprehensions persist. Do these benefits justify the practice? I am not convinced.

First, with modern palliative care, how much suffering is avoided? More importantly, we must ask ourselves if This way avoiding suffering is a good thing. Not all way to avoid suffering is good. (Use your imagination). Could this one be bad too?

Second, allowing the patient to choose does not guarantee good practice. Many adult children work hard to dissuade their elderly parents from harmful ideas. Some ideas are harmful. Is this one of them?

As for the numbers, it seems that the author herself has apprehensions. “Currently, a very small number of doctors in Vermont are assisting people through this process and only one pharmacy is involved. And as stated above, very few people have availed themselves of this process. My question is: So? If assisted suicide is a good thing, why are we so worried about the numbers? If it’s a release, why is its rarity such a relief? On the whole, the reasons in favor therefore do not seem convincing.

Besides these apprehensions, there is a more serious objection, which joins my introduction. A law on assisted suicide, whatever its composition, expresses the point of view: “We agree. At this point, your life is worth nothing. Or again: “Towards the end and in suffering, it is better to die. And that’s a nihilistic position: to argue that human life has no intrinsic value, but only has value because of what you can do, or what you can contribute, or of what you can appreciate, or… of anything except because of you. Your value, just like you, drops to zero.

A law authorizing suicide, allowing it, condoning it, ultimately denies the value of human life merely as human. You have to prove your worth.

Do you remember the horror we all felt a few years ago when young Michelle Carter encouraged her boyfriend, Conrad Roy III, to kill himself? How can we be horrified by what she did, if we’re okay with physician-assisted suicide? Who are we to insist that Conrad’s life had meaning and his death was a tragedy? Maybe some lives don’t make sense, and his was one of them. Once we admit that some human lives are useless, can you reasonably criticize someone’s suicidality?

No. Either human life has intrinsic value or it does not. Assisted suicide denies its intrinsic value. It’s much healthier, humane, and compassionate to recognize the value of human life, period.

From a religious point of view

The comments above are made simply as a citizen. They do not appeal to any faith or religion. These are understandable concerns to any thinking person. There is no premise that an atheist could not understand. Let no one, then, raise the specter of religious imposition.

What follows here, however, is done as a Catholic priest: The Catholic Church, understanding the divine spark in every individual, insists on the value of all human life as such. It repudiates any unjust attack on human life, even self-inflicted. Human life, with its immortal soul, is a unique good. Attacking and killing him is wrong and leads to hell.

Moreover, we follow a Lord who has overcome suffering and death. He did not run or hide. He showed us that suffering is redemptive, that suffering patiently borne leads to resurrection. A Christian may shrink from pain, but he knows that it will not triumph. Pain cannot rob us of who we are, of our value, of our meaning. Christianity recognizes that humanity’s greatest heroes were men and women willing to suffer for what is true and just.

Let there be no doubt that this law not only strikes at the root of human dignity, but is also profoundly anti-Christian.

Hemas Pharmaceuticals and the Pharmaceutical Society of Sri Lanka boost the skills of pharmacists – The Island


For fashion, ‘look, touch and feel’ is everything. So it may seem counterintuitive that the world’s biggest brands will soon be able to create outfits and accessories that will partially or completely exist in a virtual space. But even though it may sound like science fiction, fashion brands are betting big on the metaverse.

Morgan Stanley predicts that virtual fashion could represent a US$50 billion opportunity by 2030, adding up to 25% to total industry revenue. For context, this is about 10 times the value of Sri Lanka’s record export earnings from garment exports for 2021.

And it’s not just speculation that drives growth. Brands like Dolce and Gabbana have already made US$5.7 million from the sale of just nine non-fungible token (NFT) pieces, while Valentine’s Day 2022 brought the first-ever Metaverse Fashion Week show on the popular Second Life online game.

While enthusiasm for virtual fashion is at an all-time high, details about how the metaverse actually works and its implications for regions like South Asia and countries like Sri Lanka, where clothes represent more of 40% of national exports, remain unclear. .

Discover the value
behind the hype

A simple way to understand the metaverse would be as a future iteration of the internet, consisting of persistent, shared and linked 3D virtual spaces across a fully digital universe. Those who are immersed in such universes will communicate, pass and have fun through their virtual avatars.

So far, there are two possible paths for fashion brands to profit from the metaverse. The most direct option: producing virtual clothing for digital avatars – the first sales of NFT fashion were aimed at this market. In some cases items only exist in the metaverse, in others the item will have an In Real Life (IRL) counterpart, in addition to existing virtually.

The second: advertising designs through the metaverse equivalent of a point of sale. Through fashion shows like Decentraland’s Virtual Fashion Week, dozens of top global brands and thousands of visitors were able to virtually attend fashion shows and live music sessions at after-parties. branding and buying and wearing digital clothes directly from catwalk avatars. Some of the fashion items will even include a physical copy of the item in the sale of their NFT fashion pieces.

While the metaverse is still in its infancy, Joint Apparel Association Forum (JAAF) Secretary General Yohan Lawrence believes it could have the potential to shape the next decade of fashion in a way that is just as disruptive as which we have already seen with the rise of e-commerce and omnichannel retail to date.

“Where enterprise resource planning systems, digital payments and Web 2.0 have played a central role in the success of fashion brands over the past decade, Web 3, 5G and the Internet of objects, virtual and augmented reality, and of course NFTs and blockchain technology could lead to entirely new business models in fashion. Build on the progress we’ve made so far, while aligning for what’s to come?”

Weaving parallel skills

From humble beginnings as cut-and-sew or made-to-order products in the early 1980s, Sri Lankan garments have gradually moved into production in high-value, high-complexity niches of the global supply chain of clothes. Leading this ongoing transition are local multinationals such as MAS, Brandix, Norlanka and Hirdaramani.

“Science and technology have been instrumental in enabling faster production of more complex products such as our ‘Second Skin’ range of underwear and sports leisure, and more recently in women’s technology and recovery wear. “, says the Director of Technology Commercialization of MAS. Gihan Philippe. “A considerable amount of research and development has gone into creating these products. However, with our more recent investments in digitization, we are expanding our ability to design and prototype new lines entirely virtually. Designing fashion for the metaverse could be a logical extension of those abilities.

He noted that while many of these 3D visualization technologies have been available for some time, especially post-pandemic, both brands and manufacturers are more open to virtual collaborative design. Meanwhile, the technology itself is improving exponentially.

“There have been significant advances in materials scanning, imaging and simulation. This means we are able to capture much more detail on how different fabrics would look and how they would drape over a person. Along with platform enhancements that enable virtual collaboration, we are able to generate authentic digital twins for our designs and make changes on the fly.

Star Garments (Operations Director), Jeevith Senaratne explains, “Instead of frequent physical photo shoots, we can simply scan a model and combine those scans with garment designs to showcase them entirely virtually. We are also able to leverage social media to test consumer responses to particular designs and modify production lines based on their response. This eliminates a lot of cost and reduces the time it takes to go from design to production, which is extremely valuable. All of these capabilities take on new meaning in the context of the significant investments made by brands in the metaverse.

Virtual design was also a game-changer for Hirdaramani. Through investments in the latest 3D-Fit software systems including: CLO, Browzwear and Tuka Tech, the company has been able to significantly reduce costs and improve delivery times.

CEO/Director of Hirdaramani Industries Sri Lanka, Theodore Gunasekara says, “We have significantly increased our 3D sampling capabilities and capabilities, especially after the pandemic. Today we are able to simulate complex effects such as washing and lasering on denim. This allowed us to convert the majority of our prototype samples, pre-production samples and adjusted samples to digital. Given the severe limitations faced globally during the pandemic, these systems have helped us to shorten development times and keep production lines running despite logistical bottlenecks. They also help us advance our sustainability goals as they further reduce resource consumption. »

Filling the gaps virtually and IRL

Similar advanced capabilities have been established at Brandix. A global wearable innovation company with end-to-end capabilities in the design, technology incubation, and digital and vertical manufacturing of “smart wearables”, it has been at the heart of Brandix’s efforts to enable rapid prototyping to to proof of concept.

Among its many innovations likely to cross paths with the Metaverse are its advanced designs for motion sensing and haptic actuator integration. Powered by Artificial Intelligence, the Sensemove line is able to intelligently measure the frame of an individual’s physique, to help guide athletes’ technique.

“As the metaverse begins to grow, we believe that technologies like this have the potential to integrate with these virtual worlds, to create new applications in sport and fitness,” says the non-executive director. of Brandix Hasib Omar, “When we particularly think about how quickly we have seen e-commerce and social media become a central part of our daily lives, we see immense potential for highly specialized garments that fuse fashion with technology.

Another emerging player in Sri Lanka that could offer a glimpse of the shape of things to come for Sri Lankan clothing is Norlanka. Although engaged in the same lines of business, from design to delivery, the company has one crucial difference from larger, more established companies on the island: its asset-light business model. Although the company has a few manufacturing facilities, most of its capacity is purchased from its SME partners in the apparel industry. Using similar visualization systems, the company flexibly orchestrates production in Sri Lanka’s dynamic SME garment manufacturing sector.

Norlanka ventured into the 3D space in 2019 and is currently developing fully digital products with some of its customers. With a dedicated research and development team, the company continuously explores new opportunities to increase efficiency, while adding value for its customers and partners, thereby improving sustainability across the industry.

“One of the next big projects we’re working on is digital sampling,” says Norlanka Chief Innovation Officer Buddhi Paranamana. “In an asset-light model like ours, we need to be able to clearly present every facet of a given line to our partners and buyers. Our expertise in advanced digital design and sampling means we can easily scale to producing pure digital or hybrid designs for the Metaverse, which can also be manufactured at commercial scale for IRL retail. These digital designs can also be used as NFTs in the ever-expanding creative spaces of the Metaverse.

However, as revolutionary as this new technological paradigm might be for the fashion industry over the next decade, today’s most visible metaverse games are still made by top brands. By releasing limited designs and leveraging their brand strength and novelty of NFT support, these brands are capturing the most initial value. For clothing manufacturers to participate in this action, they will first have to create their own brands and designers.

SRM will conduct collaborative research with Himalaya


SRM Institute of Science and Technology (SRMIST), Kattankulathur has signed a Memorandum of Understanding (MoU) with Himalaya Wellness Company. The purpose of this agreement is collaborative research and educational programs such as analytical chemistry, formulation and development, phytochemistry, pharmacognosy, preclinical toxicology and pharmacology, in vitro mutagenicity, clinical pharmacology.

The MoU signing ceremony was presided over by SRMIST Registrar Dr. S. Ponnusamy, Dean (Research) Dr. Neppolian and Coordinator (IIISM) Dr. Rajesh Kumawat. Himalaya Wellness Company was represented by Dr. Rajesh Kumawat, Head (Medical Services and Clinical Development) and MVS Suresh Kumar, Director, Clinical Trials, Himalaya Wellness Company.

The main purpose of this MoU is to support postgraduate thesis/faculty research providing pure herbs to postgraduate students (also explore the possibility of polyherbal/proprietary formulation), to have a industry post-graduate training on clinical research experience and exploring new scientific indications/markers to expand the reach of herbs into unmet medical areas.

Posted: Saturday April 30th 2022, 02:13 AM IST

Chiranjeevi, Ram Charan, Pooja Hegde Movie Is A Masterclass In What Not To Do In A Star Vehicle-Opinion News, Firstpost

In Acharya, the hero’s Naxalism goes so far as to accessorize with a red scarf and camouflage. If you’re basing a film on the life of an Adivasi tribe, at least acknowledge their culture, language, and rituals.

A coal mine, created and framed as if located in KGF, location and film. People in soiled white clothes are working beyond their capacity. Children, abused and enslaved, are put to work so that the greedy can stay greedy.

This is not the main plot of Koratala Siva Acharya, but only one among many subplots. Even though the setup – a blessed people and their blessed village in danger – is promising and can create many potential moments where the star can be likened to a literal goddess, the writing is too distracted. This is the central question of the film – to think that several small ideas are better than a good idea.

Unlike the villains who populate it, viewers of Telugu commercial cinema are not greedy. When they buy a ticket, they are just waiting for a movie that allows them to boo and whistle. Instead of giving them moments worthy of actor fandom, Siva wastes time on elaborate and uninspiring exposition. Several minutes into the film, someone in the room shouted, “Hero Nope introduce cheyandi ra“, and I am with him. And when the hero finally enters, the introduction – one of the cornerstones of a successful masala film – is utterly disappointing.

Anyway, back to the coal mine. Two men enter the scene pretending to be security guards, and mild hilarity ensues. Chiranjeevi and Ram Charan share great chemistry which is naturally respectful and comfortable. This sequence uses it very well, but it also makes the viewer nostalgic for Chiranjeevi’s comedic timing. It’s one of the few moments in the film where the otherwise robotic and comatose veteran actor comes to life on screen.

Speaking of chemistry, Siddha’s (Ram Charan) and Neelambari’s (Pooja Hegde) romance, bland as it is, works. The few beats of him teaching her kushti shine with potential. The charm wears off quickly as the characters, even the tracks, are carefully underwritten with mundane motives, weak setups, and lower payouts – the sequence where Acharya helps move the tank is the exception. Siddha, whose whole personality is his rigid moral code of conduct, is not above listening to a woman in her bath.

No amount of Lal Salaams can straighten out a crumbling scenario.

I can complain that someone as talented as Regina Cassandra isn’t relegated to special numbers, but I’m sure she had more to do in the movie than the character of Hegde. The character artist’s usual suspects are here – Nasser, Tanikella Bharani, Sonu Sood, Kishore, and Jisshu Sengupta – and they do what they have to do, which they always do. Ajay is particularly impressive as a tribal leader.

Suresh Selvarajan’s production design is the only thing that works in this film set in a temple city. Traditional artifacts and colorful markets add depth to an otherwise shallow affair. Mani Sharma’s score isn’t at fault, but it barely crosses ordinary cinema. The same goes for Navin Noolis’ editing and Tirru’s camera work: decent but rendered ineffective by the script underneath.

Given the many constraints, it is probably difficult for a star vehicle with a big budget to experience the content. But Koratala Siva succeeded in innovating in the model with films like Mirchi and Srimanthudu. Even though Acharya shares many similarities with Mirchi and Janatha Garage, it’s not half as entertaining or involving as either. Things are happening, great things, but the film is never inviting enough for the viewer to invest their emotions.

One of the reasons could be the predictable scenario. When I saw Satyadev’s name in the credits of “Thank You”, I knew he was here to die, even if it’s a good role. What would have been better is if the movie featured him as young Acharya instead of the laughable VFX.

Predictability is always okay, but uninspired writing is not. To show that someone is bad, a woman must be raped. The main villain has to play golf at some point. The good people have to be trashed after the movie hits a saturation point. The naxalism of our hero will go so far as to accessorize with a red scarf and camouflage. If you’re basing a movie on the life of an Adivasi tribe, do it right. Recognize their culture, language and rituals instead of making them healers and mouthpieces shlokas in Telugu Sanskrit.

Not everything is trendy. Not everything should be used as a trend. Respect the people you are trying to represent or leave them alone. Do you remember the coal mine I mentioned at the beginning? The good news is that the children are doing well. The film, on the other hand, not so much.

Acharya plays in cinemas.

Evaluation: **

Sankeertana Varma is an engineer who took a few years to realize that bringing together two beautiful things, cinema and writing, is as great as it sounds. Writes mainly on Telugu cinema.

Read all Latest news, New trends, Cricket News, bollywood news, India News and Entertainment News here. follow us on Facebook, Twitter and instagram.

Adani Group renewable energy company gets better payment terms than us from government – ​​The Island


SL Renewable Energy Associations allege:

By Hiran H. Senewiratne

Government pays higher terms on a unit cost for Adani Group’s renewable energy company compared to local developers, which has created unfair situations for local developers, Sri Lanka’s Renewable Energy Associations say .

“The Adani Group is exploring possible investments in Sri Lanka’s wind and renewable energy sector and the government has agreed to pay six hundred US dollars for one kilowatt hour/unit, while local developers only receive a little more of two hundred US dollars, which really discourages them, said Riyaz Sangani, member of the exco, Biomass Developers Association.

Sangani made the comments during a press conference organized by renewable energy associations which include developers of small hydro, wind, solar and biomass power plants and the Solar Industries Association of Sri Lanka. The event took place at the BMICH on Wednesday.

Sangani said Adani Group has only signed the agreements but has not yet started its feasibility studies for the proposed projects. “I am sure that with the depreciation of the rupee and the bad decision-making process of the government, they will withdraw from the proposed projects,” he added.

“The government has ignored its priorities as this country’s national grid now stands to lose 1250.9 megawatts (MW) of electricity generated by renewable energy developers because the Ceylon Electricity Board (CEB) has failed to pay electricity supplied by them since August 2021. , Sangani explained.

“At this critical juncture where the country is in dire economic straits, renewable energy developers are finding it difficult to cease operations as they are unable to meet their critical payment obligations, including payment of employee salaries, l ‘maintenance and debts, Secretary, Wind Power Association Manjula Perera said.

“The net effect of this would not only be that the country would lose this mass of clean energy, but it would lead to a severe economic crisis because the alternative would be to procure thermal energy, burning fossil fuels at a Astronomical cost of around Rs.90/- per unit as opposed to the average cost of Rs.15.77 paid for renewables.This will exacerbate the forex crisis and will be unbearable for the country at this stage, Perera said.

“Overall, CEB owes around Rs. 22 billion to renewable energy operators. This has brought the industry to its knees, posing a serious threat of not being able to pay the salaries of around 7,000 employees, which could lead to a serious social crisis, he said.

“At the same time, banks have lent around Rs. 60 billion to the industry and servicing of these loans will soon stop,” said Grid Connected Solar Power Association Chairman Lasith Wimalasena.

“It can also have an impact on the banking system. On the other hand, there are about 550MW of projects in the pipeline for imminent financial close and if these are not funded and developed, the country will turn to high cost fossil fuels for electricity, further aggravating its economic difficulties, Wimalasena said.

“Sri Lanka has a huge energy deficit due to the wrong type of power plants in operation. Renewable energy is the cheapest and cleanest option available, however, these defaults will seriously discourage potential investors in the sector, completely halting the country’s ambition to become a high-generation renewable energy nation. and also failing to meet its obligations to the United Nations Sustainable Development Goals. (UNSDG), he added.

“CEB’s current average cost of a unit of electricity delivered to consumers is estimated at Rs. 60/-, as of April 20, 2022. The cost of direct generation itself from CEB power stations ranges from Rs. 154 per unit, Kelanitissa Power Station being the highest, and Rs. 7.19 (large hydro) being the lowest.

“Other renewable power plants operated by private owners are at their lowest after the cost of large reservoir-based hydropower plants and the recently commissioned 100MW wind power plant in Mannar, said the president of the Solar Industries Association, Kushaan Jayasuriya.

“The CEB should focus on cost-effectiveness and the promotion of renewable energy by creating greater flexibility in decision-making within the Sustainable Energy Authority, the Ministry of Energy, the Ministry of Finance, of the Attorney General’s office and the PUCSL for the good of the country and its people, Secretary, said Warna Dahanayake, Small Hydro Power Developers Association.

“The future target of 70% of electricity generated from renewables means it will never materialize as late payments will drive away investors,” he added.

Sri Lanka Insurance posts record profit of Rs. 11.7 billion before tax for 2021 – The Island


By Hiran H. Senewiratne

For the first time, an Indian online wholesale startup for emerging brands and distributors in Sivagangai, Tamil Nadu, will introduce Sri Lankan petrochemicals to the Indian market, said CEO of Vinayagam Associates of Tamil Nadu, T. Murugesan Vinayaga.

“We are now in the process of connecting leading and emerging brands in India to successfully reach and expand their network of customers, resellers and distributors across India. When I met the Deputy High Commissioner of Sri Lanka in Chennai, Dr. D. Venkateshwaran, he asked me to explore the possibility of marketing some of the best Sri Lankan brands in Tamil Nadu and all over India through our “DigiRiver.in”, an e-commerce site. platform, Murugesan told The Island Financial Review.

Murugesan added: “Lubricants, such as engine oils, hydraulic fluids, gear oils, transmission oils, greases and other similar lubricants are used in various applications in the agricultural sector to protect them from the wear caused by continuous use and also in the motor segment and especially for three-wheelers.

“After a visit to Sri Lanka, I discovered that Sri Lanka has a vibrant lubricants market and the products are economical and of high quality.

“The Sri Lankan lubricants market is expected to grow by more than 3% annually after suffering a setback due to the pandemic shutdowns in the country.

“Leading companies, such as Chevron Ceylon Ltd., IOC and Laugfs Holdings Ltd., have assembly plants and blending plants in Sri Lanka that offer products for the automotive and industrial sectors, with manufacturing capabilities. export to other regions.

“More recently, Ideal First Choice (Pvt.) Ltd, a wholly owned subsidiary of the Ideal Group, partnered with Gulf Oil Lubricants, India to bring lubricants to the Sri Lankan market.

“India is one of the leading countries in the world in terms of vehicle production. In 2021, India’s total vehicle production volume was around 22.7 million units, including around 400,000 three-wheelers.

“Despite manufacturing lubricants for these, India still imports around 40% and in Tamil Nadu alone over 25% of lubricants are imported. I plan to take a large share of these exports from Sri Lanka as it would be cheaper for the end user. This is because we could get benefits under several bilateral agreements with Sri Lanka.

“I intend to start imports of lubricants from Sri Lanka to India soon and distribute them all over India through our e-commerce portal. We also have a strong transportation system to support this distribution in all of Sri Lanka and this process will also help Sri Lanka to add a new item to their export basket and earn some much needed dollars for the country.

How Healthcare Professionals Can Help Consumers Supplement Smarter

In an age where the trusted voice of a single influencer can turn a trend into a phenomenon, supplement industry insiders might be asking this key question: what influence do healthcare professionals have on the use of dietary supplements by their patients? And how might their authority and expertise suggest smarter, or even more effective, supplementation strategies?

These are questions worth asking given the supplementation boom brought about by COVID-19. And given that doctors, nurses, and pharmacists are likely increasingly curious about supplements themselves, it’s a question the answer to which could open new doors for supplementation and for better human health.

mom is the word

As Medical Director of the Meno Clinic–Center for Functional Medicine (Wilson, WY), Mark Menolascino, MD, MS, ABIHM, ABAARM, IFMCP, is already curious and knowledgeable about supplements. But he also has a background in primary care medicine, and it may be through that training that he understands why supplement use “skyrocketed” at the start of the pandemic.

“Apart from masking and isolation,” he explains, “primary care medicine didn’t offer many concrete steps to protect a person’s lungs, optimize their immune system, or improve their detox.” . The result: supplements came to the rescue.

Yet while 29% of Americans are actually taking more supplements now than before the pandemic, survey finds1 conducted by The Harris Poll on behalf of the Samueli Foundation, that same survey found that less than half said they consulted their healthcare providers before taking them.

The reasons for this reluctance, according to the survey, ranged from doubt that respondents’ providers would be interested in their supplement regimen (35%) to fear that said providers might even judge them for it (26%).

But “I can tell you, as a practicing family physician, that health care providers are interested in the supplements their patients take,” insists Wayne Jonas, MD, executive director of Samueli Integrative Health Programs (New Alexandria, VA). Additionally, he says, “health care providers are the best source of information about what is appropriate and safe for patients.

“The key,” bets Jonas, “is for practitioners to engage in open, non-judgmental dialogues with their patients to develop plans that support healthy lifestyles.”

Healthy skepticism

But how can such dialogues take place when the health practitioners involved are in fact making judgments about supplementation, as many do?

For example, David Foreman, RPh, ND, founder and president of Herbal Pharmacist (Oceanside, CA), says fellow pharmacists tend to be “very skeptical of the supplement industry,” he says. “There is a definite distrust of the quality, efficacy and safety of natural products, and when you add the potential for drug interactions, you can see why my brothers and sisters in pharmacy are skeptical .”

And while certifications from organizations such as NSF International, ConsumerLab, and the US Pharmacopeia help allay some clinicians’ qualms, Jonas adds, “At a high level, we know there are many alternative therapies and supplements on the market that make outlandish claims. And often the science just isn’t there.

Thus, patients may find themselves “left alone to sort through the Internet”, laments Menolascino, “often unaware of quality or effectiveness”. And this is a state of affairs that serves no one well. “Even my patients who are familiar with supplements don’t always know exactly why they’re taking them,” he concedes. “And that’s where it’s so important for people to do their research and talk to medical professionals.”

Open minds

Alas, many medical professionals aren’t any more savvy about supplements than their patients, which is why even Foreman, the skeptic, says, “Supplements aren’t the boogeyman; it is usually a lack of knowledge that makes a practitioner anti-supplement.

Indeed, Menolascino recalls receiving little nutrition instruction in medical school, and none about nutritional supplements. “I like to say we had three hours of nutrition lectures that mostly revolved around scurvy and rickets,” he says.

It was only through training in functional and integrative medicine that he “learned that food really is medicine,” he says, “and that the quality of nutritional supplements is important. And in my medical practice, I have found that administering high quality supplements in the right doses helps patients reverse complex symptoms and regain energy and vitality.

Will Cole, IFMCP, DNM, DC, wellness expert for NOW (Bloomingdale, IL), shares this open mindset. Although some of his colleagues still view supplements as “overly available,” he says, he believes the products can be “great tools for correcting deficiencies and encouraging the healing process,” he says. “There is plenty of solid medical research readily available online that supports the benefits of many natural supplements.”

Can we talk?

To provide additional educational support, the Samueli Foundation has compiled what Jonas calls “basic information about supplement use that providers and patients need to know” on its website DrWayneJonas.com.

“We know that many doctors want information about how best to work with patients to understand their supplement use,” he says, and he says the site offers actionable tools to do that, like a questionnaire that doctors can use to ask patients about everything from their lifestyles and behaviors to social and emotional issues and, of course, supplement use.

For practitioners willing to engage with the topic of supplements, this could be just what the doctor ordered. As Foreman says, “It would be great to have practitioners initiate the conversation when someone makes a purchase or is interested in supplements. We need to ask consumers more questions, even the basics. »

For example, he wants to know if patients are taking “the right product for the right condition,” he says, as well as whether the product will interact with their current condition or their medications, which brand they choose — “to assess quality,” he says and if they are taking the right dose.

On that last point, Cole encourages his patients “to listen to their bodies,” he says, “and if they have to start at a lower dose than recommended on the label, that’s fine.”

Menolascino even asks his clients to bring “all their medications and supplements” to appointments so he can tell them “exactly what to take and what not to combine,” he says. . The clear reason? “Supplements are rarely one size fits all.”

They’re not panaceas either, which is why Cole advises patients to keep their expectations in check. “You can’t get yourself out of a bad diet with supplements,” he says. “If you’re lacking in nutrients because you’re not eating the right foods, supplementation can’t replace what you need in food. I always want to make sure the food comes first.

Patient proactivity

This underlines the important role played here by the consumers themselves. And while this role involves doing their health homework – and applying what they’ve learned in their own lives – it also involves asking questions of practitioners.

Foreman welcomes “simple questions like, ‘What should I take? Is it safe to take it with my medication? How much should I take? Does it have side effects? How long will it take to work? he says. “I would like them to always ask these questions, but I offer them the information before they ask anyway. It takes the worry away and reassures them.

This is exactly what practitioners should do. As Jonas says, “With more people taking supplements, we need to make sure they have the information they need to make informed, healthy decisions – and industry can be a major enabler by providing truthful information. and clear about the products.” Equally important, “Individuals should speak with their doctors. They are partners in care and they will know what is safe and best for their personal health goals.


  1. Marrapodi A. “More U.S. Consumers Are Using Dietary Supplements During the Pandemic, but Fewer Are Consulting Their Healthcare Professionals About Their Use, According to Harris Poll.” Nutritional Perspectives. Published online July 22, 2021.

The biosimulation market size will be worth approximately US$9.17 billion per

Ottawa, April 27, 2022 (GLOBE NEWSWIRE) — The drug-resistant characteristics of certain diseases like bacterial infections and cancer have led to an increased incidence of drug relapses. The growing investments of biotechnology companies in drug discovery and development activities have led to an increasing demand for biosimulation software. Biosimulation helps reduce costs related to research, drug development and clinical trials.

Get the Sample Report Pages @ https://www.precedenceresearch.com/sample/1646

The increasing adoption of biosimulation services and software by biosimilar companies, pharmaceutical companies and regulatory authorities has significantly fueled the growth of the global biosimulation market. There is a very high chance of failure of newly developed drugs during each phase of drug development and clinical trials. The adoption of biosimulation can help reduce the risk of failure and therefore significantly reduce drug discovery and development costs. Increased investment in the adoption of digital technologies in the pharmaceutical sector is expected to be one of the most important drivers of global development biosimulation market.

Report scope

Report attributes Details
Market size in 2021 $2.74 billion
CAGR 14.4% from 2022 to 2030
The biggest market North America
Fastest growing region Asia Pacific
Companies covered Biovia, Certara, Compugen Inc., Genedata, In Silico Biosciences, Inc., Leadscope Inc., Pharmaceutical Product Development, LLC., Schrödinger, LLC., Simulations Plus, Inc., DassaultSystemes, Advanced Chemistry Development

Report Highlights

  • Based on the product, the software segment dominated the market, constituting a revenue share of more than 66% in 2021. Increased adoption of biosimulation software by pharmaceutical companies, contract research organizations and regulatory authorities has significantly increased the growth of the software segment across the world. . Growing investments in drug discovery and development by pharmaceutical companies are further expected to fuel the demand for software in the global biosimulation market.
  • Based on an application, drug discovery is expected to be the most opportunistic segment during the forecast period. Rising demand for biosimulation software and services in the field of pharmacogenomics and pharmacogenetics is expected to propel the growth of the drug discovery segment in the near future.
  • Based on end user, the pharmaceutical and biotechnology segment accounted for more than 51% of the market share and led the global biosimulation market in 2021. The increased prevalence of various chronic diseases and genetic diseases has driven the demand for new drugs. Biopharmaceutical manufacturers are constantly engaged in the research and development process for the discovery of innovative drugs, which has driven the adoption of biosimulation in the pharmaceutical industry.

Ask here for more customization study @ https://www.precedenceresearch.com/customization/1646

Regional overview

North America dominated the global biosimulation market and constituted a revenue share of more than 45% in 2020. The favorable government policies in the United States and the increase in healthcare expenditure due to the increased prevalence chronic diseases are the main factors that have encouraged drug discovery, development and research activities in the region. The majority of proprietary rights to newly developed drugs belong to the United States. The presence of several large pharmaceutical companies has significantly boosted the demand for biosimulation in North America.

Asia-Pacific is expected to register a significant growth rate during the forecast period. Asia-Pacific is home to several leading and well-known research organizations. The presence of few major pharmaceutical companies in South Korea, China, and India is expected to present a lucrative growth opportunity for the key players operating in the biosimulation market. Favorable government policies and availability of cheap production factors are attracting huge FDI from major biopharmaceutical players across the globe. Growing investments in research, drug discovery and clinical trials in the Asia-Pacific region are expected to drive the demand for biosimulation in the coming years.

Market dynamics


Rapid growth of the biopharmaceutical industry

The biopharmaceutical industry represents about 20% of the pharmaceutical industry. The growing popularity of biosimilar and biologic medicines among consumers around the world is fueling investments in research and development of new medicines. Regulatory authorities like FDA and EMA contribute to the growth of the biopharmaceutical industry. The increasing focus on new drug development by biopharmaceutical companies is expected to significantly increase the demand for biosimulation software and services.


Lack of standardization is a major obstacle

There is a lack of standardization regarding the use of biosimulation technology in drug discovery and development. Biosimulation uses different types of models and tools to record and process various biological processes in drug discovery. The higher complexities associated with using biosimulation make it difficult for researchers to manage, modify, and share data and models. Therefore, the need for standardization is high for efficient and consistent results. The lack of standardization by regulatory authorities is a major impediment to the growth of the biosimulation market.


The growing applications of biosimulation

Biosimulation finds its place in various end-use applications such as industrial bioprocessing, agriculture, defense, and nutraceuticals, which is expected to present huge growth opportunities for market players in the foreseeable future. For example, in April 2017, Certara partnered with the Australian Department of Defense to conduct an audit of Australian MCM product research and development capability.

Related Reports


Lack of biosimulation modeling experts

Biosimulation uses complex mathematical operations and equations to represent processes in the human body. Therefore, skilled and expert professionals are needed for the management and monitoring of biosimulation software. The lack of experienced and qualified professionals in the market is a major challenge that limits the adoption of biosimulation.


  • In November 2020, Certara opened its office in Shanghai to strengthen its ties with its partners in the biopharmaceutical industry in China.
  • In September 2020, Advanced Chemistry Development launched the updated editions of the Spectrus and Percepta platforms, which aimed to improve the company’s portfolio.

Market segmentation

By product

  • Software
  • Services
    • Contract services
    • Internal Services

By app

  • drug discovery
    • Prospect identification
    • Lead Optimization
    • Target identification
    • Target validation
  • Drug development
    • Preclinical trials and clinical trials
    • In patient validation
  • Others

Per end user

  • Regulatory authorities
  • Pharmaceutical and biotechnology companies
  • Contract Research Organizations (CROs)
  • University research institutes

By delivery model

  • Subscription models
  • Ownership models

By geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Click here to View full report table of contents

Buy this Premium Research Report @ https://www.precedenceresearch.com/checkout/1646

You can place an order or ask any questions, please feel free to contact at [email protected] | +1 9197 992 333

About Us

Precedence Research is a global market research and consulting organization. We provide an unparalleled nature of offering to our customers located all over the world across industry verticals. Precedence Research has expertise in providing in-depth market intelligence as well as market insights to our clients spread across various businesses. We are obligated to serve our diverse customer base in medical services, healthcare, innovation, next-generation technology, semiconductor, chemical, automotive, aerospace and defence, among the various companies present in the world.

For the latest update, follow us:




Hemas Pharmaceuticals in collaboration with the Pharmaceutical Society of Sri Lanka improves the skills of pharmacists to serve the community – Adaderana Biz


The Certificate Ceremony Was Held for the 2nd Batch of the Pharmacy Staff Skills Development Program

Hemas Pharmaceuticals, Sri Lanka’s leading pharmaceutical importer and distributor for over seven decades, recently concluded the “Pharmaceutical Staff Skills Development Program” certificate ceremony at Hilton Residences, honoring their second batch with 35 students. The program was launched in partnership with the Pharmaceutical Society of Sri Lanka (PSSL) with the primary aim of providing the skills and knowledge needed to achieve national registration as a Registered Pharmacist in 2019.

A career development program providing comprehensive knowledge to students aspiring to become pharmacists, the “Pharmacy Personnel Skills Development Programme” is presented by Hemas Pharmaceuticals in collaboration with PSSL. This provides an opportunity for aspiring candidates who plan to take the registration exam and obtain registration as a pharmacist by the SLMC, to attend a free 6-month preparatory program and ensures that the industry and the community as a whole are well qualified. pharmacists. The course curriculum covered community pharmacy practice, pharmacy, pharmacology and therapeutics, pharmacy management, regulatory requirements, pharmacognosy, cold chain management, and patient care skills. customer base.

Commenting on the initiative, Jude Fernando, Managing Director, Hemas Pharmaceuticals and Hemas Surgicals & Diagnostics said, “It is with great pleasure that I note the conclusion of Batch 2 of the Pharmacy Staff Skills Development Program and reiterate our commitment to continue this program for the benefit of aspiring students and the community we serve. The development of pharmacists is an essential link and an essential element in providing high quality medical service to the public. Hemas Pharmaceuticals has always been at the forefront of providing high quality medical services, and we believe it is our responsibility to train industry pioneers in all areas.

“Many young people in Sri Lanka are interested in pursuing careers in the medical field, and many students are pursuing a degree in pharmacy. However, education in the fundamentals of pharmacy practice and customer and patient service skills are also of paramount importance to ensure ultimate therapeutic outcomes. I am grateful to Hemas Pharmaceuticals for their help in uplifting the pharmacy profession in Sri Lanka by partnering with PSSL,” said Tisara De Silva, president of the PSSL.

A wholly-owned subsidiary of Hemas Holdings PLC, Hemas Pharmaceuticals’ persistence and know-how in innovation has made it one of the most streamlined and modernized organizations in the domestic industry, with operations of unparalleled sales and distribution. Designed to be ultra-efficient and geared towards providing business partners with the solutions they need, Hemas Pharmaceuticals currently holds over 30% market share as the largest pharmaceutical distributor in Sri Lanka.

“On Track”: NM Students Present Science Projects at NAIOP Event

Michael Toya, 11, of Bosque Farms Elementary School, demonstrates the effects of different guitar choices Monday at a NAIOP NM event. This year, the organization distributed over $26,940 to students. (Roberto E. Rosales/Albuquerque Journal)

Copyright © 2022 Albuquerque Journal

About 20 of New Mexico’s brightest minds gathered Monday to present how their research could shape the future. And no, they are not scientists from the national state laboratories.

They were students — elementary through high school — who pitched their science projects to NAIOP New Mexico members and donors at the Marriott Albuquerque for the commercial real estate organization’s annual student showcase. This was the 16th year that NAIOP supported local students, and the organization distributed $180,000 to students through donor members.

This year, the organization distributed more than $26,940 with the help of more than 50 donors, said NAIOP NM Executive Director Rhiannon Samuel. Students who participated in the Central New Mexico STEM Research Challenge—one of five regional science fairs in the state—were judged and awarded by the NAIOP Science Fair Committee, led by Louis Abruzzo and Mary Homan, in March.

Select students who attended these regional fairs as well as the State Science Fair hosted by New Mexico Tech are eligible to attend the International Science and Engineering Fair hosted in Atlanta next month. Landon Flemming, a 17-year-old student at Explore Academy, is a student heading to ISEF on May 7. Flemming created a low-cost artificial pancreas system for his science project.

“It’s so rewarding,” Abruzzo said of seeing New Mexico’s next generation of influencers present their research. “These kids come out of all kinds of schools.”

One such student is 15-year-old Albuquerque Institute of Mathematics and Science student Sebastian Stoker, who placed second in the junior division for life sciences and first in life sciences. earth and environment in the Central New Mexico STEM Research Challenge in late March — the same fair where NAIOP members awarded money to students. More recently, Stoker also won first prize at the State Science Fair hosted by New Mexico Tech.

Stoker has received more than $900 from donors for his project, he said, and he plans to continue his research before eventually studying pharmacy.

For Aimee Linebarger, 16, a student at AIMS, her science project was inspired by close to home. Linebarger, who has acted in plays and often sings at the National Hispanic Cultural Center, said the building has been flooded three times in the past three years. So she designed a project that could detect building flooding using a series of Raspberry Pi computers.

Her project won second place in Senior Engineering at the STEM Research Challenge and she received $925 which she plans to save for college.

Sebastian Stoker explains his science project on aquatic microplastic pollution throughout the Rio Grande on Monday at the Marriott Albuquerque. (Roberto E. Rosales/Albuquerque Journal)

Salam Academy student Ryhab Jrifat, 13, focused on five specific fears for her social science project – asking a question about the fear that resonated most with middle and high school students. After gathering information and calculating the average of the data, Jrifat said his data showed that 16 to 18 year olds feared failure the most. For Jrifat, who says she’s not the best at math, the recognition for her work has motivated her to continue in the STEM field.

“Even if the math is hard — because math can be complicated — stick with it,” Jrifat said, offering words of encouragement to other students interested in the STEM field.

Path to a bright future

Calculations can be difficult, the work invested in a project can sometimes be demanding on the mind. But if you stick with it, as Jrifat said, the benefits reaped can be greater than what was sown.

Ask Devin Roach, a recent graduate of Georgia Tech University. Roach earned his doctorate in mechanical engineering from college — but he attributes his interest in science to using NAIOP NM when he was just a high school student at St. Pius X.

Roach, a self-confessed sports fan, said he created a science project that studied the rebound of different basketball shoes. Through his research, he discovered that Shaq basketball shoes – usually found at Walmart – had more bounce than some other more recognizable shoes.

His project at the time earned him $1,400 from NAIOP donors, led to his PhD, and now brought him home to Albuquerque where he is a post-doctoral researcher at Sandia National Laboratories working in the additive manufacturing.

“Getting NAIOP recognition and kind of getting the ability to go speak in front of people, other scientists (and have) people in projects when I was showing my bulletin board – that sort of thing – really inspired me and reassured me that I was on the right track,” Roach said. “It’s just validation.”

Ryhab Jrifat, 13, explains his fear science project to the curious on Monday at the Marriott Albuquerque. (Roberto E. Rosales/Albuquerque Journal)

Buffalo Next: The Rise of Millionaire Buyers |

With home sales prices soaring across the country, million dollar home sales are becoming more common in many places.

Not so much in Western New York yet, although they’ve picked up here too.

According to a report by Inspection Support Network, the Buffalo Niagara area had the second-lowest home sales, exceeding $1 million in 2020, of all major US cities, accounting for just 0.19% of all the transactions. That’s just one in 500 sales in Western New York.

sale sign (copy)

Few homes sell for over a million dollars in the Buffalo Niagara area.

Sharon Cantillon/Buffalo News

By comparison, nationwide, 4.76% of all transactions were for homes selling for more than $1 million. And statewide — which includes the pricey markets of New York and Long Island where million-dollar homes cost a dime a dozen — it’s 9.7%, meaning that one in 10 homes is a million dollar deal.

People also read…

Of course, that’s not surprising, given the more affordable nature of housing in Western New York. It’s well known that you don’t have to be a millionaire to buy a nice big house here – an often touted selling point in the area.

But other statistics in the report showed surprising similarities and differences. For example:

  • The median value of homes sold above the $1 million magic threshold locally was $1.28 million, just $75,000 less than the national median of $1.355 million. This indicates that most million-dollar homes are still on the lower end of the spectrum, not the multi-million dollar mega properties that grabbed the headlines.
  • Million-dollar buyers in Western New York had a median income of $528,500, significantly higher than the median of $330,000 across the country. This means that it is mainly the wealthy who buy such houses here, while even upper middle class households are in this market in many other areas – probably because prices in general are much higher in other areas. cities, so almost everyone pays.
  • The median down payment for homes over $1 million is $275,000 in Buffalo, but $410,000 nationally. That means local buyers aren’t digging as deep in the beginning to get their million-dollar home, or buyers elsewhere have accumulated more equity in the home they’re selling to go up.

The study used data filed with banking regulators under the Home Mortgage Disclosure Act and looked at conventional home purchase loans in 348 metropolitan areas with at least 100,000 residents. Buffalo was tied with Rochester at the bottom of the big city rankings, but Rochester’s median home price and median income were both lower.

Not surprisingly, more than one in five California homes have sold for more than $1 million, as the top four cities for million-dollar homes are all located in the Golden State. In fact, in the San Jose area — which led the nation — nearly two out of three homes are over $1 million.

Hawaii and Massachusetts were next among states, with 17.51% and 10.18% of all homes exceeding that mark, followed by New York. In contrast, 16 states had less than 1% of homes sold at this level.

Median prices have generally been rising steadily and accelerating for over 60 years, but the rate of increase has accelerated in recent years, particularly since the start of 2020 and the onset of the Covid-19 pandemic. The national median topped $400,000 for the first time in 2021, while Buffalo’s median topped $200,000 for the first time. Buffalo also broke the $2 million cap for single-detached home sales earlier this year.

On the other hand, the share of homes selling for less than $300,000 – including the first-time buyer market – has fallen from 52% in 2018 to 46% in 2020. That means it’s getting harder for buyers low end to find a home.

Want to know more? Three stories to catch up with you:

Welcome to Buffalo Next. This newsletter from The Buffalo News will bring you the latest coverage on the changing economy of Buffalo Niagara – from real estate to healthcare to startups. Learn more at BuffaloNext.com.


Brothers-of-Mercy-Expansion-Clarence (copy)

This is an aerial view of the Brothers of Mercy Nursing and Rehabilitation Center in Clarence. (Photo courtesy of the Brothers of Mercy)

Center of the Brothers of Mercy

A rendering of the proposed new Brothers of Mercy Center on its Clarence campus, with a doctors practice, research office, and pharmacy in part of the former Sacred Heart Home building.

Clarence Planning Council

Golf carts and swimming pools. The Hamburg Planning Board on May 4, during its working session ahead of the official meeting on May 4, will consider a proposal and application for a special use permit from Golf Carts Unlimited to construct a 2,000 square foot building , an addition to its existing building and a roof extension for a parking garage at 2330 Lakeview Road. The committee will also consider Colley’s Pools’ request for a “sketch plan direction” for its proposal to build a new 6,000 square foot warehouse at 4953 Camp Road.

Rising costs. On April 20, the Hamburg Industrial Development Agency authorized an increase in a previously approved mixed-use infill project at 290 Lake Street in Hamburg Village, on the corner of Church Street, due to rising construction costs. construction. The project by developers Joseph Battin, Christian Gorino and Paul Lamparelli calls for the construction of a 19,260 square foot apartment building on the site of a Schmidt’s Collision and Glass building, which collapsed under the weight of snow after the November 2014 storm. The new three-story building will feature 10 market-priced units with one or two bedrooms each, totaling 12,840 square feet, plus an additional 6,420 square feet of office or retail space. The cost of the project has increased from $3.16 million when initially approved to $4.52 million. Under the new terms, the developer will now receive $136,524 in sales tax relief, $267,517 in property tax abatement and $23,250 in mortgage registration tax relief.


Keep up to date with news related to Buffalo Niagara’s economy:

A small, eight-room Airbnb-style boutique hotel is planned in Lancaster, near Lake Como Park. The $2.8 million project would be a two-story, 18,000-square-foot mixed-use building, utilizing vacant land that once housed Desiderio and then Brother restaurants.

A new A four-story, $2.5 million self-storage facility with 164 rental storage units is proposed for 321 Commerce Drive in Amherst by landscape contractors Eric Bogart and Michael Sinatra.

M&T Bank is halfway to hiring 1,000 technologists in the Buffalo areaan ambitious goal set three years ago, just before making the Seneca One tower the place where the bank would establish its “technology hub”.

Dr. Todd Shatkin and Daemen University Seek Nearly $394,000 in Sales Tax Relief for the $7.85 million project to develop a new dental school and physical rehabilitation center on the Amherst campus.

About a month after a deal was announced and weeks after the state approved a budget that included funding, Erie County Legislature to finally begin talks on Buffalo Bills Stadium deal this week.

Empire State Development prioritizes efforts to work with local regions seize new investment and employment opportunities by building the skills of their workforce and helping communities gather more shovel-ready land for new projects.

Fattey Beer Co. will open in three more locations, including one in Kenmore and additional stores in the Strong National Museum of Play’s Neighborhood of Play in Rochester and in Westerville, Ohio, near Columbus. There are five craft brewery and beer shop hybrids in the area.

LCB Capital hopes to bring a new five-story building with 44 market-priced apartments to Delaware Avenue in Allentown. The Kenmore-headquartered real estate company already owns eight residential and commercial properties in Buffalo and Kenmore.

For the first time in over a decade, mortgage rates hit 5% – from 3.1% in December – driving up the cost of buying a homewhich could lead to slower sales and more modest increases in house prices, according to M&T Bank’s chief financial officer.

Buffalo Next reporters Jonathan D. Epstein, Jon Harris, Natalie Brophy, Janet Gramza and Mike Petro contributed to this roundup.


Five reads from Buffalo Next:

1. A new statewide energy plan being debated would phase out the use of natural gas in favor of electricity, bringing big changes to the way New Yorkers in the West heat their home and operate their appliances.

2. Three local growers are among the first 52 licenses granted to grow recreational marijuana for adult use in the state. They include The Releaf Market in Jamestown, Yager Farms in Eden, and Wheatfield Gardens in Wheatfield.

3. Some companies, such as Independent Health and Freed Maxick, are embracing “hoteling”, where remote employees book a workstation for the days when they come to the office to do their job, rather than having their own dedicated desk.

4. Build a New Buffalo Bills Stadium expected to create 10,000 local jobs for construction workersbut some contractors feel left out due to the stadium pact, including plans for a project labor agreement that requires contractors to pay prevailing wages.

5. The remarkable revival of the house of Bethlehem Steel: With a handful of new developments, and more on the way, the gated Bethlehem Steel complex is becoming a sign of renewal.

The Buffalo Next team gives you insight into the economic revitalization of the region. Contact real estate and development reporter Jonathan D. Epstein at (716) 849-4478 or email him at [email protected]

Was this email forwarded to you? Sign up to get the latest news delivered to your inbox five days a week.

Email tips to [email protected]

Support people who abuse alcohol

Communication and therapeutic skills can help pharmacists screen and educate patients on this sensitive topic.

As trusted healthcare professionals, community pharmacists have a responsibility to support patients who abuse alcohol.

According to the 2019 National Survey of Drug Use and Health, 14.5 million people in the United States suffer from alcohol use disorder (AUD) and alcohol-related causes are the third preventable cause of death in the United States behind smoking and poor diet. and physical inactivity.1 Pharmacists can screen and educate patients about various conditions, including AUD.


Many drugs interact with alcohol.2 These interactions have broad consequences, such as an increased risk of dizziness, drowsiness, and gastrointestinal bleeding. Heavy alcohol consumption worsens many chronic diseases, including cancer, cardiovascular disease, diabetes, digestive disorders and liver disease. Mental health disorders often coexist with AUD.2.3 Pharmacists can explore a patient’s alcohol consumption during a consultation for drugs that interact with alcohol and when dispensing drugs for comorbidities or conditions affected by alcohol abuse.4

The accessibility of community pharmacists goes beyond filling patients’ prescriptions. Patients may seek counseling for managing minor and limiting symptoms associated with alcohol.4 These include over-the-counter medications for emergency contraception, hangovers, headaches, indigestion, minor injuries, nausea, and vomiting. These conditions warrant investigation of alcohol use.4

Pharmacists should use a tool that is short, validated and easy to implement when screening for AUD. The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) is a convenient screening tool (Table 1).5

The pharmacist’s next steps vary. They must have communication and therapeutic skills to navigate AUD conversations.4 Pharmacists should refer patients to a physician if they suspect potential AUD. The American Psychiatric Association recommends patient-centered treatment with non-pharmacological and pharmacological components.3

Appropriate therapy

Evidence-based non-pharmacological treatment for AUD includes motivation enhancement therapy (MET) and cognitive-behavioral therapy (CBT). MET is a technique derived from motivational interviewing, in which the patient’s beliefs and goals lead to change. The MET is generally a 90-day, 4-session framework.6 CBT integrates behaviors, feelings and thoughts, helping to manage triggers associated with alcohol consumption.7

Despite a high prevalence of AUD, less than 4% of people are prescribed one of 4 FDA-approved treatments for moderate to severe AUD1: oral acamprosate (Campral), oral disulfiram (Antabuse), intramuscular naltrexone (Vivitrol) and oral naltrexone (Révia). Gabapentin and topiramate are used off-label as treatments. Table 2 provides information on FDA-approved drugs.8,9,10,11 When identifying barriers to adherence or unsuccessful treatment, pharmacists should refer patients to their physician for potential treatment changes.

Limited literature examines pharmacist screening and brief interventions for substance use disorders, so more evidence is needed.4 Community pharmacists are expanding their role to provide advanced services, including chronic disease screening and management, smoking cessation, and treatment of minor ailments.12 Eventually, community pharmacies may offer brief AUD screening interventions. As with many services, reimbursement and staffing will be a challenge for the implementation of AUD interventions.


Whether it’s being the first contact with health care, screening patients with potential comorbidities, or counseling patients undergoing treatment, pharmacists can support people who misuse alcohol. Pharmacists must have the appropriate communicative and therapeutic skills to manage this sensitive topic.

Linsday Sawtelle is a PharmD candidate at the University of Connecticut School of Pharmacy at Storrs.


1. Facts and statistics about alcohol. National Institute on Alcohol Abuse and Alcoholism. Updated March 2022. Accessed March 1, 2022. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics

2. Weathermon R, Crabb DW. Drug and alcohol interactions. Alcohol Res Health. 1999;23(1):40-54.

3. Reus VI, Fochtmann LJ, Bukstein O, et al. American Psychiatric Association practice guidelines for the pharmacological treatment of patients with alcohol use disorders. Am J Psychiatry.2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101

4. Hattingh HL, Tait RJ. Pharmacy alcohol abuse services: current perspectives. Integr Pharm Res Practice. 2018;7:21-31. doi:10.2147/IPRP.S140431

5. Kriston L, Hölzel L, Weiser AK, Berner MM, Härter M. Meta-analysis: Are 3 questions enough to detect unhealthy alcohol consumption? Ann Medical Intern. 2008;149(12):879-888. doi:10.7326/0003-4819-149-12-200812160-00007

6. Lenz AS, Rosenbaum L, Sheperis D. Meta-analysis of randomized controlled trials of motivational enhancement therapy to reduce substance use. J Addict Offender Couns. 2016;37(2):66-86. doi:10.1002/jaoc.12017

7. Epstein EE, McCrady BS. A cognitive-behavioral treatment program for overcoming alcohol problems: A therapist’s guide. Oxford University Press; 2022.

8. Revia. Prescribing Information. Duramed Pharmaceuticals Inc.; 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf

9.Vivitrol. Prescribing Information. Alkermes, Inc.; 2021. https://www.vivitrol.com/content/pdfs/prescribe-information.pdf Comments limited to one page

10. Camprai. Prescribing Information. Forest Pharmaceuticals, Inc; 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021431s013lbl.pdf

11. Antabuse. Prescribing Information. Duramed Pharmaceuticals Inc.; 2010.file:///C:/Users/cmollison/Downloads/20120420_12850de3-c97c-42c1-b8d3-55dc6fd05750.pdf

12. Mossialos E, Courtin E, Naci H, et al. From “retailers” to healthcare providers: transforming the role of community pharmacists in chronic disease management. Health policy. 2015;119(5):628-639. doi:10.1016/j.healthpol.2015.02.007

COVID and CBD prove to be a powder keg for federal regulators | Bradley Arant Boult Cummings LLP


Cannabis operators (from marijuana to hemp-derived products such as CBD) often feel like they are one of the prime targets of the federal government’s reach. But they haven’t been in the same league lately as the COVID-19 virus. Earlier this month, these worlds collided.

The United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have jointly issued warning letters to companies that have claimed or implied that these companies’ products will cure, mitigate, treat, or prevent coronavirus disease 2019 (COVID-19). As the agencies have made clear, no drugs containing CBD have been approved for the treatment or prevention of COVID-19. We have previously covered similar warning letters regarding the marketing of CBD products (here and here). These warning letters are also not limited to CBD companies; the FTC has already sent similar warning letters in 2020 to companies for making similar claims about the ability of other products to treat or prevent COVID-19.

The agencies warned these companies that such statements violated the Federal Food, Drug, and Cosmetic Act (FDCA) and the Federal Trade Commission Act, and demanded that these companies take immediate action to end these representations. regarding their products. In one case, the agencies noted that the company’s website contained a link to a 2021 National Institute of Health study indicating that CBD “reverses many of the effects of COVID-19, preventing the infection from getting worse. and promoting future immunity”; a study by researchers at the University of Chicago showing “a significant negative association with positive COVID tests” for people taking CBD; and a 2022 study from the American Chemical Society and the American Society of Pharmacognosy concluding that CBD binds to COVID-19 spike proteins and prevents the virus from entering cells and causing infection. After citing these studies published on the company’s website, the agencies demanded that the company “take immediate action to remedy the violations cited in [the] letter.” The agency letters are a stark reminder that companies should avoid marketing a substance’s purported health benefits or effectiveness in treating or preventing disease, regardless of what evidence may exist to support it. such statement, unless such product has been approved, cleared, or cleared by the FDA for such purpose.

Belarus, Uzbekistan discuss ways to advance pharmaceutical cooperation


Photo courtesy of the Ministry of Health

MINSK, April 25 (BelTA) — Representatives of the pharmaceutical industries of Belarus and Uzbekistan are discussing ways to advance cooperation, the press service of the Belarusian Ministry of Health told BelTA.

A Belarusian government delegation headed by Prime Minister Roman Golovchenko is currently in Uzbekistan. The delegation includes Deputy Health Minister Boris Androsyuk and representatives of the management company of the holding company Belpharmprom and the pharmaceutical companies of the holding company.

Boris Androsyuk and the first deputy general director of the management company of the Belpharmprom holding company Pyotr Vorobyov met with the director of the Pharmaceutical Industry Development Agency of Uzbekistan Sardor Kariyev. Ways to advance cooperation in the joint production of medicines were discussed.

Photo courtesy of the Ministry of Health

Photo courtesy of the Ministry of Health

Boris Androsyuk also visited the Belarusian-Uzbek drug manufacturer Belpharm, where a project for the manufacture of antibiotics is being implemented. The project is stipulated by the action plan on promoting cooperation between Belarus and Uzbekistan.

On April 25, Belarusian Deputy Health Minister also met with Uzbek Deputy Health Minister Otabek Fazilkarimov. The parties discussed bilateral cooperation in the field of medical goods and pharmaceutical drugs.

At present, the enterprises of the Belarusian holding company Belpharmprom have 166 certificates of drug registration in Uzbekistan. Belpharmprom enterprises have signed 12 drug supply contracts with Uzbek partners. In 2021, Belpharmprom’s exports to Uzbekistan totaled $14 million. The figure stood at $3 million in January-February 2022.

The Surprising Effects of Eating Cinnamon, Say Dietitians – Eat This, Not That


We know that there is no magic pill for perfect health – it’s a combination of our eating habits, our drinking habits, our exercise habits, our sleep and even our stress levels that make all the difference. However, sometimes the smallest changes in our diet can make a huge difference to our overall health, even as simple as a sprinkle of cinnamon.

Eating cinnamon has been touted as a powerful health ingredient, and science backs up those claims. A review in Research in pharmacognosy researched different studies on cinnamon and found it beneficial due to its antioxidant, anti-inflammatory, antilipemic, antidiabetic, antimicrobial, and anticancer effects.

So what exactly does this mean for our health? We asked some of the Registered Dietitians on our Medical Expert Council to share the specific ways eating cinnamon can positively impact the health of your body. Here’s what they had to say, and for even more healthy advice, here’s The Best Juice to Drink Every Day.


“Cinnamon contains antioxidants like polyphenols,” says Amy Goodson, MS, RD, CSSD, LDauthor of The Sports Nutrition Handbook. “Antioxidants help buffer free radicals (i.e. the bad guys that cause cell damage in the body) and, by default, can help reduce inflammation.”

Reducing inflammation in your body has also been shown to help maintain body composition and prevent certain weight-related diseases.

“Cinnamon [has] It has been shown to reduce body weight and belly fat, helping to prevent obesity,” say Tammy Lakatos Shame, RDN, CDN, CFTand Lyssie Lakatos, RDN, CDN, CFT, also known as Nutrition Twins. “Research shows it improves insulin resistance, improves A1C (a measure of long-term blood sugar control), lowers triglycerides, and has even improved the regularity of menstrual cycles. Plus, it’s packed with antioxidants that help prevent cell damage.”

cinnamon apple oatmeal

Due to the polyphenols in cinnamon, Lisa Young, Ph.D., RDNauthor of Finally full, finally thin and The teller plansays these “powerful antioxidants contain anti-inflammatory properties [that] can help prevent chronic diseases”

“Cinnamon can help lower blood sugar and reduce insulin sensitivity, making it the perfect spice for people with type 2 diabetes,” says Young. “It may also help prevent heart disease by lowering cholesterol and triglyceride levels.”


“It has been shown to decrease the amount of glucose that enters your bloodstream after a meal by interfering with many digestive enzymes, which slows the breakdown of carbohydrates in your digestive tract,” says Goodson. “It can also act on cells by mimicking insulin, which helps improve your cells’ uptake of glucose. However, it acts much more slowly than insulin itself.”

cinnamon coffee

“Naturally sweet cinnamon saves calories and staves off the blood sugar swings and energy highs and lows that come from eating too much sugar,” say The Nutrition Twins. “It’s the perfect calorie-free sugar substitute because it adds sweetness without creating the sugar-induced inflammation that makes losing weight harder and gaining weight easier.”

oatmeal with cinnamon, bananas and blueberries

In order to reap the powerful benefits of cinnamon, it’s important to find other ways to sprinkle it into your food, not just your morning cup of java.

“To reap the benefits of cinnamon, you probably need to do more than just sprinkle your coffee,” Goodson says. “It’s important to note that the effective dose is 1 to 6 grams or about 1/2 to 2 teaspoons per day, which is a lot of cinnamon.”

You do not know where to start ? The Nutrition Twins list a few recommendations.

“Replace sugar with cinnamon in pancakes, French toast, smoothies, coffee, muffins, cereal, oatmeal, granola, yogurt, milk, hot chocolate, tea, toast, fruit, etc.”, say The Nutrition Twins. They even recommend baking in their searing cinnamon oatmeal.

Kiersten Hickman

Kiersten Hickman is associate editor of Eat This, Not That!, with a particular focus on food coverage, nutrition, and recipe development. Read more

Commissioners meet April 4, EMS motions are a big part of the agenda

Submitted by Terri Crothers

The Adams County Board of Commissioners met in regular session on April 4, 2022 at the Government Center with the following members in attendance: Barbara Moore, Diane Ward and Ty Pell. The meeting was opened by President Moore and opened with prayer and the Pledge of Allegiance led by Pastor Christian Martin via teleconference. Juvenile Court Registrar Christy Kirker was present at the hearing.

Moved by Diane Ward and seconded by Ty Pell to approve the minutes. Vote: Everyone agrees.

It was moved by Ty Pell and seconded by Barbara Moore to approve the invoices for payment. Vote: Everyone agrees.

Moved by Barbara Moore and seconded by Diane Ward to approve the transfers. Vote: Everyone agrees.

Angela Richmond, Director of Employment and Family Services, met with council to discuss the following issues: Personnel – Employment – Boldman; Personal – Discipline; Remote Labor – Pay West Union Village Taxes when not working inside the Village.

It was moved by Diane Ward and seconded by Barbara Moore to enter into executive session at 9:34 a.m. with the Director of Employment and Family Services Angela Richmond to discuss certain personnel matters (discipline) in accordance with the ORC 121.22 (G) (1). Vote: Everyone agrees. Commissioner Moore resumed the meeting at 9:46 a.m.

It was moved by Diane Ward and seconded by Barbara Moore to approve the employment of Shay Boldman as Desk Specialist 1 in the Adams County Department of Employment and Family Services effective April 11 2022, as submitted by JFS Director Angela Richmond. Vote: Everyone agrees.

It was moved by Diane Ward and seconded by Barbara Moore to go into executive session at 10:02 a.m. with Sheriff Kimmy Rogers, Deputy Randy Walters and FOP Union Representative Mark Scranton to discuss collective bargaining matters pursuant to the ORC 121.22(G)(4). Vote: Everyone agrees.

Commissioner Moore resumed the meeting at 10:20 a.m.

It was proposed to Diane Ward and seconded by Barbara Moore to accept Adriana Carter’s resignation as Janitor effective April 1, 2022, as presented by Maintenance Supervisor Jason Hayslip. Vote: Everyone agrees.

It was moved by Barbara Moore and seconded by Diane Ward to enter into an agreement between the Village of West Union and the Adams County Board of Commissioners for the transportation of emergency medical services to inmates at the County Jail. Adams at a rate of $200 per transport starting in April. From December 4, 2022 to December 31, 2022.Vote: Yes.

It was moved by Diane Ward and seconded by Ty Pell to enter into an agreement with the Association of County Commissioners of Ohio Service Corporation (CCAOSC) for participation in the Workers Compensation Retro Group Assessment Plan. Vote: Everyone agrees.

It was moved by Barbara Moore and seconded by Diane Ward to approve the following travel request: Lisa Newman CTA 2022 Summer Conference May 23-26, 2022 $880. Vote: Everyone agrees.

Moved by Ty Pell and seconded by Barbara Moore to approve Drawdown Request #1 in the amount of $10,258 for FAA Airport Grant 3-39-0112-013-2021 (CRSSA) Alexander Salamon and to authorize Commissioner Ward to sign on behalf of the county. Vote: Everyone agrees.

Moved by Diane Ward and seconded by Ty Pell to approve Drawdown Request #2 in the amount of $2,000 for FAA Airport Grant 3-39-0112-010-2020 (CARES) Alexander Salamon and to authorize Commissioner Ward to sign on behalf of the county. Vote: Everyone agrees.

DPE Director Holly Johnson met with the Board to discuss the following matters: Adams Lake Sewer Project – Discussion focused on placement of manhole covers and extensions for residential partials ;

Water Extension Projects – Request from resident on Hawkins Road for water service; Highland County Water has shown no interest in serving Cow Run Road, Heron Road, Raines Road and State Route 770; Replacement of the roof of the annex building – will be advertised for tenders; opening April 25, 2022 10:30 a.m.; Airport Package Plant – Requested a quote request for maintenance; MOU agreement for operation and maintenance; Adams County Training Center – Fire hydrant on the sidewalk in the village right-of-way. Relocation to be discussed at the next construction meeting; Faith Based Grant – Faith Based and Community Initiative Grant available from the Governor’s office; Adams County Airport-Problem with NOTAM posting during construction; problem fixed immediately.

At 10:30 a.m., the second public hearing was held for the Community Housing Improvement Program (CHIP) with Holly Johnson, Director of ECD. An application will be submitted in June 2022 for $300,000 in funding to support housing rehabilitation, down payment assistance and home repairs.

The board met with EMS Chief Peggy McCleese and Deputy Chief Adam Dozier to discuss the following issues: Personnel – Resignation – Sims, Eagle, Miskell; New team – Delay in delivery due to chassis; Quarterly Budget Update – Review of Quarterly Budget and Statistics – Number of cycles almost doubled compared to 2021; Squad maintenance and repairs due to engine and transmission replacement; Wage increases – necessary overtime reductions; Increased supplies due to the opening of new stations; Utilities – will apply to discounts and budget billing for savings; Fuel – Unbudgeted fuel price increase. Look for ways to reduce costs; Medicount – Will reduce fees on income amounts; EFT of revenue to county account; Station #500 – Schedule presented for completion and inspection. The pharmacy board will approve the license after the final inspection.

It was moved by Barbara Moore and seconded by Diane Ward to accept Brian Sims’ resignation with Adams County Emergency Medical Services effective April 1, 2022, as recommended by Chief Peggy McCleese. Vote: Everyone agrees.

It was moved by Ty Pell and seconded by Barbara Moore to accept Matt Eagle’s resignation from Adams County Emergency Medical Services effective April 16, 2022, as recommended by Chief Peggy McCleese. Vote: Everyone agrees.

It was moved by Diane Ward and seconded by Ty Pell to accept Phil Miskell’s resignation with Adams County Emergency Medical Services effective April 1, 2022 as recommended by Chief Peggy McCleese. Vote: Everyone agrees.

It was moved by Ty Pell and seconded by Barbara Moore to approve the employment of Brian Baldridge as a volunteer physician with Adams County Emergency Medical Services effective April 4, 2022. Vote: All yes.

Council met with County Engineer Lee Pertuset to discuss the following matters: Bid Award – Adams County Paving Project – Various Roads/2022; Coffee Hollow Road flooding issue.

It was moved by Ty Pell and seconded by Barbara Moore to approve the awarding of the Adams County Paving Project – Various Roads to the lowest bidder Brown County Construction Company, LLC at the bid of $947,363 on the recommendation of engineer Lee Pertuset. Vote: Everyone agrees.

A public meeting was held at 1 p.m. regarding a petition filed by John McCormick that requested the partial release of Virginia Road, T-421, Scott Township. Those present at the hearing were: Landowners John McCormick and Lois McCormick. No evidence was received against the proposed partial vacation. It was moved by Ty Pell and seconded by Diane Ward to approve the partial release of Virginia Road, T-421, Scott Township, as requested by John McCormick. County Engineer Lee Pertuset will file a report on the closure. Vote: Everyone agrees. The executive session requested by McCormick to discuss the continued closure of Virginia Road, but the request was denied due to lack of provisions in the guidelines.

Assistant Attorney Randalyn Worley met with the board to discuss the following legal issues: requesting a waiver of fees for delinquent property tax on the property that was inherited; Kelly Day – Protocols for establishing Kelly Day for EMS staffing.

Moved by Barbara Moore and seconded by Ty Pell to adjourn

Scotia Band celebrates longtime musician – Times-Standard

Scotia Band member Phil Sams will receive a special honor this summer.

The Ferndale musician has been a member of the Scotia Band for 50 years, attending 2,500 weekly rehearsals and some 300 performances along the way.

Each year, the Scotia Band honors its members with a lapel pin for every five years of rehearsal and concert attendance. Sams’ 50th birthday pin, which he will receive in July, brings him into an elite league of band members, which also includes Henry Bender, Merle Adams, Charles Langdon, Al Pollard, Woody Thompson and, more recently, Cecil Williams.

Sams is modest about his achievement, saying, “Music has always come easy to me.”

When he was in second grade, his parents signed him up for piano lessons with Catherine Mikkelsen on Ferndale’s Main Street. “

Everyone in town took lessons from her or Edna Marvel,” said Ferndale Museum historian Wendy Crisp Lestina.

When the band was introduced in sixth grade at Ferndale Elementary, Sams chose the trombone, often considered one of the hardest instruments to learn. From there it was a small jump to baritone (a valved instrument voiced between bass and tenor).

He began attending Scotia Band rehearsals on Monday nights with retired Ferndale High music teacher Bill Crane. Although Sams still played trombone at Ferndale Elementary, he played baritone in the Scotia Band. At the time, the Scotia Band’s bandleader was Sewell Lufkin.

Music was a beacon for Sams when he was a teenager. He joined the All-County and Tri-County Honor Bands in high school and accompanied All-County Choirs. As a junior, he was a member of the Northern California Honor Band. And even though he left Humboldt County for college and later pharmacy school, he joined

Scotia Band for his concerts during the summer and whenever he was home.

Sams’ 1983 graduation from the pharmacy program at the University of the Pacific in Stockton led to residency and a position as a pharmacist at Palo Alto VA Hospital for several years. He and his wife – whom he met in pharmacy school – moved back to Humboldt County in 1986. By then he returned to the Scotia Band regularly.

Since his return, Sams has not only anchored the Scotia Band’s low brass section on trombone, baritone and euphonium, but he also performs with

Trombones @4 quartet, Eureka Symphony, CR Jazz Band and Cal Poly Humboldt Wind Symphony and subs as needed with the Cal Poly Humboldt Jazz Band. He has also performed with the Lake County Symphony, the Cal Poly Humboldt Brass Band with Gil Cline; and sometimes with the local All Seasons Orchestra.

Sams is also a piano accompanist at Our Savior Lutheran Church in Ferndale and for the Chameleon Singers as well as its parent group, the Ferndale Community Choir, where he also occasionally plays a brass instrument.

Sams and his wife, Lani, live in Ferndale where they raised two musical children. Their daughter spent two years playing trombone in the Scotia Band with her father, and their son brought his euphonium to the Northern California Honor Band when he was a senior at Eureka High.

Sams and his wife work full time locally as pharmacists. Lani is also a musician, singing in the Ferndale Community Choir. Sams introduced her to the euphonium, which she plays in the College of the Redwoods Concert Band. Sometimes he joins her there.

After a two-year hiatus due to COVID-19, Scotia Band is now holding its regular Monday rehearsals in preparation for its show season, starting with the Eel River Valley Little League fundraiser at Firemen’s Park in Ferndale on May 7 at 3 p.m. be back to trombone.

The Scotia Band has been active in Humboldt County since 1935 and welcomes new members of all ages who play woodwind, percussion or double bass. For more information, visit www.scotiaband2.org or email the group leader at [email protected] The training space is provided by the Humboldt Swiss Club.

A SOJOURNER’S VIEW: Do you hear the Babaylans singing?


Part 1

BABAYLAN SING BACK: Filipino Shamans and Voices, Gender and Place
Author – Grace Nono
Posted by – Southeast Asia Program Publications
An imprint of Cornell University Press (Ithaca and London)

DAVAO CITY (MindaNews/April 23) – One of the memorable songs from the critically acclaimed but also wildly popular West End and Broadway musical Wretched which cannot fail to stir the hearts of the audience is the song – Do you hear people sing?

This remarkable song speaks of the aspirations of a poor and oppressed people for equality, freedom and fraternity. Referring to people who are among the poorest and most oppressed among the Filipinos today, namely the Lumad or indigenous peoples, especially with regard to their shamans who sing their prayers, one could ask: hear you shamans sing? Or more exactly – have you ever heard the babaylans sing?

Babaylans are known to play a variety of roles in their indigenous communities, ranging from sharing authority with chiefs to ritual specialists and healers. If we gave them their equivalents today, they would be our teachers, historians, pharmacists, guidance counsellors, conflict management facilitators and spiritual directors. No wonder they are called the “Keepers of Wisdom!” Their authority has always been indisputable, which is why throughout the Spanish regime, they were able to mobilize their people to revolt against the colonizers.

Even till today, there are Filipinos who have hardly any idea what a shaman is or who a babaylan is. In pre-conquest times until today, they are known by various names of bailan/baylan (Bukidnon Manobo), Ballyan (Mandaya), Balian (Tagakolo Mansaka & Subanen), beliyan (Teduray) walian (Arumanen-Livunganen Manobo), walian (Negrito), Balyan (Negrito), and mabayan (Gaddang) almo-os (White), LoKes (Dulagan Manobo), tau m’tom bu/tu meton drunk (Tboli), insup-ok/insupak (Bontoc), pandaniwan (Mangyan), mambunong (Ibaloy), mangilu (Ibanag), mumbaki (Ifugao), magnigput (Ilongot), magnify (Tinggian), alopogan (Isneg) mandadawak/andadawak (Kalinga), machinery (Ivatan), and mambunog/mang-gengey (Kankanay).

Even among the Islamized communities, there are also shamans whose patutunong (Maguindanao), pamomolong/pundarpaan (Maranaw), mangungubat (Tausog) and mangobat (Samaly). Among the mostly lowland Filipinos, there were and still are Catalan (Tagalog), mamalalyah/memalyyan (Pampango), and baglan (Ilokano). It is of course not surprising given our proximity to the rest of Southeast Asia (especially Indonesia and Malaysia) that in these two countries there are also shamans ngadju dyak of the old and sun of the last.

At first viewing, it might seem that the country inhabited by Hugo Wretched – the oppressed people of France at the height of their revolution in the 18th century – were a world apart from that of the Indigenous Peoples of the 21st century. Their songs would have been different as the former would have mainly sung revolutionary songs while the latter’s repertoire would range from creation myths to current lamentations. But both suffer oppression at the hands of a power-hungry elite and would use it to defeat their struggles for self-determination.

The power of songs is beyond doubt. In our country, from the days of the Katipunan to the martial rule of Marcos and now – at the heart of a political campaign that would determine our country’s future as a free, just and progressive nation-state – the people sang freedom songs. However, this is only one aspect of the integral value of songs in the cultural life of a people.

It extends to virtually every facet of their lives and has always been instrumental in their sustained quest to nurture their cultural heritage while protecting their rights to their ancestral territories. It is in this context that the baylan occupied a most important place in the space of the ancestral homeland. It also proves how songs – which are thoughts/ideas and desires/aspirations/dreams “spoken” in the form of chants/psalms/chants – have the power to inspire people to come together and fight for their full humanity.

Now comes a book that is undoubtedly one of the most important to have arisen in the landscape of Philippine literature. Its value encompasses a whole range of scientific fields: indigenous studies, culture studies, feminism, sociology/theology of religion, linguistics, musicology and pharmacognosy (study of herbal medicine, for example the medicinal plants which are the basis of traditional medicine).

On the other hand, it carries a whole series of pleas: the need for the peoples of intellectual property themselves to continue to make their voices heard in the public sphere, the need for us, non-owners, to show solidarity with them, the need for religions to take a more inculturated view of the richness and value of the indigenous belief system and for the world to realize that the key to what would enable us to combat the impact of climate change lies in the wisdom of the IP peoples of planet Earth!

The book is BABAYLAN SING BACK: Filipino Shamans and Voices, Gender and Place by Grace Nono, originally from Bunawan, Agusan del Sur. Ms. Nono’s name may not ring a bell to you the way Lea Salonga, Regine Velasquez, Sarah Geronimo or Sharon Cuneta does. But more than these singers combined – no matter how popular and famous they are – Ms. Nono contributes much more to enriching our cultural tradition with music and songs.

For Ms. Nono is not just a “singer”, she is a composer, performance artist, researcher, scholar, author and IP rights advocate. And with this book, she proves once again the importance that an artist who sings can play in pushing the culture of our country to help make us a truthful, just and sovereign people, anchored in the wisdom of our brothers. and indigenous sisters who, more than us plain Filipinos, have kept our indigenous roots intact.

Given the historical revisionism that seems to have infected Filipino society with the fake news and disinformation spread by troll farms financially supported by our past and present political powers, many of our young people are growing up ignorant of their own history. including contemporary events. So the timing of this book is perfect for this election session.

So dear reader, take a break and stay still… because you might just hear the babaylans singing!

[MindaViews is the opinion section of MindaNews. Redemptorist Brother Karl Gaspar is a professor at St. Alphonsus Theological and Mission Institute (SATMI) in Davao City and until recently, a professor of Anthropology at the Ateneo de Davao University. Gaspar is author of several books, including “Manobo Dreams in Arakan: A People’s Struggle to Keep Their Homeland,” which won the National Book Award for social science category in 2012, “Desperately Seeking God’s Saving Action: Yolanda Survivors’ Hope Beyond Heartbreaking Lamentations,” and his latest, “Handumanan (Remembrance): Digging for the Indigenous Wellspring.”. He writes two columns for MindaNews, one in English (A Sojourner’s Views) and the other in Binisaya (Panaw-Lantaw). Gaspar is a Datu Bago 2018 awardee, the highest honor the Davao City government bestows on its constituents.]

Virtual Seminar Highlights Binh Duong as Gateway to Southeast Asia | Business

Delegates from the Vietnamese Embassy in Belgium attend the event (Photo: VNA)

Brussels (VNA) – A virtual seminar was held on April 22 to highlight the southern province of Binh Duong as a gateway to Southeast Asia, with the participation of Belgian delegates and companies.

Binh Duong is named among the 21 localities in the world with smart city development strategies (Smart21) by the Intelligent Community Forum (ICF). The event aimed to define the province’s potential as an international destination for investment and business development.

In his opening speech, Andries Gryffroy, Member of the Belgian Senate and Chairman of the Vietnamese-Belgian-Vietnamese Alliance, underlined that the EU-Vietnam Free Trade Agreement (EVFTA) has created favorable conditions for investment cooperation between Belgium and Vietnamese localities, including Binh Duong.

He praised the potential of the southern province and its cooperation projects with the Belgian province of East Flanders, as well as its prospects for attracting foreign investment.

Belgian Ambassador to Vietnam Paul Jansen stressed that cooperation in the fields of economy, trade and investment is essential for the prosperity and benefits of the two countries, citing areas conducive to bilateral cooperation such as such as seaports, agricultural products, medicinal chemicals and information technology.

Belgian companies are currently channeling more than $1 billion into 82 projects in Vietnam, ranking 22nd among 140 countries and territories investing in the country.

Speaking to Vietnam News Agency, Vietnamese Ambassador to Belgium Nguyen Van Thao said three potential areas where Vietnam and Belgium hold huge potential for cooperation are logistics, agriculture sustainability and innovation-digital economy. Binh Duong has advantages in forging partnerships with Belgian localities in innovation and digital economy, he added.

In March 2022, Binh Duong ranked second across the country in terms of attraction of foreign investment, only after the southern economic hub of Ho Chi Minh City. It is home to five Belgian projects with a combined registered capital of over 39 million USD.

The business climate of the province, the projects in progress and especially the orientations in the construction of a smart city in the times to come were also highlighted during the event./.

Kenton among eight KY counties to achieve major impact of UK’s HEALing Communities study

By Elizabeth Chapin
University of Kentucky

More than two years into the University of Kentucky’s $87 million HEALing Communities Study (HCS) to address Kentucky’s opioid epidemic, it’s possible to see the impacts that have already changed lives in the eight counties of the first wave of the study.

Launched in 2019, the ambitious four-year study includes a multidisciplinary team of over 25 researchers across seven colleges across the UK, and builds on existing resources and initiatives in partnership with communities to implement various strategies aimed at reducing opioid-related deaths in Kentucky.

Sharon Walsh, Ph.D., UK CDAR Director and HEAL Principal Investigator, presented on community engagement in WAVE 1 of the UK HEALing Communities study at the 2022 Summit on Rx and illegal drugs. (Photo by UKNOW)

Evidence-based practices implemented by the HCS team in partnership with behavioral/health and criminal justice agencies include effective medication administration for opioid use disorder (MOUD), overdose prevention education and distribution of naloxone, a life-saving drug that reverses the effects of opioids. The team also worked with various pharmacies and healthcare providers to implement safer opioid prescribing and dispensing.

The randomized study includes 16 Kentucky counties affected by opioid abuse and is divided into two waves of eight counties each. The first wave, known collectively as WAVE 1, includes Boyd, Boyle, Clark, Fayette, Floyd, Franklin, Kenton and Madison counties. Community coalitions in each county determined which interventions to implement based on individual community needs.

With WAVE 1 nearing completion, the current measurements illustrate the impact of the project so far. In partnership with 146 agencies in WAVE 1 communities, HCS has:

• Distributed 55,147 units of naloxone to 166 locations that have so far distributed 40,243 units to individuals in high-risk populations.

• assisted 38 MOUD treatment centers with financial support for staff and transport.

• helped 38 organizations implement peer support programs and 28 organizations implement care orientation programs.

• increased capacity for MOUD treatment, as well as bridging and retention programs in criminal justice settings, including sheriff’s departments, pre-trial services, home incarceration, drug courts, jails and probation and parole programs.

• provided 206 people with opioid use disorder with financial support to overcome barriers to obtaining drug treatment, including transportation, vehicle repairs, prison communication service fees and utility bills.

• Provided 16 people with housing assistance including rent and emergency housing.

• Provided transportation assistance to connect and retain people in treatment. As of March 10, 1,531 rides to treatment programs and recovery-related appointments have been provided to 121 unique individuals for a total of 80,007 miles.

• Installed medication receptacles in 35 pharmacies, with over 1,400 lbs of medication incinerated to date.

• Led training sessions on the safe prescribing and dispensing of opioids for more than 150 healthcare professionals, including dentists, primary care providers and pharmacists.

“The evidence-based practices implemented by the HEALing Communities study team, along with state and community partners, have impacted thousands of lives in WAVE 1 communities. As the study continues, their work will help us better understand what is needed in each community and where to focus and scale efforts to better support patients to reduce opioid overdose deaths,” said Sharon Walsh, Ph.D., HCS Principal Investigator, Prof. at the College of Medicine and the College of Pharmacy in the United Kingdom and Director of the Center for Drug and Alcohol Research. “Our goal is for the changes implemented in these communities to turn into lasting solutions for the opioid epidemic in the Commonwealth and across the country.”

The response also includes community engagement to support key stakeholders to apply evidence-based practices and a communication campaign to build demand for treatment and reduce stigma towards people with substance use disorders. opioids.

The WAVE 1 intervention ends this summer, with the sustainability phase starting in July. This phase aims to build capacity to help community coalitions and partner organizations sustain evidence-based practices after the study ends. Walsh says that includes community staffing and budget planning, and that HCS is also working with state partners in the Kentucky Opioid Response Effort (KORE) on maintaining naloxone distribution.

Response for WAVE 2 communities – Bourbon, Campbell, Carter, Greenup, Jefferson, Jessamine, Knox and Mason – begins July 1. WAVE 2 is currently in the preparation phase, which aims to establish the infrastructure in communities to support interventions. So far, the HCS team has had 134 meetings with 174 stakeholders and identified 85 potential coalition members for WAVE 2.

Elizabeth Chapin writes for UKNOW

Pharmacists urge FG to tackle decay in medical practice

The Community Pharmacists Association of Nigeria (ACPN) has called on the Federal Government to pay attention to the rotting medical practice in the country.

The National Chairman of the CNPA, Mr. Adewale Oladigbolu, who called as hypocritical a recent statement by the Registrar of the Medical and Dental Council of Nigeria (MDCN), Dr. Tajudeen Sanusi, calling on health regulators to awaken their responsibility to regulate, monitor, evaluate and punish the behavior of their offending members.

In a document signed by Dr Oladigbolu, he referred to Dr Sanusi’s prescription of disciplinary action against licensed doctors caught “gambling with the lives of their patients by being negligent, corrupt and in some cases , by displaying blatant incompetence in the management of their patients”, ACPN accused the MDCN of being guilty of an inability to enforce discipline against its offending members.

“Contrary to the MDCN Registrar’s insinuations that he punishes the behavior of his offending members, we have never seen this happen to the bigwigs of the medical profession in Nigeria.

“The ACPN recalls an incident when the late President Musa Yar’Adua ordered the EFCC to arrest a serving medical minister of health who was accused alongside others of being in pain managed unspent Federal Ministry of Health (FMoH) funds in the previous year’s fiscal budget.

“All medical professionals offered through the Nigeria Medical Council (NMA) was to regret this development while giving the impression that its members had integrity.”

Oladigbolu claimed that “even the umbrella model once produced a ruler who squandered tens of millions of naira donated by the FG under the watch of a military leader, through lost deposits in financial institutions.” This tragedy, he said, comes on top of the “careless management of Victoria Island property given to the same group in 1982 by the Lagos State government under the Alhaji Lateef Jakande administration. This are the reasons why the “big boys” of the health sector do not have their own national secretariat until today.

According to him, “the MDCN in the two exemptions of the Doctor-Minister and the President of the group never brought these people before the Disciplinary Tribunal of the MDCN, but it claims to punish the offending members.

“A recent audit of civil service systems by the ICPC confirmed that health MDAs are the most corrupt in the country,” Dr Oladigbolu added.

He further alleged that the leadership of MDCN and its members have become experts in the moral hypocrisy of seeing no evil in their profession, adding that “over the past few months there have been tones and cries of outright decapitation of DRF accounts in virtually all of our countries”. Federal healthcare facilities that have MDCN-regulated physicians in charge without MDCN attempting to seek clarification from anyone.

“The FMoH like last year had resolved in a memo to the PSN to probe the affairs of the DRF in the NOH, Igbobi who was singled out in the perversion of the DRF regime. Even when the calls are louder in this sense, how many of these CEOs, especially the sacred cow of NOH, Igbobi have been summoned to appear before the MDCN commission of inquiry?

“It is crystal clear that half-hearted measures to punish errant doctors only target neophyte members or outsiders at best, while the real culprits walk away with their boots on,” Oladigbolu alleges.

He added: “It is imperative that we remind the guardian of medical laws and ethics at MDCN that his tribe of physicians take professional oaths upon graduation, while those privileged to enjoy bureaucratic positions senior officers also take administrative oaths in accordance with their leadership positions in the various MDAs. Why has the MDCN not been able to call to order its very tyrannical hierarchy when it refuses to enforce the Civil Service Regulations, government circulars, directives and related texts. ”

He specifically dismissed Dr. Sanusi’s reference to community pharmacy as becoming “centres where patients see pharmacists and then obtain medication from pharmacies,” as a blatant lack of knowledge by the MDCN Registrar.

“There is a National Health Act – 2014 which recognizes Pharmacies, Laboratories, Physioclinics and others as health institutions in Nigeria. This same document allows all registered care providers to have access to patients and their records. A community pharmacist who is consulted by a patient for his health and medication needs is therefore not breaking any law in Nigeria.

“When it comes to managing medicines globally, the Registrar must understand that medicines are categorized as Over-the-Counter (OTC), Pharmacist Initiated Medicines (PIM), Prescription Only Medicines (POM ) and controlled medications.

Continuing, he explained that a pharmacist has unfettered freedom to dispense OTC and PIM without liaising with another practitioner because the scope of their training covers it. The Registrar of the MDCN does not see the aberrations committed by its outlaw members who operate in particular in the private sector.

More than 99% of private hospitals operate unregistered pharmacies without a pharmacist to oversee dispensing and counseling efforts related to drugs contrary to the Poison and Pharmacy Act. The exploitation of patients who sometimes pay more than 500% more than the basic cost of drugs through scam schemes is one of the bases of the survival of private doctors in Nigeria.

Oladigbolu also asserted that private hospitals in Nigeria are the centers for the unlimited and unchecked creation of under-professional cadres in health “because that is where nursing assistants, drug dispensing assistants and medical assistants diagnosticians are trained and sometimes certified while the various private hospital registration authorities and the MDCN look the other way to protect their fellow physicians.

The CNPA president, who blamed the FMoH for rotting medical practices, called on the federal government to urgently address the anomalies.

NLS Pharmaceuticals at Participa – GuruFocus.com


ZURICH, SWITZERLAND/ACCESSWIRE/April 22, 2022/ NLS Pharmaceuticals Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, CEO and co-founder, participate in a fireside chat at the B. Riley Neurology and Ophthalmology Annual Investor Conference to be held April 27-28, 2022.

The details of the conference are as follows:

About NLS Pharmaceuticals Ltd.

NLS Pharmaceuticals Ltd. is a clinical-stage Swiss biopharmaceutical company led by an experienced management team with a proven track record in the development and reuse of product candidates to treat rare and complex central nervous system disorders. The Company’s lead product candidate, Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy and potentially other sleep and wakefulness disorders such as than idiopathic hypersomnia (IH). Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist that has been used for many years to treat patients with narcolepsy in compassionate use programs. A Phase 2a clinical trial evaluating Quiilience® in adult subjects with narcolepsy is currently underway in the United States. Previously, NLS successfully completed a Phase 2 study in the United States evaluating Nolazol® (Mazindol Controlled-Release) in adult subjects with ADHD. The study met all primary and secondary endpoints and Nolazol® was well tolerated. Quilience® has received orphan drug designation in the United States and Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD. NLS announced plans to allow patients diagnosed with IH to access treatment with Quiilience® through an Early Access Program (EAP). EAPs have great potential to benefit all stakeholders involved, from the patient who receives the drug as soon as possible to the pharmaceutical company who supplies it. While EAPs can be big business, companies that invest in them can reap significant benefits in terms of launch readiness, relationship building, and market penetration.

Corporate contact details

Alex Zwyer, CEO: +41 44 512 21 50

Investor Relations

Cindy Rizzo: +1 908-229-7050

Media Contact

Pascal Nigen: +1 917-385-2160
Alpha Bronze, LLC

THE SOURCE: NLS Pharmaceuticals SA

See the source version on accesswire.com:


NASC Colloquim welcomes Elizabeth Berry Drago – The Colgate Maroon-News

The Natural Sciences and Mathematics Colloquium (NASC) hosted Elizabeth Berry Drago on Wednesday, April 13 for a talk entitled “Alchemy’s Rainbow” in collaboration with the Art & Art History Lecture Series, CORE Scientific Perspectives, Museum Studies Program and Picker/Longyear Galleries . The conference took place and was broadcast live from 300 Olin Hall, and was followed by a question and answer session and ended with refreshments and snacks. Drago, Research Curator at the Science History Institute of Philadelphia, gave an in-depth lecture on her work and the interdisciplinary aspects of her studies as an art historian focused on the art of color. Drago spoke about the intersection of artistic and scientific exploration, particularly in relation to nature, and the essential relationships between art, alchemy, medicine and nature. According to Drago, color was used as an indicator of chemical processes in early alchemy, making it a crucial part of this practice.
As early as the 16th century, artists claimed the creative powers of nature through alchemy. Art and alchemy are linked by experimental practice, but also the ability (or attempt) to recreate nature and all its subtleties. Draco discusses an interesting dichotomy with this relationship, as the processes of alchemy and pigment-making can create both cures and poisons. Similar to how alchemy attempts to recreate nature and its colors, the toxicity of these supplies reflects their toxicity in nature. The paintings often included depictions of deadly things in nature to capture the contrast between the poisonous qualities of nature and its healing beauty.
“They used artificial toxic pigments to portray toxic natural beauty,” Drago explained. “They explore the power of art to hurt or heal, to frighten and delight, and the power of artists to not only capture nature, but to capture the sometimes toxic essence of nature itself.”
Drago then highlighted the raw qualities of the painting itself. Many supplies may still carry the toxicity they have in nature, but within the existing duality of this natural, many of the same compounds used to make pigments also have medicinal properties. For example, copper carbonate, the same compound that is used to create the greenish pigment verdigris, has also been used to treat seizures in children.
Sophomore Ali Kercher, who attended the lecture, reflected on what she found most intriguing about Drago’s speech.
“I think the most interesting thing I learned was that the chemicals used to make pigments were also used in medicine,” Kercher said. “So art and nature, and medicine are all connected, which I didn’t really know before.”
Drago also explained how the evolution of alchemy and medicine parallels the evolution of the art. The distillation of substances such as turpentine was seen as a means of reducing matter to its pure essence – a symbolic process of purity and self-transformation. This reflects the healing abilities of turpentine; it has also been used as a topical muscle relaxant. Distillation was an advancement in both alchemy and medicine, as well as art, because paint thinner had a glazing effect that allowed for smoother skin texture in paints. These developments in painting, which allowed advances in light, texture and illusion in art, were made possible not only by the ability of artists to invent with color, but also by the ability of alchemists to invent color and its different dimensional qualities. The overlap of alchemy, art and medicine that intersects with color confirms the importance of color in the progression of art and medicine in modern times.
“I teach from scientific perspectives, and we always try to think about how we communicate science and the great diversity of science,” Patricia Jue – event organizer and chemistry lab teacher – told about the interdisciplinary nature of the event in the context of the NASC Colloquium Series in general. “The question is, where do you place one of these speakers whose discipline is art history, but who is really interested in ancient science; when I listen to it, I think of chemical reactions because I live in the world of chemistry. She explained her decision, saying, “I thought it was really good to have this intersection.”

Spotting the next biotech unicorn EJINSIGHT


Unicorns. Private start-up companies valued at over US$1 billion. Also the source and subject of desire for many, an engine of growth and thought leadership for the burgeoning start-up scenes around the world, and – most importantly – the recipe for the privileged few to get rich in the very, very not much time. Unicorns are hard to spot – especially when it comes to the biotech and medtech sectors, where rigorous research with pinpoint accuracy is of paramount importance, downside costs and risks are substantial and investors could easily get caught up in the intricate technicalities behind product comparisons.

I was introduced to “Lessons for Investment in Biotech Companies” (available in Chinese) by Liu Da (CEO of CR – CP Life Science Fund) through a mutual friend, who pointed out that the book was among the best he had read in recent years on financial innovation. As a relative layman with a burgeoning interest in venture capital and start-ups (I’m involved in a few, but none directly related to biotech), I took the opportunity to broaden my horizons, finally, restricted. And I was certainly not disappointed by the exceptional work of Liu Da et al., who lucidly and comprehensively described a polite and incisive introduction to what makes it “click” and what makes it “stick”.

The book makes three major claims. The first, as proven by extensive and in-depth case studies, is that biotech companies thrive on a mix of business and commercial acumen, innovatively refined research strategies, carefully controlled feedback loops incorporating other people’s recipes for success. The second is that biotech companies are intrinsically linked to developments in technology and genetic modification (think CRISPR, mRNA, etc., for a few examples), as seeking to decouple biotechnology from the underlying mechanisms of the pharmaceutical technology and the biological sciences would be frankly futile. The third, and perhaps most relevant to the interests of potential investors, is how investors might engage in a fair and prescient valuation of early stage start-ups (specifically, during the seed cycle and of the Series A phase, perhaps Series B) which allows them to maximize their chances of investing in the “good”. The chosen one is hard to find, indeed.

As I perused the work, I couldn’t help but be amazed and impressed in equal measure by the voluminous detail and extensive research that clearly went into the work. There is a strong sense that the evidence is not provided for evidence’s sake, but with the end goal of establishing many vital, impactful and often overlooked points – for example, the highly relevant discussion of the development of Penicillin and AIDS Treatments/HIV Drugs brought together an insider’s intelligence and insights from the market and facts about the broader sociological and political contexts in which drug development research has been undertaken. The deep dive into the technical aspects of mRNA – although at times perhaps a little inaccessible to the completely science illiterate – was both intriguing and relevant to our understanding of the contemporary competition over vaccine technology between Beijing and Washington. . For a geopolitical analyst and writer like yourselves, the latter was – of course – a subject of interest.

Although the text draws quite heavily on examples from the United States, the authors made it clear that the sampling approach was deliberate, as opposed to the product of omission. The intent is simple: America has always been the largest and most developed biotech nexus in the world, and it would be fair if accounts of bio/life science-centric finance and innovation begin – and end – with the United States. Yet this fact raises another question, indeed raised by the astute observations regarding China’s rapid rise and growing innovative technological power. Now, some will say, indeed, that China is set to overtake America in the next decade, on the fronts of science and technology, research and development – although I remain reluctant to draw any conclusions regarding the future, if only for the fact that it would be premature to do so. Regardless of how bullish/bearish one is on China’s technology trajectory, however, readers are bound to find the contextual and macro analysis of Liu Da et al. fascinating to read, and certainly food for thought at this critical time in world history.

Liu Da is a guru. Coming from a dual background in finance and pharmacy, Liu is as well-versed in the financial investment scene as he is in the finer intricacies that make up the mortar and pestle of biotechnology. I can’t think of anyone better placed to put together this impressive magnus opus than Liu. I would frankly and wholeheartedly recommend this read to anyone – and don’t worry if you don’t read Chinese, the English and Japanese versions are, I’ve been reliably informed, in the pipeline! May the best unicorn(s) win, as they say in The Hunger Games.

— Contact us at [email protected]

Florida House passes redistricting cards after Democrat sit-in protest | Florida News | Orlando

Click to enlarge

Screenshot via Florida Senate

The Florida House passed a new congressional map on Thursday after Democratic lawmakers interrupted the session with a sit-in protest.

Florida Governor Ron DeSantis’ redistricting map has sparked protests for halving black representation in the state. Knowing that Republicans stood in solidarity with the governor, who had vetoed earlier maps that kept districts intact, Democrats protested by disrupting the process.

The protest came after Rep. Yvonne Hayes Hinson was told she was going over her debate time and was continuing to speak, and her microphone was cut off.

The chamber of the House was cleaned and the cards passed shortly after they met.

If the map is approved, the nearly half-black District 5 would be replaced with a district that is only 12% black, according to the Orlando Sentinel.

The map also decreases black voters in District 10 in Orlando because it shifts a large number of voters to District 11, which is Republican-friendly. The map reduces predominantly black neighborhoods from four to two.

Representative Carlos G. Smith of Orlando said Republicans were violating the Constitution by endorsing the governor’s card.

The maps passed the House in a 68-38 vote. The House also passed a bill on Thursday that will dissolve Disney’s Reedy Creek Improvement District, a unique theme park oversight body that exempts them from Florida land use laws.

Both invoices will be sent to DeSantis for approval.

Stay up to date with Central Florida news and views through our weekly newsletters and consider supporting this free publication. Our small but mighty team works tirelessly to bring you news from Central Florida, and every little bit counts.

To reduce drug costs, control intermediaries

The worst inflation in 40 years is hammering American families. The price of gasoline jumped 49.6% from December 2020 to December 2021, according to recent analysis from the Bureau of Labor Statistics. Used car prices jumped 37.3%, meat prices 12.5% ​​and electricity prices 6.3%.

Indeed, of the 31 categories of goods and services measured, only one did not become more expensive: prescription drugs.

This fact will surely shock most Hoosiers, who – like the rest of the country – feel that drugs are getting harder and harder to afford. And in a very real sense, they are right. Patients assume that drugs become more expensive because they pay higher co-payments and coinsurance at pharmacy counters.

But this extra money is not going to the pharmaceutical companies. It is gobbled up by intermediaries in the drug supply chain, who cleverly – but secretly – pass the costs on to patients.

By cutting these middlemen down to size, policymakers here in Indiana and in our nation’s capital could make drugs cheaper for patients — without deterring drug companies from pursuing the next generation of treatments and cures.

Let’s unpack the problem.

Like any other industry, the pharmaceutical sector has a multitude of intermediaries involved in getting pills from factories to the medicine cabinets of patients.

There is nothing inherently wrong with intermediaries. It would be inefficient for a diabetic patient to drive to Lilly’s factory in Indianapolis every time she needs more insulin – just as it would be inefficient for shoppers to drive to a farm every time they need to buy produce or meat, rather than visiting a grocery store.

But unlike grocery stores, whose profit margins are notoriously only 1-3%, middlemen in the pharmaceutical supply chain rake in outsized profits. A recent report from Berkeley Research Group found that 2020 marked “the first year on record that non-manufacturer stakeholders” – including insurance companies and pharmacy benefit managers – pocketed more than half total expenditure on brand name drugs. This revenue normally comes in the form of rebates that insurers and in particular “drug benefit managers” – the secret societies that help insurers administer drug benefit plans – extract

pharmaceutical companies. These PBMs decide which drugs to include in insurers’ plans, giving them immense power to negotiate huge discounts – on average around 30% for most drugs, but up to 70% for many insulins.

In theory, these discounts should save patients money. But in practice this is not the case, at least not when patients go to the pharmacy.

This is because PBMs do not disclose the value of these discounts. So if patients show up at the pharmacy and their insurance plan says they owe a 25% coinsurance payment on a drug, they must pay more than a quarter of the total cost of the drug before reimbursement.

For example, let’s say a supply of insulin nominally costs $400. Patients with this 25% coinsurance requirement would have to shell out upwards of $100 at the pharmacy.

But if the PBM actually negotiated a 70% discount, that means the insulin really only costs $120 in total. Patients end up paying almost all of the actual cost of the drug – with PBMs and insurers barely lifting a finger.

If these patients could instead base their coinsurance payments on the actual post-reimbursement drug price, they would only pay $30 – a huge savings.

Imposing transparency requirements on PBMs and requiring them by law to share a portion of discounts with patients at the pharmacy should be a top priority. Fortunately, the Indiana legislature is already considering a bill that would require PBMs to pass more of their savings on to patients.

PBMs, insurers and other intermediaries are the reason medicines often seem so expensive – even though data shows that prescription drugs are one of the few goods and services to escape the current inflationary crisis. Cutting these middlemen down would bring immense relief to many households here in Indiana and across the country.

Acrivon Therapeutics Announces Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

WATERTOWN, Mass., April 20, 2022 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc.a clinical-stage oncology therapeutics company with proprietary technologies unlocking a new era of precision medicine, today announced the appointment of Rasmus Holm-Jorgensen as the company’s Chief Financial Officer, along with other senior executives at within its management team.

“It is with great pleasure that I welcome Rasmus who brings to Acrivon a wealth of expertise and a proven track record of more than twenty-five years of successful strategy and operations, including finance, portfolio management and business development. business, which will be invaluable as we pursue our growth aspirations,” said Peter Blume-Jensen, MD, Ph.D., President and Chief Executive Officer of Acrivon. “In addition to Rasmus, I am delighted to announce that we have strengthened our leadership team with top talent and accomplished executives in key leadership positions across multiple functional areas. A critical part of our execution strategy is building domain expertise and human resources to further develop the vast potential of our next-generation precision oncology platform and advance our promising pipeline of targeted oncology agents. , best in class and clinically effective.

Prior to his appointment as Chief Financial Officer of Acrivon, Mr. Holm-Jorgensen was part of the founding team and Chief Strategy and Portfolio Officer of Kiniksa Pharmaceuticals from its inception in 2015 until the launch of its first product. through the IPO. Previously, he was Group Vice President and General Manager of Synageva BioPharma, where he established a new business unit with a portfolio of multiple rare disease programs following the company’s IPO in 2011 and which has resulted in the sale of the company for $9 billion. From 2008 to 2011, Mr. Holm-Jorgensen led the successful turnaround of the global commercial audiology organization of GN Group, a global leader in intelligent audio solutions. From 1996 to 2008, Mr. Holm-Jorgensen worked for Novo Nordisk in Denmark, the United States, Brazil and Mexico, where he held positions of increasing responsibility in general management, economics and planning, portfolio analysis, investor relations for North America and finance for LATAM. . Mr. Holm-Jorgensen holds a master’s degree in economics from the University of Copenhagen and completed executive education at INSEAD, Stanford University and Harvard Business School.

Mr. Holm-Jorgensen added, “I am very impressed with the company’s proprietary AP3 precision medicine platform, which defines a whole new era of precision medicine and is initially being applied for the accelerated and risk-free development of a robust pipeline of precision oncology therapies. I look forward to working with the high caliber team at Acrivon to bring our therapies to the patients who can benefit the most. »

Additional Named Executives Bruce Close, Vice President of Quality and Compliance, is a leader in the design, implementation and oversight of quality management systems and compliance operations. He has over 20 years of experience in GxP quality roles at major biopharmaceutical companies such as Celgene/BMS, Schering Ag/Bayer and Regeneron. Additionally, he has worked with over 35 different health regulatory authorities across the Americas, Europe, Asia, the Middle East, Russia, Africa, Australia and Japan.

James P. Dunyak, Ph.D., Vice President of Biostatistics is an experienced statistician, modeler, engineer, and mathematician focused on realizing the promise of precision medicine and translating research achievements into products. viable businesses in a highly regulated environment. His previous experience includes leadership roles in biostatistics, research and development, bioinformatics and clinical pharmacometrics at Certara, AstraZeneca, Metamark Genetics, Novartis and MITRE.

Joon Jung, Ph.D., VP and Head of Data Science, is a computational and translational science leader with a successful track record in drug discovery and development, including experience in target identification and optimization, clinical biomarkers and patient stratification strategies, and systems biology. He led data science, translational discovery and informatics at Theonys, Cyclerion Therapeutics/Ironwood Pharmaceuticals, and was a principal investigator at Merck, Johnson & Johnson and Triad Therapeutics.

Crystal Mercado, Global Head of Human Resources, is an accomplished human resources leader with expertise in managing key business opportunities and challenges to develop an engaged workforce, including experience in acquiring and retention of global talent in North America, LATAM, EMEA and APAC regions. She previously held positions at Kira Pharmaceuticals, SpringWorks Therapeutics, Purdue Pharma and Alexion Pharmaceuticals.

Thomas P. Nifong, MD, CDx Clinical Operations Manager, has extensive experience leading clinical operations and as a medical director providing strategic and technical expertise, with responsibilities spanning corporate strategy, laboratory, regulatory compliance and biomarker development, with direct involvement in commercialization and business development activities. He has served on the management team of companies such as Pacific Edge Diagnostics, Definiens (acquired by MedImmune/AstraZeneca) and Metamark Genetics.

Sam Rua, Vice President of CDx Regulatory, is a regulatory affairs and quality assurance manager with experience in global regulatory submissions and registration strategies, having successfully moved investigational product candidates through the processes regulations and in the marketplace in the United States, Canada, Europe and Australia. . He has held positions in regulatory and clinical affairs, quality systems and operations at HTG Molecular Diagnostics, Roche Tissue Diagnostics, Beckman Coulter, Third Wave Technologies and Ventana Medical Systems.

John van Duzer, Ph.D., Vice President of CMC, is a senior pharmaceutical industry executive with more than 30 years of experience in medicinal chemistry research, chemical development programs and GMP manufacturing to support IND filing and clinical trials. He is the inventor of Lumiracoxib, a marketed cyclooxygenase 2 inhibitor, as well as ricolinostat and citarinostat, which are HDAC6 inhibitors for the treatment of multiple myeloma. He has held leadership positions in manufacturing and technical operations at Collegium Pharmaceutical, Eloxx Pharmaceuticals, Acetylon Pharmaceuticals, Mersana Therapeutics and ActivBiotics Corporation, in addition to consulting for Celgene.

About AcrivonAcrivon is a clinical-stage oncology company that leverages its proprietary phosphoproteomics technology called Acrivon Precision Predictive Proteomics, or AP3, in the development of its oncology drug portfolio. The AP3 platform enables the creation of proprietary OncoSignature® drug-specific companion diagnostics that can be used to identify patients most likely to benefit from Acrivon’s medicines. Through its highly specific patient selection, the company seeks to accelerate clinical development and increase the likelihood of treatment success for patients. The Company’s pipeline includes the clinically advanced lead program, ACR-368 (also known as prexasertib), a targeted oncology asset licensed from Eli Lilly and Company that has demonstrated evidence of durable responses, in solid cancers in Phase 2 trials. Acrivon is also developing additional pipeline programs targeting critical nodes of DNA damage response (DDR) and cell cycle regulation. Please visit the company’s website at https://acrivon.com for more information.

Acrivon contacts:Alexandra Santos [email protected]

Aljanae [email protected]

main logo

Source: Acrivon Therapeutics

New Initiatives for DPSRU Students: Aiming to Strengthen Student Wings

DPSRU facilitates its students with new avenues and technologies. One such initiative is taken by the Pharmacy and Allied Health Sciences and Management University by establishing the GPAT Club, a platform to motivate and guide undergraduate students for GPAT preparation under the leadership of VC Prof RK Goyal .

This is an affordable initiative that all students can participate in for better orientation for upcoming Graduate Pharmacy Aptitude Test (GPAT) exams.

The activity was kicked off with an interactive session by Dr. Gaurav Jain, Associate Professor, Department of Pharmacy, and Professor Rajiv K. Tonk, Dean – Student Welfare. During this event, a tremendous response was received from the 4th and 6th semester students of B. Pharm.


You have successfully voted

As part of its technology initiatives, all DPSRU students can now use the new digital printing kiosk which can be connected via mobile data enabled smartphones. The kiosk was installed in the new campus building.

“This is one of the first of many new technology initiatives to come for students. Students can now print by scanning the QR code and downloading the document via their mobile phone. Payment is made automatically once the print is released. said the Dean of Student Welfare, Professor Rajiv K. Tonk.

DPSRU students were quite satisfied with this initiative. “We had to go to the nearby shops which are more than 1 km away to take impressions. With the advent of this new technology, things have become easier,” says B. Pharm student Amar Singh. 6th semester.

The kiosk was inaugurated during a ceremony in the presence of the newly constituted Academic Council of the DPSRU. The Academic Council of DPSRU has Prof. RK Goyal (VC, DPSRU) as Chairman and Dr. OP Shukla (Registrar, DPSRU), Prof. N. Udupa, Dr. S. Chooramani Gopal, Prof. Surender Singh, Dr. Rajiv Gulati , Dr Harvinder Popli, Dr PK Sahoo, Prof. Tonk, Prof. Geeta Aggarwal, Dr Shilpa Jain, Dr Jaseela Majid, Prof. Shard Wakode, Dr Richa Rai and Prof. Ajay Sharma as members.

Walgreens Boots Alliance | Modern Fortune 25 Tray

Former Walmart executive and Starbucks COO Roz Brewer assumed leadership of Walgreens Boots Allilance in March 2021. The company’s lead independent director is William C. Foote, former chairman and chief executive officer of Walgreens Boots Allilance. USG Corporation, a manufacturer of building materials. Stefano Pessina, former CEO of the company, is the current executive chairman.

Walgreens earns third place thanks to high scores for board independence, age dispersion, ESG and having senior independent non-executive directors. (A non-executive director is a member of the board of directors who does not currently hold an executive position in the company. Having a high percentage of non-executive directors on the board of directors is considered a best practice, according to Diligent, because it is easier for these directors to offer objective advice to the management team.)

Walgreens has won over some analysts and investors with a long-term strategy that includes investments in primary care clinics, a move intended to increase convenience for customers and further expand the company’s role beyond healthcare services. retail and pharmacy. The other two former CEOs on Walgreens’ board reflect the key areas in which its business is focused. Ginger L. Graham is the former president and CEO of Amylin Pharmaceuticals, and Nancy M. Schlichting is the former CEO of Henry Ford Health System. Valerie Jarrett, senior adviser to President Barack Obama from 2009 to 2017, is also a trustee.

Kashmir University PhD student arrested over ‘highly provocative and seditious’ magazine article


Abdul Aala Fazili was arrested for his article titled “The Chains of Slavery Will Break”

Abdul Aala Fazili was arrested for his article titled “The Chains of Slavery Will Break”

The J&K State Investigation Agency (SIA), set up to investigate cases related to militancy, on Sunday arrested a Kashmiri academic for his 2011 article published by the magazine, The Walla of Kashmir.

The arrest was made after the SIA raided the office and home of those arrested. ‘Kashmir Wallaeditor Fahad Shah in the Rajbagh and Soura region of Srinagar, as well as the residence of scholar Abdul Aala Fazili in Humhama. Mr. Fazili, who holds an MSc in Pharmacy, is currently a PhD student in the Department of Pharmaceutical Sciences, University of Kashmir.

“The searches were carried out within the framework of FIR n° 01/2022 under article 13, 18 of the UA(P) law read with articles 121, 124, 153 B and 120-B IPC of the police station of JIC Police (SIA) Jammu, against the author of the seditious article Abdul Aala Fazili and the editor and other associates of The Kashmir Wala,” a SIA spokesperson said.

The SIA said that the article titled “The Chains of Slavery Will Break”, published on November 6, 2011, “is highly provocative, seditious and intended to create trouble in Jammu and Kashmir, written with the aim of incite young people to take the path of violence by glorifying terrorism and, on the other hand, the article has promoted and spread the false narrative, which is essential to support the secessionist and terrorist campaign aimed at breaking territorial integrity from India “.

The SIA said the article used normative language for educational purposes, encouraging secessionist elements to carry out terrorist activities. The SIA quoted some excerpts, which read as follows: “On the occasion of Eid al-Azha, let us all pledge in the name of the blood of our martyrs and the tears of our mothers and our sisters: that we we will always remember their sacrifices, that we never stop our fight for freedom.

In another paragraph, the author had written that there was no need to be in anxiety and despair about the success of our struggle for freedom. “I have this total and most remote belief; we will finally get freedom – Insha’Allah.

The SIA said the repeated reference to the rhetoric of freedom and terror groups makes it clear that the article is not simply propaganda. “Rather, it is the articulation of the Pakistani ISI and the vision of its sponsored terrorist secessionist networks,” he said.

Gadgets seized

Meanwhile, the SIA said that during raids on the homes and offices of editors Mr. Shah and Mr. Fazili, it had seized “incriminating evidence, which includes material in computers, laptops and other digital equipment”.

In a report, The Walla of Kashmir said searches at Mr Shah’s residence, where his family lives, began at 7:17 a.m. and at the office at around 8:20 a.m. “The search and paperwork formalities took more than three hours at both locations,” the statement said. mentioned.

According to the magazine, the laptops of two journalists, a Macintosh laptop from the multimedia department, six hard drives containing backups and five CDs were seized during the raid.

“They also checked the reporting logs and phones of two reporters, who arrived at the office during the raid. The Walla of Kashmir cooperated with the authorities during the raid and facilitated the formalities,” he said.

During the raid on Mr Shah’s home, a laptop belonging to another staff member, who was also present during the searches, a tablet and a voice recorder was seized, he added.

“We condemn the seizure of journalists’ gadgets and other equipment from Shah’s office and residence. We once again call on the administration headed by Lieutenant Governor Manoj Sinha to withdraw the charges against Shah and the work of The Walla of Kashmir“, reads the press release.

Mr Shah, who was arrested on February 4 and then convicted under the strict Public Security Act (PSA) on March 16, despite courts granting him bail at least twice in two different cases. He is currently incarcerated in Kupwara prison.

The Children’s Services Center celebrates 160 years of service

WILKES-BARRE – Founded as a home for friendless children during the Civil War, the Children’s Service Center celebrates 160 years of service in 2022 by honoring all those who have helped CSC become the premier behavioral health provider for the area for children, adults and families in northeastern Pennsylvania.

Mike Hopkins, president and CEO of the Children’s Service Center, said the mere fact that CSC has been around for so long speaks volumes about the agency’s success.

“Over the years, we’ve made the changes we needed to make to stay relevant and continue to have a positive impact on the community we serve,” Hopkins said. “It’s mind-boggling when you realize we were founded when Abraham Lincoln was president.”

Extensive service area

CSC now operates 26 programs in seven locations and 19 school districts, and its adult care subsidiary, Robinson Counseling Center (RCC), served more than 11,000 people in 2021.

CSC’s specialized teams support families in Luzerne, Lackawanna, Montour, Northumberland, Schuylkill, Snyder, Susquehanna, Wayne and Wyoming counties.

“Together with our partners in care, the Children’s Service Center and Robinson Counseling Center are working to reduce the stigma associated with mental health and substance use disorders so that more people reach out, considering professional help as a natural step toward a more fulfilling life,” says Hopkins. “Furthermore, our ability to change and adapt has been essential for CSC to continue to provide the services the people we serve need. »

A major shift, Hopkins said, is CSC’s clientele. He said that less than 10 years ago CSC served a few hundred adult clients, but today that number has grown to 5,200 adults.

“CSC’s ability to adapt to the needs of our customers is critically important,” Hopkins said. “CSC has continued to grow as our community has changed and serving adults is a big change for us. Ten years ago, I don’t think any of us thought we would be serving over 5,000 adult customers today. It’s a great example of the organization being flexible enough to evolve with the changing needs of the community.

CSC continues to serve children — more than 6,700 a year, Hopkins said.

“In our 160 years, children have always been our primary focus,” Hopkins said. “But we also worked for adults.”

Hopkins said CSC’s annual budget is $31 million and the agency employs 485 full-time and part-time staff.

“The longevity of CSC speaks volumes about the support we have received from our funders, foundations, our board of directors, political advocates, our local community and the people we serve,” Hopkins said. . “I don’t know of any nonprofit the size of CSC with a mission to serve the needs of the community that has been able to survive 160 years – and not just survive, but thrive in an ever-changing world. The resilience of the organization is matched only by the people we serve. It is also a testament to current and past staff who have made the sacrifice to help those in need.

Going forward, Hopkins said CSC hopes to continue adding essential services, such as primary health care and expanded services for substance use disorders, with the goal of improving health and general well-being of those served.

“Ability to adapt”

Colleen Horn Doyle, Esq., general counsel at McCarthy Tire Service, is chair of CSC’s board of directors. She said she found CSC to be a remarkable organization, and she said she is truly honored to serve as Chair of the Board.

“I attribute the success and longevity of the Children’s Services Center to its ability to adapt to changing times and its proactive approach to the leadership of CSC,” she said. “Mike Hopkins and his team have a tremendous dedication to this organization and its mission. He constantly analyzes the additional needs of members of the community that CSC already serves, and explores the needs of other communities outside of CSC’s current footprint to see how we can help.

Horn Doyle said as a mother she can appreciate how the past two years have been particularly difficult for children and for entire families.

“I believe the wonderful staff at the Children’s Service Center rose to the challenge and provided the essential services needed by these members of our community during these difficult times,” she said.

Progress, expansion

In November 2021, CSC announced the expansion of its outpatient clinic as “the right thing to do”.

Several local legislators, board members, staff and supporters gathered at CSC on South Franklin Street to officially open the new, $5.5 million, three-story, 12,516-square-foot addition.

At the time, Hopkins said the outpatient clinic needed to be expanded to compensate for CSC’s immense growth in terms of clients served.

“This addition of space is timely for the Children’s Service Center,” Hopkins said. “When we built the addition to the clinic in 2018, we were serving 6,048 clients. By the end of 2022, that number is expected to be 11,383.”

Hopkins said that in 2018, the Children’s Service Center introduced an integrated physical and behavioral health care program when it opened a new 27,400 square foot clinic on South Franklin Street in Wilkes-Barre. At that time, CSC and its affiliate, the Robinson Counseling Center (RCC), served approximately 6,048 children, adolescents and adults through 25 programs.

Hopkins said that since the start of the COVID-19 pandemic, CSC and RCC have remained open and seen an increase in the number of people seeking service in most programs.

Hopkins added that the success of CSC’s integrated health care program comes with challenges. He said that to address space issues, in January 2021, the CSC Board of Trustees approved a construction plan for the new three-story, 12,516 square foot addition to the CSC Clinic.

Plans for the new space include:

• Relocation of primary care to the first floor of the annex with a separate entrance. This move opens the possibility of being available for services seven days a week.

• Addition of laboratory services to CSC’s integrated care program.

• Addition of 34 offices for individual therapy and medication management.

To advance

In 2017, the Children’s Service Center integrated primary care with its behavioral health services to provide more comprehensive medical care for Wilkes-Barre clients. Current construction on the main campus in Luzerne County will complete the Conyngham Primary Health Care Center in 2022. Named after one of CSC’s founding families, the center will house a primary care team of physicians , medical assistants and nurse practitioners licensed to treat children. , adults and families, offering pharmacy and other services in a convenient setting.

Hopkins said CSC remains true to its roots as a beloved home for orphans by continuing a very active and successful adoption and foster care program.

“Just as this mission-driven effort was aimed at ensuring the health and well-being of children in need, CSC and RCC are committed to further developing an integrated model of behavioral health and primary care that will meet the needs of our clients for generations to come,” said Hopkins. “Much of our community is at risk when it comes to the social determinants of health, namely poverty, education, employment and related challenges. lifestyles that deter them from leading healthy and productive lives.”

Given that national statistics indicate that more than half of Americans with mental health and addictions issues do not seek care for their conditions, CSC and RCC know there is still work to be done to address the stigma, prejudice and discrimination often present for people with mental illness.

To put it simply, Hopkins said the goal of the CSC and RCC is to encourage more people to reach out, seeing professional help as a natural step towards a more fulfilling life.

Contact Bill O’Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.

Specialty Networks Announces Acquisition of United Rheumatology

April 16, 2022

1 minute read

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Specialty Networks, LLC, a portfolio company of Linden Capital Partners, announced the acquisition of United Rheumatology, LLC, according to a company press release.

“We are delighted to welcome United Rheumatology to the Specialty Networks family of companies,” David Courry, CEO of Specialty Networks, said in a press release. “Our shared mission to help improve patient care by strengthening independent specialty providers makes this acquisition a great fit for both of our companies. With the acquisition of United Rheumatology, Specialty Networks adds a third specialty to its portfolio of specialty companies.

Enterprise handshake_Adobe
Specialty Networks, LLC, a portfolio company of Linden Capital Partners, announced the acquisition of United Rheumatology, LLC. Source: Adobe Stock

Founded in 2014, United Rheumatology is the leading exclusive rheumatology group purchasing organization and real-world evidence and analytics company with 635 active independent rheumatology providers in its network. United Rheumatology brings a suite of complementary services to specialty networks, including group buying services, sponsored educational events, life sciences data and analytics, and value-based payment programs.

Specialty Networks intends to further enhance United Rheumatology’s capabilities by introducing additional service offerings to its network practices and industry customers, which include in-office pharmacy/dispensing services; clinical and administrative programming; patient identification, retention and engagement technology; outsourced clinical navigation; and decentralized clinical trials.

Max I. Hamburger

“Joining forces with Specialty Networks will further enable community rheumatology practices to remain independent and advance the standard of care for their patients,” Max I. Hamburger, MD, founder and executive chairman of United Rheumatology and managing partner of Rheumatology Associates of Long Island. “This is a fantastic opportunity for our organizations to continue to evolve precision medicine to ensure that every patient receives the right care at the right time.”

Cannabis Education Conference to Feature Scholarships for Students – The North Wind

Senior medicinal plant chemistry majors Morgan Naumaan and Haylee Kuehl-Weisser have been researching cannabis for a year. Now that they’ve completed their research, produced results, and created poster presentations, they’re ready to show off their findings at the first annual Great Lakes Cannabis Education Conference.

The Northern Center invites industry professionals, professors, students and anyone interested in learning more about cannabis research to attend this event. The conference will take place on Tuesday, April 19 from 8 a.m. to 5 p.m. Discussion topics range from scientific advances in the study of cannabis to consumption, use and distribution of cannabis.

“[This event] is a way for students and other people in the scientific cannabis industry to network and connect with each other when it comes to research, job potential and things like that,” said said Kuehl-Weisser. “I’m really excited to network and hear other students’ research.”

The event will begin with a keynote from Riley Kirk, research scientist and cannabis educator. Kirk’s work has revolved around the use of smoke extracts in the cannabis industry.

“In the herbal medicine lab, we make extracts using solvents and plant materials, not smoke,” Naumaan said. “I’m super interested to see what [Kirk] has to say about smoke extracts and how they make their products using smoke.

Although the event is designed as an educational conference, Naumaan and Kuehl-Weisser are also interested in connecting with industry professionals in preparation for post-graduation. Due to Marquette’s relatively remote location, job opportunities in the cannabis industry are few and far between.

“It’s kind of hard to network in this industry, especially being here in UP. It’s hard to attend more events and meet people down-state,” Kuehl-said Weisser. “It would be really cool to find more opportunities that I haven’t been able to find online, so I’m excited to connect.”

In addition to Kuehl-Weisser and Naumaan, several other students from the Medicinal Plant Chemistry and Indoor Agriculture programs will present their research to the array of legal advisers, academics and entrepreneurs who will be in attendance.

Indoor agriculture students like Naumaan will showcase hydroponic growing systems they themselves have designed and built. These systems use water as the growing medium rather than soil.

“I created a hydroponic drip feeding system for cannabis plants,” Naumaan said. “It will be really cool to see all the other systems and ideas floating around within the student body.”

In addition to his work on indoor agriculture, Naumaan will also present his research on the chemistry of medicinal plants, which is directly related to his construction of a hydroponic power system.

“My research attempted to investigate cannabinoid production between plants grown in soil versus plants grown in different variations, such as hydroponic mediums,” Naumaan said.

Kuehl-Weisser’s research focuses on the degradation rates of cannabinoids and terpenes, two compounds contained in a cannabis plant. The most well-known cannabinoids are CBD and THC, and terpenes, such as pinene and limonene, help determine the specific smell of hemp.

Taking hemp from flowers grown on campus, Kuehl-Weisser extracted oils using heat and pressure. After placing the extracted oil in three different environments, a refrigerator, a dark space, and under an LED light, Kuehl-Weisser attempted to measure how quickly the oils broke down.

“I got the idea when I was at a dispensary,” Kuehl-Weisser said. “I saw how they displayed snippets and was curious to see how that would essentially affect the products that were being sold.”

Naumaan and Kuehl-Weisser hope to receive professional feedback on their research presentations, as well as exchange ideas with other students.

“I hope my research can help future students understand some of my mistakes so they can learn, create, and show a better research project,” Kuehl-Weisser said. “There are so many little things that can affect your data. I’m open to see if other students can catch something I haven’t.

While the Cannabis Education Conference is an academic experience for attendees, it also raises awareness of the role of cannabis in society and the thriving herbal medicine chemistry program on campus. Kuehl-Weisser sees this conference as an opportunity for NMU to expand the program and its needs.

“Space and faculty are the main things the MPC program desperately needs,” Kuehl-Weisser said. “It’s hard to get that one-on-one experience with the teachers. In terms of growth and space for instruments, there are so many students per instrument that it’s difficult.

The Cannabis Education Conference will also welcome many local cannabis industry leaders and entrepreneurs, particularly from Fire Station, Lume, and Higher Love dispensaries, to speak at the event.

Those interested in attending the event can register here. NMU students will be able to join for free, while other students can join for $25 and general attendees for $50. Coffee and refreshments will be provided at the start of the conference and lunch will be provided at 12:30 p.m.

“[Cannabis] is super important because it is gaining popularity so quickly and people are consuming it at such a rapid rate every day. I think the conversation needs to happen more often about what this plant really entails, what chemicals it makes, are they harmful, aren’t they, and how can we use them to make medicine,” said said Naumaan. “[Cannabis] is a truly complex and unique plant that needs much more study and research.

Plasmid DNA and Messenger RNA Delivery Systems for Advanced Therapies


April 15, Kawasaki/Japan

The Nanomedicine Innovation Center (Centre Director: Prof. Kazunori Kataoka) announced that Prof. Satoshi Uchida (Senior Research Scientist), who is also an Associate Professor at Kyoto Prefectural Medical University, has published an article review on non-viral messenger RNA (mRNA delivery) and plasmid DNA (pDNA) by addressing the different mRNA and pDNA delivery technologies, from basic research to application therapeutic and clinical; Pharmaceutical 2022, 14(4), 810.

The vast potential of non-viral mRNA and pDNA delivery systems has been demonstrated in vaccines against coronavirus disease 2019 (COVID-19). Indeed, two mRNA vaccine formulations from Pfizer-BioNTech and Moderna were approved for emergency use within a year of the pandemic outbreak and have been administered to billions of people worldwide. In addition, a pDNA vaccine developed by Zydus Cadila also got emergency approval in India, showing high efficacy in preventing infection in a large clinical trial. These success stories inspire further research and development of mRNA and pDNA-based vaccines and therapies. Target areas are not limited to preventive vaccination against infectious diseases, but extend to therapeutic cancer vaccines, genome editing and protein replacement therapy.

However, current non-viral systems need to be improved. For example, the relatively intense adverse effects of mRNA vaccines, including myocarditis, cause vaccine hesitancy and debates over repeated boosters. Thus, safer formulations are demanded for mRNA vaccines to become platforms for various infectious diseases. Meanwhile, therapeutic cancer vaccines require more effective formulations to overcome the immunosuppressive nature of cancers. For other applications, including genome editing and protein replacement therapy, delivery carriers must reach specific tissues and introduce pDNA and mRNA without tissue damage. This special issue discusses vigorous efforts to develop mRNA and pDNA delivery systems and apply them to disease treatment to meet these demands.

The development of non-viral delivery systems has two directions. One focuses on general enhancement of delivery processes, which includes prevention of extracellular degradation of mRNA and pDNA by nucleases, intracellular targeting of mRNA and pDNA to desired sites and extension of protein expression time from mRNA and pDNA. In the other direction, delivery systems are refined for specific purposes, such as reaching particular tissues and cells to achieve therapeutic goals and stimulating the innate immune system when used in vaccinations.

This article provides comprehensive reviews of non-viral mRNA and pDNA delivery by addressing the various mRNA and pDNA delivery technologies from basic research to therapeutic and clinical application.

/Public release. This material from the original organization/authors may be ad hoc in nature, edited for clarity, style and length. The views and opinions expressed are those of the author or authors.View Full here.

Lily’s Weston Market, opening in May

April 14, 2022 | by Ted Craft

Lily’s Weston Market is set to open in early May, with almost everything about the place new, from above the ceiling to below the floor.

Final touches are being applied to the completely renovated market, which features a bright, open design with shiny new floor, ceiling, lighting, equipment and furnishings.

In a guided tour, owners Jay Stasko, Mark McWhirter and DJ Hall told us that Lily’s would contain more than four times the refrigerated dairy space than before, meat crates, frozen foods, produce, a bar to personalized salad, hot food, a chicken rotisserie, and a large section with prepared dishes ready to go.

Up front, shoppers will find chilled soft drinks, ice, and a new point-of-sale checkout system. A large deli at the back of the store sports twin 65-inch monitors to display the menu.

“Everyone is wondering why it took so long,” Mr McWhirter said.

Part of the problem was the supply chain. ‘If you don’t believe what you hear in the news about it,’ Mr McWhirter told planning and zoning commissioners in November, ‘they are real’. Orders for new ovens, stoves, grills, freezers and even doors have been delayed for months.

The building itself also required a significant amount of work. Repairs were made to the roof, new plumbing and electrical wiring was installed. The replacement of the floor required major excavation work. Mr McWhirter said the work also included the installation of hundreds of meters of copper piping for the new refrigeration systems.

“It will be a full-service grocery store,” Mr. Stasko said, “with premium meats, the best seafood from local vendors, frozen food options, organic foods, and more.”

“We want to get back to where people can come and get whatever they need.”

A photo of DJ Hall, Jay Stasko and Mark McWhirter

Lily’s owners, left to right: DJ Hall, Jay Stasko, Mark McWhirter

A photo inside the market

A photo inside the market

A photo inside the market

A photo inside the market

Related stories:

November 23, 2021: P&Z OKs Lily’s, Weston Gardens, Aspetuck Plans

August 24, 2021: Lily’s Weston Market on the way, the pharmacy too

Co-treatment with esculin and erythropoietin protects against renal ischemia-reperfusion injury via inhibition of P2X7 receptors and activation of PI3K/Akt


plant material

Vachellia farnesiana flowers were collected from Al-Qaliobia Governorate, Egypt in March 2020. Identification and authentication of the collected plant was carried out by Dr. Terase Labib, Department of Flora and Taxonomy, El-Orman Botanical Garden, Giza, Egypt. A reference specimen (n° Vf/fl/2020) is kept in the garden herbarium. Experimental research and field studies on plants, including the collection of plant material, have been approved by the IRBT Research Ethics Board and comply with relevant institutional, national and international guidelines and legislation.

Extraction and splitting

fresh flowers from V. farnesiana (1.350 kg) were soaked for 3 days in 85% methanol (5 × 2 l) at room temperature. The combined extracts were filtered and evaporated in vacuo using a rotary evaporator to obtain an 85% methanol extract (132.85g). The dried methanol aqueous extract was defatted using petroleum ether (60–80°C). Then, the defatted methanol extract underwent successive fractionation using organic solvents (e.g., dichloromethane, ethyl acetate and not-butanol) in order to obtain 17.36, 15.85, 21.43, 43.74 and 31.18 g for petroleum ether, dichloromethane, ethyl acetate, not-butanol and aqueous extracts, respectively.

Chromatographic isolation and purification of the ESC compound

The chemical constituents of the tested extract were tentatively identified using a Thermo Finnigan (Thermo electron Corporation, OK, USA), coupled to an LCQ Duo ion trap mass spectrometer with an ESI source in dimmer mode. negative ionization (ThermoQuest Corporation, Austin, TX, USA)54. The ethyl acetate extract (20.0 g) was then fractionated via column chromatography (5 × 60 cm) packed with polyamide 6S as stationary phase and eluted via a mixture elution system. gradient (water: MeOH). A total of five major subfractions (F1-F5) were obtained. The obtained subfractions (F1-F4) were separately subjected to further further purification using several Sephadex LH-20 subcolumns (2 × 30 cm) eluted with (water:MeOH with MeOH gradient) to get gallic acid, methyl gallate, p-coumaric acid, quercetin, taxifolin, naringenin and quercetin 3-O-glucoside. While F5 (5.2 g) eluted with 85% MeOH from the main polyamide column was subjected to several Sephadex LH-20 sub-columns for further purification eluted with methanol:water in an elution system at gradient to get the ESC.


Forty male Sprague-Dawley rats weighing 280-300 g were kept in the animal facility of Theodor Bilharz Research Institute (TBRI), Egypt. Rats were maintained in individual polypropylene cages at 22–25°C, with a 12–12 h dark-light cycle and free access to standard laboratory diet and water. All procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (Eighth Edition) of the National Institutes of Health, consistent with ARRIVE guidelines, and approved by the TBRI Research Ethics Board for conduct animal experiments ( PT: 584; 2/22/2021).

Surgical interventions

Each rat was anesthetized with 6% Desflurane (Desflurane®, Baxter, UK) in 100% v/v oxygen by inhalation. The rats were placed in the supine position, the abdominal skin was shaved after disinfection with 70% alcohol and a midline laparotomy incision was made. Subsequently, both kidneys with their pedicles were gently exposed and non-traumatic vascular clamps (Bulldog clamps) were placed bilaterally over both the artery and the vein of each kidney. After 45 min, successful reperfusion was achieved by removing the clamps, restoring blood supply. The surgical incisions were stitched up and covered with sterile gauze. After recovery from anesthesia, the rats were returned to their sterile cages for 24 h with free access to food and water. An identical operation was performed for the sham group without clamping the bilateral renal pedicles.

Experimental design

The rats were randomly divided into five groups of eight rats in each group. The groups of animals were as follows; Sham (vehicle received alone), vehicle + RI/R, ESC + RI/R, EPO + RI/R and ESC + EPO + RI/R. Rats were pretreated with ESC (50 mg/kg11) or vehicle (0.5% carboxymethylcellulose in phosphate buffered saline (PBS), Sigma Aldrich, USA) by oral gavage for 7 days and 30 min before RI/R. Meanwhile, EPO (Eprex®, Janssen-Cialg, Switzerland) was administered in a single dose of 1000 U/kg, IP, 30 min20 before IR/R. Twenty-four hours after reperfusion, rats were sacrificed under light anesthesia by inhalation of isoflurane (Forane®, Baxter, UK), then blood and kidney tissues were collected and processed for biochemical examinations, RT – Subsequent PCR, histopathology and immunohistochemistry (IHC). .

Biochemical analyzes

Collected blood samples were centrifuged at 3000×g for 10 min, then sera were separated and stored at -80°C for spectrophotometric evaluation of creatinine and urea levels (Biodiagnostics, Egypt), while levels of neutrophil gelatinase-associated lipocalin (NGAL ) were determined using the commercial enzyme linked immunosorbent assay (ELISA) kit (MyBiosource San Diego, USA), according to the manufacturer’s instructions.

Additionally, part of the right kidney was homogenized in ice-cold PBS and the supernatants were used for measurement of malondialdehyde (MDA), glutathione peroxidase (GPx), and superoxide dismutase (SOD) levels using specific assay kits, as described by the manufacturer. (Biodiagnostics, Egypt). Additionally, levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, NF-κB p65, endothelial nitric oxide synthase (eNOS), p-PI3K, p-Akt , bax and bcl2 were quantified using ELISA kits according to the manufacturer’s instructions (MyBiosource San Diego, USA).

Quantitative real-time polymerase chain reaction (qRT-PCR).

Total RNA was isolated from kidney tissues homogenized with Easy-spin RNA extraction kit (Intron biotechnology, Korea). The RNA was then converted into its complementary DNA (cDNA) RevertAid First Strand cDNA Synthesis Kit (Thermoscientific, USA). qRT-PCR was performed with StepOne™ Real-Time PCR (Applied Biosystems, USA) using Maxima SYBR Green qPCR Master Mix, no ROX (2×) (Thermoscientific, USA), according to the manufacturer’s instructions. Reverse transcription reaction conditions were run at 42°C for 15 min, followed by 3 min at 95°C. Thermal cycling conditions were run at 95°C before denaturation, followed by 40 cycles (95° C for 15 s; 60°C for 30 s; 72°C for 60 s). The following oligonucleotide primers were used: 5′-GTGGAGATCCTAGGTTTCTCTG-3′ (forward), 5′-CAGGATCTCATTCTCTTGGATC-3′ (reverse) for NLRP3, 5′-TTTCTTCCCCTACATCCTGCT-3′ (forward), 5′-CTGTCAGAAGTCTTGTGCTCTG-3′ (antisense) for Caspase-1, 5′-CTACTCTTCGGTGGGGGCTT-3′ (sense), 5′-CTCTGGATCCGGGTGACTTT-3′ (antisense) for P2X7R, 5′-ACACCACGGTTTGGACTATGG-3′ (sense), 5′-GGCTACAGTAGTGGGCTTGG-3′ (antisense) for PI3K, 5′-ATGTCCGAGATCCTACCCTACG-3′ (sense), 5′-AGCGAAGAAGGAGTGGTGTC-3′ (antisense) for Akt and 5′-TGATACAAAGACGGGACATCG-3′ (sense) and 5′-CACGATTTCCCTCTCAGC-3′ (antisense ) for β-actin as an internal control for normalization of target genes according to 2−ΔΔCt method55. All qRT-PCR expression experiments were performed in triplicate to ensure reproducibility of the results obtained.

Histological examination

The kidneys were grossly examined for corticomedullary demarcation, hemorrhage, and necrosis. Next, the left kidney samples were divided into two parts, one for histopathology and the other for electron microscopy examinations. Briefly, kidney tissues were immediately fixed in 10% formalin solution, processed, and embedded in paraffin. Sections 4 microns thick were then stained with: (1) hematoxylin and eosin (H&E) staining for histological evaluation of parenchymal injury (necrosis of the tubular lesion, interstitial inflammatory infiltrate and glomerular changes), (2) periodic acid Schiff’s reagent (PAS) to demonstrate capillary and tubular basement membranes, and (3) Masson’s trichrome stain (MTC) to assess fibrosis and demonstrate necrosis fibrinoid and fibrinous thrombosis At least 10 cortico-medullary fields were examined in each section at different magnifications, and a semi-quantitative analysis of the tubulointerstitial lesion was performed. Total tubular injury was scored on a scale of 0 to 4 based on percentage of normal tubules and extent of injury as follows: 0, absent; 1 (minimal, 6-10%)); 2 (Focal, 11–25%)); 3 (Moderate, 26–50%)); 4 (Diffuse, >50%).

Transmission electron microscope (TEM)

Kidney samples for TEM were fixed in 2.5% glutaraldehyde in cacodylate buffer for 2 h at 4°C. Tissues were then washed twice for 1 h each in cacodylate-sucrose buffer and post-fixed for 1 h at 4°C in 2% osmium tetroxide. After dehydration in ascending graded ethanol, the samples were impregnated with Epon 812 substitute (EMBed-812 kit, Electron Microscopy Science, USA) at room temperature and polymerized at 60°C for 48 h. Semi-thin sections were cut, stained with methylene-azure blue II and examined under a light microscope to choose the region of interest for the ultra-thin section. Ultrathin sections at 70 Å thick were then prepared using an Ultracut R ultramicrotome (Leica, Vienna, Austria) and stained twice with uranyl acetate and lead citrate. Ultrastructural examinations of glomerular capillary loops, basement membrane, podocytes and signs of tubular damage were performed at 80 kV with a Philips EM 208 S electron microscope (Philips Optics, Eindhoven, The Netherlands) provided by the Department of electron microscopy of the TBRI.

Immunohistochemical examinations of caspase-3 activity

Sections (5 microns thick) of formalin-fixed, paraffin-embedded tissue specimens were prepared on loaded and deparaffinized glass slides, hydrated, and then treated for antigen retrieval at elevated pH (pH = 8) using an automated immunostainer (Sigma, Aldrich, USA). Rabbit polyclonal anti-caspase antibodies (Sigma, Aldrich, USA); at a dilution of 1:200 was used to detect apoptosis. Biotinylated goat anti-rabbit/HRP immunoglobulins (Sigma, Aldrich, USA) were used at a dilution of 1:300. The detection method for streptavidin-biotin-peroxidase complex and peroxidase-DAB (3,3′-diaminobenzidine) (Sigma, Aldrich, USA) was carried out according to the manufacturer’s instructions. Sections were counterstained with Mayer’s hematoxylin. Positive and negative control slides were included in each run. As a negative control, a tissue section was treated as described but with the primary antibody omitted.

statistical analyzes

All data are expressed as mean ± SD. Statistical analyzes were conducted using one-way analysis of variance (ANOVA) followed by post hoc Tukey–Kramer multiple comparison test for parametric analysis, while Kruskal–Wallis test followed by the Dunn’s post hoc was used for the nonparametric analysis. Statistical differences were assessed using GraphPad Prism software (USA, version 5.03). Statistical significance was set at ppp

Pfizer’s Lorbrena for the treatment of NSCLC shows positive data in phase 3 trial

The results show that 64% of people treated with lorlatinib did not progress after 3 years, compared with around 19% of those treated with crizotinib (Xalkori).

Pfizer announced updated results from the Phase 3 CROWN trial, which evaluated lorlatinib (Lorbrena) versus crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) positive for previously treated anaplastic lymphoma kinase (ALK).

The analysis showed that after a median follow-up of 3 years, lorlatinib continued to demonstrate a significant improvement in progression-free survival assessed by blinded independent central review compared to crizotinib, corresponding to a reduction of approximately 73% rate of death or progression. .

The data was presented April 12, 2022 at the 2022 Annual Meeting of the American Association for Cancer Research.

“The long-term results of the CROWN trial confirm the compelling safety and efficacy profile of lorlatinib in the first-line setting, providing sustained benefit for up to 3 years for this patient population”, Chris Boshoff , MD, PhD, director of oncology development at Pfizer Global Product Development, said in the statement. “Since its first-line approval based on groundbreaking early results from the CROWN trial, lorlatinib has cemented its place as a practice-changing medicine, and these updated data add to the growing body of evidence supporting its use from the onset of metastatic disease.”

In the analysis, investigators found that about 64% of people treated with lorlatinib had not progressed after about 3 years, compared with about 19% of people treated with crizotinib for the same duration.

For the secondary endpoint, the objective response rate (ORR) was approximately 77% with lorlatinib and approximately 59% with crizotinib. In addition, treatment with lorlatinib resulted in an approximately 92% reduction in the rate of intracranial progression.

The intracranial ORR for people with measurable brain metastases at baseline was approximately 83% with lorlatinib and approximately 23% with crizotinib, with an intracranial complete response rate of 72% and 8%, respectively.

For people without brain metastases at baseline, lorlatinib demonstrated a 98% reduction in the rate of intracranial progression.

“About 25-40% of people with ALK-positive advanced non-small cell lung cancer have brain metastases at diagnosis or develop brain metastases within 2 years of initial diagnosis, and drugs based on biomarkers like lorlatinib have transformed the way we treat this typically aggressive disease,” Benjamin Solomon, MBBS, PhD, professor in the department of medical oncology at the Peter MacCallum Cancer Center in Melbourne, Australia, said in the release. “New results from the CROWN trial confirm that lorlatinib is a treatment option that significantly improves outcomes for people with previously untreated ALK-positive advanced NSCLC.”

The investigators reported that the safety profile in the 3-year follow-up analysis was consistent with the safety profiles established with both drugs.

In the initial 2020 analysis, the most common adverse events (AEs) in people treated with lorlatinib were cognitive effects, diarrhea, dyspnea, edema, hypertriglyceridemia, peripheral neuropathy, and taking weight.

Serious AEs occurred in approximately 34% of people treated with lorlatinib, including cognitive effects, dyspnoea, pneumonia, pyrexia and respiratory failure.

Investigators reported that fatal AEs occurred in approximately 3.4% of people treated with lorlatinib, and approximately 6.7% permanently discontinued the drug due to the AEs.


Three-year follow-up data from the Phase 3 CROWN trial of Pfizer’s Lorbrena (lorlatinib) confirms prolonged progression-free survival in first-line ALK-positive advanced lung cancer. Pfizer. Press release. April 8, 2022. Accessed April 12, 2022. https://www.pfizer.com/news/press-release/press-release-detail/three-year-follow-data-phase-3-crown-trial-pfizers

Colorado Department of Local Affairs Celebrates Building Affordable Housing Communities

By Chynna Cowart

The Colorado Department of Local Affairs (DOLA), through the Division of Housing (DOH), has contracted with several community partners to provide more affordable housing options for Coloradans across the state.

As average rental rates rise and the number of low-cost rental units available declines, the scale of the housing crisis for low-income households continues to grow. We know that access to decent and affordable housing provides stability for vulnerable families and helps prevent homelessness.

With a combination of federal COVID19 stimulus funds and state funds, Colorado is poised to make an unprecedented investment in its future housing affordability. Public investment can have a profound impact on the housing situation of those most in need by financing the gap between the cost of buying and building a home and what the end user (buyer or tenant) can afford to pay in the form of a mortgage or rent, but public funding alone cannot solve the housing affordability challenge. We will continue to align with other affordable housing advocates to create these housing opportunities for Coloradans.

Developing communities

1. Archway Communities was founded with the belief that affordable housing is a critical component to building healthy communities. Like DOLA, they believe in finding opportunities to purchase vacant land for new construction or renovate outdated multi-family developments.

On North Wadsworth in Lakewood, Colorado, Archway Communities, in partnership with DOLA and other community actors, purchased land and received tax credits to build profitable homes.

Designed for low-to-moderate income seniors aged 62 and over, Robinson Place will have 67 units and a variety of amenities, including a large community hall with an entertainment kitchen, two rooftop terraces, a central laundry room and a storage room. on bicycles. With a focus on health and fitness, community development, fine arts and culture, and more, Archway will provide a full range of on-site services.

In addition to high frequency bus service with quick access to light rail, the location is walkable and features a neighborhood shopping center, convenience store, park, grocery store , a Walmart and a pharmacy.

The Homeless Research Institute predicts that the number of homeless people over the age of 62 will increase by 33% between 2010 and 2020 (from 44,172 to 58,772 people) and will more than double between 2010 and 2050. It is imperative that we Make affordable housing easily accessible to eligible older populations because housing is one of the largest expenses in the typical budget of a household aged 65 and over.

2. The Telluride Foundation, another community partner, is committed to enriching the quality of life for residents, visitors and the workforce of the Telluride area. The Foundation does this by developing and supporting initiatives that make direct investments and create meaningful change. Recently they opened their newest community investment – Pinion Park Norwood.

“There’s been a lot of hysteria around regional affordable housing, but there are actually solutions, and we can move forward,” Paul Major, president and CEO of the Telluride Foundation, previously said. DailyPlanet.

Over the past decade, housing needs in rural communities have only increased. The lack of large-scale development in rural areas means that construction costs are often higher in rural areas than in urban areas, reducing incentives for private investment. In many rural areas, credit is also difficult to obtain, making it difficult to maintain existing units.

To combat this, the Telluride Foundation is restructuring rural housing by integrating donated land, modular home design and manufacturing, and low-cost construction financing into a toolkit that makes it cheaper to build rural housing for essential labor in rural areas.

3. Crosswinds at Arista, by Gorman & Company, will bring 159 affordable apartments to Broomfield. One- to three-bedroom apartments will be offered as part of the three-story complex at rents ranging from $500 to $2,000, with an average rent of $1,200 per month. According to city and county planning documents, rents will range between 30 and 80 percent of the area’s median income. Facilities will include picnic and play areas, dog parks, community gardens and outdoor gathering areas.

The 6.2-acre site received unanimous approval from Broomfield City Council last November after council identified the need for more affordable housing in Broomfield.

“We are extremely grateful to have had the opportunity to create Crosswinds in Arista in partnership with the City and County of Broomfield, the Broomfield Housing Authority, and the State of Colorado Division of Housing. This new community meets the goals set out by the Broomfield Housing Advisory Committee and will expand the range of housing options available in the Arista neighborhood,” said Kimball Crangle, president of Colorado Market at Gorman & Company, in a statement. communicated. “This project could not have come to fruition without alignment with the seller of the property, the Colorado State Land Board. Our shared goals helped put this project on the map.

As DOLA continues to collaborate with a multitude of partners across the state, we remain focused on providing safe, secure, and affordable housing to the Coloradans we serve.

Chynna Cowart is a press secretary with the Colorado Department of Local Affairs.

Publish a contributor

The Pagosa Daily Post welcomes submissions, photos, letters and videos from people who love Pagosa Springs, Colorado. Call 970-903-2673 or email [email protected]

Kidney In Profiteering by Drug Industry Intermediaries – InsideSources

Last month, the Federal Trade Commission sought public comment on the effect of pharmaceutical industry intermediaries on affordability and access to medicines. Unfortunately, the commissioners missed an opportunity to rein in these bad actors, even as they deny access to life-saving treatments and inflate the cost of drugs.

Better known as PBMs, or PBMs, these are the unknown middlemen who handle prescription drug benefits for insurers and large employers. As part of their role, PBMs negotiate discounts with drug manufacturers and decide which drugs insurance companies will make available. They also reimburse pharmacies for dispensing drugs to patients. Some PBMs even own insurance companies or drugstore chains themselves.

Just three big PBMs control about 85% of the market, giving them enormous control over what drugs you can buy, where you can get them, and how much you pay.

Intermediaries are expected to act as mere intermediaries and operate with very thin margins. But PBMs have figured out how to play with the market. From the consumer’s perspective, the problem is that PBMs inflate outlays. As millions of Americans struggle to afford prescription drugs, the discounts PBMs get from drugmakers should, in theory, go to patients. Instead, they pocket most of the savings and pass the rest on to insurers, with consumers rarely seeing a penny. An insurer may even charge a patient more for a given drug than they paid for the PBM – a practice that, oddly, remains perfectly legal.

As bad as PBMs are for consumers, they are also squeezing the independent, non-chain pharmacies that are the lifeblood of so many communities – and in some cases pushing them out of business.

Independent pharmacies bear the cost of storing drugs and dispensing them to patients, but have little control over their own revenues, as PBMs determine patient fees and decide how much to reimburse pharmacies for drugs covered by the assurance. The difference between what a PBM charges the insurance plan for a drug and what it charges the pharmacy is called the “spread”. Spreads are growing so rapidly that PBM’s profits have nearly doubled in the past 10 years, growing by more than $10 billion.

Often, PBMs reimburse pharmacies below cost, forcing them to incur a loss. And of course, PBMs reimburse their own pharmacies at better rates than those outside their networks – an anti-competitive, anti-small business and anti-consumer practice.

Communities are seeing the effect. In the 16 years ending in 2018, 16% of independent rural pharmacies in the United States closed, according to a study by the Rural Policy Research Institute at the University of Iowa. Meanwhile, PBM pressure has resulted in “pharmaceutical deserts” in many urban areas, particularly affecting black and Latino neighborhoods.

To remedy this situation, we urgently need a study of PBMs that compels them to provide information on their pricing and reimbursement practices. Previous studies of PBMs have looked at how they affect big payers, like insurance companies, but we need to know more about how these obscure, unregulated businesses affect American households.

As Federal Trade Commission Chair Lina Khan said after the failed motion for a new study, the agency has “a real moral imperative” to curb PBMs. It’s time to stop letting their profiteers trump our health.

Can cancer blood tests hold the promise of saving lives?

Joyce Ares had just turned 74 and was feeling great when she agreed to donate a blood sample for research. So she was surprised when the screening test came back positive for signs of cancer.

After a new blood test, a PET scan and a needle biopsy, he was diagnosed with Hodgkin’s lymphoma.

“I cried,” said the retired real estate broker. “Just a few tears and thought, ‘OK, now what do we do?'”

The Canby, Oregon resident had volunteered to take a blood test that is being touted as a new frontier in cancer screening for healthy people. It searches for cancer by checking DNA fragments released by tumor cells.

Such blood tests, called liquid biopsies, are already used in cancer patients to tailor their treatment and check if tumors come back.

Now, a company is promoting its blood test to people with no signs of cancer to detect tumors in the pancreas, ovaries, and other sites for which no screening method is recommended.

The question remains whether such cancer blood tests — if added to routine care — could improve Americans’ health or help meet the White House’s goal of halving the death rate. by cancer over the next 25 years.

With advances in DNA sequencing and data science making blood testing possible, California-based Grail and other companies are racing to bring them to market.

And US government researchers are planning a big experiment – possibly lasting seven years and with 200,000 participants – to see if blood tests can hold the promise of catching more cancers sooner and saving lives.

“They look wonderful, but we don’t have enough information,” said Dr. Lori Minasian of the National Cancer Institute, who is helping plan the research. “We don’t have definitive data that shows they will reduce the risk of dying from cancer.”

Grail is far ahead of other companies with 2,000 doctors willing to order the $949 test. Most insurance plans do not cover the cost. The tests are marketed without the endorsement of medical groups or the recommendation of US health authorities. Food and Drug Administration review is not required for this type of test.

“For a drug, the FDA requires that there is a high probability that not only are the benefits proven, but that they outweigh the harms. This is not the case for devices like blood tests” said Dr. Barry Kramer of the Lisa Schwartz Foundation for Truth in Medicine.

Grail plans to seek FDA approval, but markets its test as it submits data to the agency.

The history of cancer screening has taught caution. In 2004, Japan halted mass screening of infants for childhood cancer after studies showed it was not saving lives. Last year, a 16-year study of 200,000 women in the UK found that regular screening for ovarian cancer made no difference in deaths.

Cases like these have revealed some surprises: Screening reveals some cancers that don’t need to be cured. The other side of the coin? Many dangerous cancers grow so quickly that they escape detection and prove fatal anyway.

And screening can do more harm than good. False positive anxiety. Unnecessary charges. And the serious side effects of cancer care: PSA tests for men can lead to treatment complications such as incontinence or impotence, even when some slow-growing prostate cancers would never have caused problems .

The evidence is strongest for screening tests for breast, cervical and colon cancers. For some smokers, screening for lung cancer is recommended.

Recommended tests – mammography, PAP tests, colonoscopy – look for cancer at a time. New blood tests look for multiple cancers at once. That’s a plus, according to Grail director Dr. Joshua Ofman.

“We screen for four or five cancers in this country, but (many) cancer deaths are from cancers that we don’t screen for at all,” Ofman said.

Dr. Tomasz Beer of Oregon Health & Science University in Portland led the company-sponsored study that Joyce Ares joined in 2020. After a miserable winter of chemotherapy and radiation, doctors told her that the treatment was successful.

His case isn’t an outlier, “but it’s the kind of ideal outcome hoped for, and not everyone will have that,” Beer said.

Although there were other early cancers detected among study participants, some had less clear experiences. For some, the blood tests led to scans that never found cancer, which could mean the result was a false positive, or it could mean there is a mystery cancer that will show up later. For others, blood tests detected cancer that turned out to be advanced and aggressive, Beer said. An older participant with a bad case refused treatment.

Grail continues to update its test as it learns from these studies and is sponsoring a trial with Britain’s National Health Service in 140,000 people to see if the blood test can reduce the number of cancers detected at an early stage. advanced.

Although Ares feels lucky, it’s impossible to know if her test added healthy years to her life or made no real difference, said Kramer, former director of the Cancer Prevention Division of the National Cancer Institute.

“I sincerely hope Joyce benefited from this test,” Kramer said when told about her experience. “But unfortunately we cannot know, on an individual Joyce level, if that is the case.”

Cancer treatments can have long-term side effects, he said, “and we don’t know how quickly the tumor would have grown.” The treatment for Hodgkin’s lymphoma is so effective that delaying treatment until she experiences symptoms could have had the same happy outcome.

For now, health experts emphasize that the Grail blood test is not diagnostic of cancer; a positive result triggers further tests and biopsies.

“It’s an avenue in diagnostic testing that has never been tried before,” Kramer said. “Our ultimate destination is a test that has a clear net benefit. If we don’t do it carefully, we will get out of the way.


The Associated Press Health and Science Department is supported by the Howard Hughes Medical Institute Department of Science Education. The AP is solely responsible for all content.